, and the actions you performed just before this error.</p>,Rank,NCTId,BriefTitle,LeadSponsorName,LocationCountry
0,,1001.0,NCT00883337,A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,Sanofi,Belgium
0,,1001.0,NCT00883337,A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,Sanofi,Canada
0,,1001.0,NCT00883337,A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,Sanofi,Czech Republic
0,,1001.0,NCT00883337,A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,Sanofi,France
0,,1001.0,NCT00883337,A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,Sanofi,Germany
0,,1001.0,NCT00883337,A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,Sanofi,Greece
0,,1001.0,NCT00883337,A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,Sanofi,Hungary
0,,1001.0,NCT00883337,A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,Sanofi,Italy
0,,1001.0,NCT00883337,A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,Sanofi,Poland
0,,1001.0,NCT00883337,A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,Sanofi,Spain
0,,1001.0,NCT00883337,A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,Sanofi,Switzerland
0,,1001.0,NCT00883337,A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,Sanofi,Tunisia
0,,1001.0,NCT00883337,A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,Sanofi,United Kingdom
1,,1002.0,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),Bayer,Australia
1,,1002.0,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),Bayer,Austria
1,,1002.0,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),Bayer,Bahrain
1,,1002.0,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),Bayer,Belgium
1,,1002.0,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),Bayer,Canada
1,,1002.0,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),Bayer,Colombia
1,,1002.0,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),Bayer,Czech Republic
1,,1002.0,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),Bayer,Denmark
1,,1002.0,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),Bayer,Egypt
1,,1002.0,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),Bayer,France
1,,1002.0,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),Bayer,Germany
1,,1002.0,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),Bayer,Greece
1,,1002.0,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),Bayer,Indonesia
1,,1002.0,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),Bayer,Israel
1,,1002.0,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),Bayer,Italy
1,,1002.0,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),Bayer,Jordan
1,,1002.0,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),Bayer,Kazakhstan
1,,1002.0,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),Bayer,"Korea, Republic of"
1,,1002.0,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),Bayer,Kuwait
1,,1002.0,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),Bayer,Lebanon
1,,1002.0,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),Bayer,Mexico
1,,1002.0,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),Bayer,Netherlands
1,,1002.0,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),Bayer,Norway
1,,1002.0,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),Bayer,Oman
1,,1002.0,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),Bayer,Portugal
1,,1002.0,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),Bayer,Slovenia
1,,1002.0,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),Bayer,Spain
1,,1002.0,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),Bayer,Sweden
1,,1002.0,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),Bayer,Switzerland
1,,1002.0,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),Bayer,Taiwan
1,,1002.0,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),Bayer,Thailand
1,,1002.0,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),Bayer,United Arab Emirates
1,,1002.0,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),Bayer,United Kingdom
2,,1003.0,NCT00873340,Physical Disability in Patients Treated With Betaferon,Bayer,Colombia
4,,1005.0,NCT00852722,Low Fat Diet and Multiple Sclerosis,Oregon Health and Science University,United States
7,,1008.0,NCT00828204,Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects,Biogen,United States
8,,1009.0,NCT00819195,Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis,"University of California, San Francisco",United States
9,,1010.0,NCT00819000,Therapy Optimization in Multiple Sclerosis (MS),"Teva Neuroscience, Inc.",United States
12,,1013.0,NCT00811902,"Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis",Sanofi,United States
12,,1013.0,NCT00811902,"Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis",Sanofi,Canada
12,,1013.0,NCT00811902,"Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis",Sanofi,Finland
12,,1013.0,NCT00811902,"Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis",Sanofi,France
12,,1013.0,NCT00811902,"Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis",Sanofi,Germany
12,,1013.0,NCT00811902,"Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis",Sanofi,Norway
12,,1013.0,NCT00811902,"Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis",Sanofi,Spain
13,,1014.0,NCT00811395,Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis,Sanofi,United States
13,,1014.0,NCT00811395,Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis,Sanofi,Austria
13,,1014.0,NCT00811395,Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis,Sanofi,Canada
13,,1014.0,NCT00811395,Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis,Sanofi,Germany
13,,1014.0,NCT00811395,Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis,Sanofi,Italy
13,,1014.0,NCT00811395,Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis,Sanofi,Spain
13,,1014.0,NCT00811395,Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis,Sanofi,United Kingdom
14,,1015.0,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,Sanofi,United States
14,,1015.0,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,Sanofi,Austria
14,,1015.0,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,Sanofi,Canada
14,,1015.0,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,Sanofi,Chile
14,,1015.0,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,Sanofi,Czech Republic
14,,1015.0,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,Sanofi,Denmark
14,,1015.0,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,Sanofi,Estonia
14,,1015.0,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,Sanofi,Finland
14,,1015.0,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,Sanofi,France
14,,1015.0,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,Sanofi,Germany
14,,1015.0,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,Sanofi,Italy
14,,1015.0,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,Sanofi,Netherlands
14,,1015.0,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,Sanofi,Norway
14,,1015.0,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,Sanofi,Poland
14,,1015.0,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,Sanofi,Portugal
14,,1015.0,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,Sanofi,Russian Federation
14,,1015.0,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,Sanofi,Sweden
14,,1015.0,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,Sanofi,Switzerland
14,,1015.0,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,Sanofi,Turkey
14,,1015.0,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,Sanofi,Ukraine
14,,1015.0,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,Sanofi,United Kingdom
16,,1017.0,NCT00784836,Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients,Biogen,United States
18,,1019.0,NCT00766272,Lokomat Training Effects on MS Gait Abnormalities,US Department of Veterans Affairs,United States
19,,1020.0,NCT00765544,Targeted Lower Extremity Joint Training,US Department of Veterans Affairs,United States
21,,1022.0,NCT00755807,Duloxetine for Multiple Sclerosis Pain,Eli Lilly and Company,United States
21,,1022.0,NCT00755807,Duloxetine for Multiple Sclerosis Pain,Eli Lilly and Company,Belgium
21,,1022.0,NCT00755807,Duloxetine for Multiple Sclerosis Pain,Eli Lilly and Company,Canada
21,,1022.0,NCT00755807,Duloxetine for Multiple Sclerosis Pain,Eli Lilly and Company,Poland
22,,1023.0,NCT00754832,American Ginseng Treatment for Multiple Sclerosis Related Fatigue,Oregon Health and Science University,United States
25,,1026.0,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,Sanofi,United States
25,,1026.0,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,Sanofi,Australia
25,,1026.0,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,Sanofi,Austria
25,,1026.0,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,Sanofi,Belarus
25,,1026.0,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,Sanofi,Belgium
25,,1026.0,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,Sanofi,Canada
25,,1026.0,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,Sanofi,Chile
25,,1026.0,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,Sanofi,China
25,,1026.0,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,Sanofi,Czech Republic
25,,1026.0,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,Sanofi,Estonia
25,,1026.0,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,Sanofi,France
25,,1026.0,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,Sanofi,Germany
25,,1026.0,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,Sanofi,Greece
25,,1026.0,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,Sanofi,Mexico
25,,1026.0,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,Sanofi,Netherlands
25,,1026.0,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,Sanofi,Philippines
25,,1026.0,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,Sanofi,Poland
25,,1026.0,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,Sanofi,Romania
25,,1026.0,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,Sanofi,Slovakia
25,,1026.0,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,Sanofi,Spain
25,,1026.0,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,Sanofi,Sweden
25,,1026.0,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,Sanofi,Thailand
25,,1026.0,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,Sanofi,Tunisia
25,,1026.0,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,Sanofi,Turkey
25,,1026.0,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,Sanofi,Ukraine
25,,1026.0,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,Sanofi,United Kingdom
26,,1027.0,NCT00744679,A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State,Biogen,United States
27,,1028.0,NCT00735007,12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.,EMD Serono,United States
27,,1028.0,NCT00735007,12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.,EMD Serono,Canada
27,,1028.0,NCT00735007,12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.,EMD Serono,Germany
27,,1028.0,NCT00735007,12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.,EMD Serono,Italy
27,,1028.0,NCT00735007,12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.,EMD Serono,Spain
27,,1028.0,NCT00735007,12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.,EMD Serono,Sweden
28,,1029.0,NCT00725985,Oral Cladribine in Early Multiple Sclerosis (MS),"EMD Serono Research & Development Institute, Inc.",United States
28,,1029.0,NCT00725985,Oral Cladribine in Early Multiple Sclerosis (MS),"EMD Serono Research & Development Institute, Inc.",Argentina
28,,1029.0,NCT00725985,Oral Cladribine in Early Multiple Sclerosis (MS),"EMD Serono Research & Development Institute, Inc.",Austria
28,,1029.0,NCT00725985,Oral Cladribine in Early Multiple Sclerosis (MS),"EMD Serono Research & Development Institute, Inc.",Belgium
28,,1029.0,NCT00725985,Oral Cladribine in Early Multiple Sclerosis (MS),"EMD Serono Research & Development Institute, Inc.",Bosnia and Herzegovina
28,,1029.0,NCT00725985,Oral Cladribine in Early Multiple Sclerosis (MS),"EMD Serono Research & Development Institute, Inc.",Bulgaria
28,,1029.0,NCT00725985,Oral Cladribine in Early Multiple Sclerosis (MS),"EMD Serono Research & Development Institute, Inc.",Canada
28,,1029.0,NCT00725985,Oral Cladribine in Early Multiple Sclerosis (MS),"EMD Serono Research & Development Institute, Inc.",Croatia
28,,1029.0,NCT00725985,Oral Cladribine in Early Multiple Sclerosis (MS),"EMD Serono Research & Development Institute, Inc.",Czechia
28,,1029.0,NCT00725985,Oral Cladribine in Early Multiple Sclerosis (MS),"EMD Serono Research & Development Institute, Inc.",Estonia
28,,1029.0,NCT00725985,Oral Cladribine in Early Multiple Sclerosis (MS),"EMD Serono Research & Development Institute, Inc.",Finland
28,,1029.0,NCT00725985,Oral Cladribine in Early Multiple Sclerosis (MS),"EMD Serono Research & Development Institute, Inc.",France
28,,1029.0,NCT00725985,Oral Cladribine in Early Multiple Sclerosis (MS),"EMD Serono Research & Development Institute, Inc.",Georgia
28,,1029.0,NCT00725985,Oral Cladribine in Early Multiple Sclerosis (MS),"EMD Serono Research & Development Institute, Inc.",Germany
28,,1029.0,NCT00725985,Oral Cladribine in Early Multiple Sclerosis (MS),"EMD Serono Research & Development Institute, Inc.",India
28,,1029.0,NCT00725985,Oral Cladribine in Early Multiple Sclerosis (MS),"EMD Serono Research & Development Institute, Inc.",Italy
28,,1029.0,NCT00725985,Oral Cladribine in Early Multiple Sclerosis (MS),"EMD Serono Research & Development Institute, Inc.","Korea, Republic of"
28,,1029.0,NCT00725985,Oral Cladribine in Early Multiple Sclerosis (MS),"EMD Serono Research & Development Institute, Inc.",Lebanon
28,,1029.0,NCT00725985,Oral Cladribine in Early Multiple Sclerosis (MS),"EMD Serono Research & Development Institute, Inc.",North Macedonia
28,,1029.0,NCT00725985,Oral Cladribine in Early Multiple Sclerosis (MS),"EMD Serono Research & Development Institute, Inc.",Norway
28,,1029.0,NCT00725985,Oral Cladribine in Early Multiple Sclerosis (MS),"EMD Serono Research & Development Institute, Inc.",Poland
28,,1029.0,NCT00725985,Oral Cladribine in Early Multiple Sclerosis (MS),"EMD Serono Research & Development Institute, Inc.",Portugal
28,,1029.0,NCT00725985,Oral Cladribine in Early Multiple Sclerosis (MS),"EMD Serono Research & Development Institute, Inc.",Romania
28,,1029.0,NCT00725985,Oral Cladribine in Early Multiple Sclerosis (MS),"EMD Serono Research & Development Institute, Inc.",Russian Federation
28,,1029.0,NCT00725985,Oral Cladribine in Early Multiple Sclerosis (MS),"EMD Serono Research & Development Institute, Inc.",Serbia
28,,1029.0,NCT00725985,Oral Cladribine in Early Multiple Sclerosis (MS),"EMD Serono Research & Development Institute, Inc.",Singapore
28,,1029.0,NCT00725985,Oral Cladribine in Early Multiple Sclerosis (MS),"EMD Serono Research & Development Institute, Inc.",Spain
28,,1029.0,NCT00725985,Oral Cladribine in Early Multiple Sclerosis (MS),"EMD Serono Research & Development Institute, Inc.",Sweden
28,,1029.0,NCT00725985,Oral Cladribine in Early Multiple Sclerosis (MS),"EMD Serono Research & Development Institute, Inc.",Taiwan
28,,1029.0,NCT00725985,Oral Cladribine in Early Multiple Sclerosis (MS),"EMD Serono Research & Development Institute, Inc.",Thailand
28,,1029.0,NCT00725985,Oral Cladribine in Early Multiple Sclerosis (MS),"EMD Serono Research & Development Institute, Inc.",Turkey
28,,1029.0,NCT00725985,Oral Cladribine in Early Multiple Sclerosis (MS),"EMD Serono Research & Development Institute, Inc.",Ukraine
28,,1029.0,NCT00725985,Oral Cladribine in Early Multiple Sclerosis (MS),"EMD Serono Research & Development Institute, Inc.",United Arab Emirates
28,,1029.0,NCT00725985,Oral Cladribine in Early Multiple Sclerosis (MS),"EMD Serono Research & Development Institute, Inc.",United Kingdom
31,,1032.0,NCT00702065,"A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment",EMD Serono,United States
31,,1032.0,NCT00702065,"A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment",EMD Serono,Argentina
31,,1032.0,NCT00702065,"A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment",EMD Serono,Australia
31,,1032.0,NCT00702065,"A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment",EMD Serono,Austria
31,,1032.0,NCT00702065,"A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment",EMD Serono,France
31,,1032.0,NCT00702065,"A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment",EMD Serono,Germany
31,,1032.0,NCT00702065,"A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment",EMD Serono,Israel
31,,1032.0,NCT00702065,"A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment",EMD Serono,Italy
31,,1032.0,NCT00702065,"A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment",EMD Serono,Norway
31,,1032.0,NCT00702065,"A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment",EMD Serono,Spain
31,,1032.0,NCT00702065,"A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment",EMD Serono,Turkey
31,,1032.0,NCT00702065,"A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment",EMD Serono,United Kingdom
34,,1035.0,NCT00676156,A Study of the Pharmacokinetics and Immunologic Effects of Lipoic Acid in Multiple Sclerosis,Oregon Health and Science University,United States
36,,1037.0,NCT00670449,An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis,Novartis,Japan
38,,1039.0,NCT00662649,Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,Australia
38,,1039.0,NCT00662649,Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,Belgium
38,,1039.0,NCT00662649,Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,Canada
38,,1039.0,NCT00662649,Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,Czech Republic
38,,1039.0,NCT00662649,Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,Estonia
38,,1039.0,NCT00662649,Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,Finland
38,,1039.0,NCT00662649,Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,France
38,,1039.0,NCT00662649,Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,Germany
38,,1039.0,NCT00662649,Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,Greece
38,,1039.0,NCT00662649,Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,Hungary
38,,1039.0,NCT00662649,Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,Ireland
38,,1039.0,NCT00662649,Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,Israel
38,,1039.0,NCT00662649,Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,Netherlands
38,,1039.0,NCT00662649,Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,Poland
38,,1039.0,NCT00662649,Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,Romania
38,,1039.0,NCT00662649,Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,Russian Federation
38,,1039.0,NCT00662649,Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,Slovakia
38,,1039.0,NCT00662649,Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,South Africa
38,,1039.0,NCT00662649,Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,Sweden
38,,1039.0,NCT00662649,Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,Switzerland
38,,1039.0,NCT00662649,Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,Turkey
38,,1039.0,NCT00662649,Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,United Kingdom
39,,1040.0,NCT00654927,"Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis",Acorda Therapeutics,United States
39,,1040.0,NCT00654927,"Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis",Acorda Therapeutics,Canada
40,,1041.0,NCT00649792,"Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial",Acorda Therapeutics,United States
40,,1041.0,NCT00649792,"Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial",Acorda Therapeutics,Canada
41,,1042.0,NCT00648908,"Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial",Acorda Therapeutics,United States
41,,1042.0,NCT00648908,"Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial",Acorda Therapeutics,Canada
49,,1050.0,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,Sanofi,United States
49,,1050.0,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,Sanofi,Australia
49,,1050.0,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,Sanofi,Austria
49,,1050.0,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,Sanofi,Bulgaria
49,,1050.0,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,Sanofi,Canada
49,,1050.0,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,Sanofi,Chile
49,,1050.0,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,Sanofi,Czech Republic
49,,1050.0,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,Sanofi,Denmark
49,,1050.0,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,Sanofi,Estonia
49,,1050.0,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,Sanofi,Finland
49,,1050.0,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,Sanofi,France
49,,1050.0,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,Sanofi,Germany
49,,1050.0,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,Sanofi,Hungary
49,,1050.0,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,Sanofi,Lithuania
49,,1050.0,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,Sanofi,Mexico
49,,1050.0,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,Sanofi,Poland
49,,1050.0,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,Sanofi,Romania
49,,1050.0,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,Sanofi,Russian Federation
49,,1050.0,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,Sanofi,Turkey
49,,1050.0,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,Sanofi,Ukraine
49,,1050.0,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,Sanofi,United Kingdom
51,,1052.0,NCT00618267,"ATP Expression in Lymphocytes of MS Patients by Means of ""ImmuKnow®"" Assay.",Biogen,United States
54,,1055.0,NCT00605215,BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®),Teva Pharmaceutical Industries,United States
54,,1055.0,NCT00605215,BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®),Teva Pharmaceutical Industries,Bulgaria
54,,1055.0,NCT00605215,BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®),Teva Pharmaceutical Industries,Croatia
54,,1055.0,NCT00605215,BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®),Teva Pharmaceutical Industries,Czech Republic
54,,1055.0,NCT00605215,BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®),Teva Pharmaceutical Industries,Estonia
54,,1055.0,NCT00605215,BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®),Teva Pharmaceutical Industries,Georgia
54,,1055.0,NCT00605215,BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®),Teva Pharmaceutical Industries,Germany
54,,1055.0,NCT00605215,BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®),Teva Pharmaceutical Industries,Israel
54,,1055.0,NCT00605215,BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®),Teva Pharmaceutical Industries,Italy
54,,1055.0,NCT00605215,BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®),Teva Pharmaceutical Industries,Lithuania
54,,1055.0,NCT00605215,BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®),Teva Pharmaceutical Industries,"Macedonia, The Former Yugoslav Republic of"
54,,1055.0,NCT00605215,BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®),Teva Pharmaceutical Industries,Poland
54,,1055.0,NCT00605215,BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®),Teva Pharmaceutical Industries,Puerto Rico
54,,1055.0,NCT00605215,BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®),Teva Pharmaceutical Industries,Romania
54,,1055.0,NCT00605215,BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®),Teva Pharmaceutical Industries,Russian Federation
54,,1055.0,NCT00605215,BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®),Teva Pharmaceutical Industries,Slovakia
54,,1055.0,NCT00605215,BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®),Teva Pharmaceutical Industries,South Africa
54,,1055.0,NCT00605215,BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®),Teva Pharmaceutical Industries,Spain
54,,1055.0,NCT00605215,BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®),Teva Pharmaceutical Industries,Ukraine
55,,1056.0,NCT00599274,Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis,Biogen,United States
55,,1056.0,NCT00599274,Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis,Biogen,Australia
55,,1056.0,NCT00599274,Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis,Biogen,Austria
55,,1056.0,NCT00599274,Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis,Biogen,Canada
57,,1058.0,NCT00548769,Firategrast (SB683699) Surface Area Study in Multiple Sclerosis Patients,GlaxoSmithKline,Czechia
57,,1058.0,NCT00548769,Firategrast (SB683699) Surface Area Study in Multiple Sclerosis Patients,GlaxoSmithKline,Germany
57,,1058.0,NCT00548769,Firategrast (SB683699) Surface Area Study in Multiple Sclerosis Patients,GlaxoSmithKline,Poland
58,,1059.0,NCT00544037,BENEFIT Extension Study,Bayer,Austria
58,,1059.0,NCT00544037,BENEFIT Extension Study,Bayer,Belgium
58,,1059.0,NCT00544037,BENEFIT Extension Study,Bayer,Canada
58,,1059.0,NCT00544037,BENEFIT Extension Study,Bayer,Czech Republic
58,,1059.0,NCT00544037,BENEFIT Extension Study,Bayer,Denmark
58,,1059.0,NCT00544037,BENEFIT Extension Study,Bayer,Finland
58,,1059.0,NCT00544037,BENEFIT Extension Study,Bayer,France
58,,1059.0,NCT00544037,BENEFIT Extension Study,Bayer,Germany
58,,1059.0,NCT00544037,BENEFIT Extension Study,Bayer,Hungary
58,,1059.0,NCT00544037,BENEFIT Extension Study,Bayer,Israel
58,,1059.0,NCT00544037,BENEFIT Extension Study,Bayer,Italy
58,,1059.0,NCT00544037,BENEFIT Extension Study,Bayer,Netherlands
58,,1059.0,NCT00544037,BENEFIT Extension Study,Bayer,Norway
58,,1059.0,NCT00544037,BENEFIT Extension Study,Bayer,Poland
58,,1059.0,NCT00544037,BENEFIT Extension Study,Bayer,Slovenia
58,,1059.0,NCT00544037,BENEFIT Extension Study,Bayer,Spain
58,,1059.0,NCT00544037,BENEFIT Extension Study,Bayer,Sweden
58,,1059.0,NCT00544037,BENEFIT Extension Study,Bayer,Switzerland
59,,1060.0,NCT00537082,Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (MS),Novartis,Japan
60,,1061.0,NCT00536120,The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis,Biogen,United States
61,,1062.0,NCT00525343,Avonex 15 Year Long Term Follow-up Study,Biogen,United States
62,,1063.0,NCT00516893,Natalizumab High Titer Immunogenicity and Safety,Biogen,United States
66,,1067.0,NCT00501943,Neuroprotection With Riluzole Patients With Early Multiple Sclerosis,"University of California, San Francisco",United States
67,,1068.0,NCT00501696,"A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone","University of California, San Francisco",United States
68,,1069.0,NCT00498199,"Visual Impairment, Oscillopsia and Multiple Sclerosis",Hospices Civils de Lyon,France
70,,1071.0,NCT00493077,Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy,Biogen,Sweden
71,,1072.0,NCT00492765,Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis,Biogen,Denmark
72,,1073.0,NCT00489489,Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis,Sanofi,United States
72,,1073.0,NCT00489489,Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis,Sanofi,Canada
72,,1073.0,NCT00489489,Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis,Sanofi,Germany
72,,1073.0,NCT00489489,Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis,Sanofi,Italy
72,,1073.0,NCT00489489,Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis,Sanofi,Spain
75,,1076.0,NCT00483847,TYGRIS - ROW: TYSABRI Global Observational Program in Safety - Rest of World,Biogen,Germany
76,,1077.0,NCT00483652,Study of Fampridine-SR Tablets in Multiple Sclerosis Patients,Acorda Therapeutics,United States
76,,1077.0,NCT00483652,Study of Fampridine-SR Tablets in Multiple Sclerosis Patients,Acorda Therapeutics,Canada
77,,1078.0,NCT00477113,TYSABRI Global Observational Program in Safety,Biogen,United States
78,,1079.0,NCT00475865,Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis,Sanofi,United States
78,,1079.0,NCT00475865,Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis,Sanofi,Austria
78,,1079.0,NCT00475865,Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis,Sanofi,Canada
78,,1079.0,NCT00475865,Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis,Sanofi,Germany
78,,1079.0,NCT00475865,Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis,Sanofi,Italy
78,,1079.0,NCT00475865,Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis,Sanofi,United Kingdom
80,,1081.0,NCT00469378,Study Of White Blood Cells In The Cerebrospinal Fluid And Blood Of Patients With Relapsing Forms Of Multiple Sclerosis,GlaxoSmithKline,Belgium
80,,1081.0,NCT00469378,Study Of White Blood Cells In The Cerebrospinal Fluid And Blood Of Patients With Relapsing Forms Of Multiple Sclerosis,GlaxoSmithKline,Czech Republic
80,,1081.0,NCT00469378,Study Of White Blood Cells In The Cerebrospinal Fluid And Blood Of Patients With Relapsing Forms Of Multiple Sclerosis,GlaxoSmithKline,Denmark
80,,1081.0,NCT00469378,Study Of White Blood Cells In The Cerebrospinal Fluid And Blood Of Patients With Relapsing Forms Of Multiple Sclerosis,GlaxoSmithKline,Norway
80,,1081.0,NCT00469378,Study Of White Blood Cells In The Cerebrospinal Fluid And Blood Of Patients With Relapsing Forms Of Multiple Sclerosis,GlaxoSmithKline,Sweden
82,,1083.0,NCT00464074,Evaluation of Natalizumab for thE Relief of MS Associated FatiGue,Biogen,United States
82,,1083.0,NCT00464074,Evaluation of Natalizumab for thE Relief of MS Associated FatiGue,Biogen,Puerto Rico
85,,1086.0,NCT00439257,"Costs, Quality of Life and Functional Outcomes in Veterans Treated for Multiple Sclerosis With Beta-Interferon l-B (Betaseron)",US Department of Veterans Affairs,United States
86,,1087.0,NCT00436826,A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD),"EMD Serono Research & Development Institute, Inc.",United States
86,,1087.0,NCT00436826,A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD),"EMD Serono Research & Development Institute, Inc.",Italy
86,,1087.0,NCT00436826,A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD),"EMD Serono Research & Development Institute, Inc.",Russian Federation
86,,1087.0,NCT00436826,A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD),"EMD Serono Research & Development Institute, Inc.",Spain
87,,1088.0,NCT00432900,Brain Peripheral Benzodiazepine Receptors in Patients With Multiple Sclerosis,National Institute of Neurological Disorders and Stroke (NINDS),United States
91,,1092.0,NCT00423111,Correlation Between Cognitive Functions and MRI in Multiple Sclerosis,Sheba Medical Center,Israel
94,,1095.0,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),"Merck KGaA, Darmstadt, Germany",Argentina
94,,1095.0,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),"Merck KGaA, Darmstadt, Germany",Australia
94,,1095.0,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),"Merck KGaA, Darmstadt, Germany",Austria
94,,1095.0,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),"Merck KGaA, Darmstadt, Germany",Belgium
94,,1095.0,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),"Merck KGaA, Darmstadt, Germany",Bulgaria
94,,1095.0,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),"Merck KGaA, Darmstadt, Germany",Canada
94,,1095.0,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),"Merck KGaA, Darmstadt, Germany",Croatia
94,,1095.0,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),"Merck KGaA, Darmstadt, Germany",Czech Republic
94,,1095.0,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),"Merck KGaA, Darmstadt, Germany",Estonia
94,,1095.0,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),"Merck KGaA, Darmstadt, Germany",Finland
94,,1095.0,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),"Merck KGaA, Darmstadt, Germany",France
94,,1095.0,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),"Merck KGaA, Darmstadt, Germany",Germany
94,,1095.0,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),"Merck KGaA, Darmstadt, Germany",Greece
94,,1095.0,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),"Merck KGaA, Darmstadt, Germany",Israel
94,,1095.0,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),"Merck KGaA, Darmstadt, Germany",Italy
94,,1095.0,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),"Merck KGaA, Darmstadt, Germany",Latvia
94,,1095.0,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),"Merck KGaA, Darmstadt, Germany",Lebanon
94,,1095.0,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),"Merck KGaA, Darmstadt, Germany",Morocco
94,,1095.0,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),"Merck KGaA, Darmstadt, Germany",Poland
94,,1095.0,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),"Merck KGaA, Darmstadt, Germany",Portugal
94,,1095.0,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),"Merck KGaA, Darmstadt, Germany",Romania
94,,1095.0,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),"Merck KGaA, Darmstadt, Germany",Russian Federation
94,,1095.0,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),"Merck KGaA, Darmstadt, Germany",Saudi Arabia
94,,1095.0,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),"Merck KGaA, Darmstadt, Germany",Serbia
94,,1095.0,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),"Merck KGaA, Darmstadt, Germany",Slovakia
94,,1095.0,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),"Merck KGaA, Darmstadt, Germany",Spain
94,,1095.0,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),"Merck KGaA, Darmstadt, Germany",Turkey
95,,1096.0,NCT00395317,Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS),GlaxoSmithKline,Australia
95,,1096.0,NCT00395317,Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS),GlaxoSmithKline,Austria
95,,1096.0,NCT00395317,Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS),GlaxoSmithKline,Canada
95,,1096.0,NCT00395317,Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS),GlaxoSmithKline,Finland
95,,1096.0,NCT00395317,Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS),GlaxoSmithKline,France
95,,1096.0,NCT00395317,Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS),GlaxoSmithKline,Germany
95,,1096.0,NCT00395317,Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS),GlaxoSmithKline,Italy
95,,1096.0,NCT00395317,Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS),GlaxoSmithKline,Netherlands
95,,1096.0,NCT00395317,Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS),GlaxoSmithKline,New Zealand
95,,1096.0,NCT00395317,Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS),GlaxoSmithKline,Norway
95,,1096.0,NCT00395317,Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS),GlaxoSmithKline,Poland
95,,1096.0,NCT00395317,Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS),GlaxoSmithKline,Russian Federation
95,,1096.0,NCT00395317,Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS),GlaxoSmithKline,Spain
95,,1096.0,NCT00395317,Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS),GlaxoSmithKline,United Kingdom
97,,1098.0,NCT00393588,Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis,National Institute of Neurological Disorders and Stroke (NINDS),United States
98,,1099.0,NCT00391079,Sativex Versus Placebo When Added to Existing Treatment for Central Neuropathic Pain in MS,GW Pharmaceuticals Ltd.,Canada
101,,1102.0,NCT00370071,"Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis",Bayer,China
103,,1104.0,NCT00355134,Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,United States
103,,1104.0,NCT00355134,Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,Australia
103,,1104.0,NCT00355134,Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,Austria
103,,1104.0,NCT00355134,Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,Canada
103,,1104.0,NCT00355134,Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,Poland
103,,1104.0,NCT00355134,Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,Romania
103,,1104.0,NCT00355134,Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,Turkey
103,,1104.0,NCT00355134,Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,United Kingdom
105,,1106.0,NCT00342134,Immunological Mechanisms of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis,National Institute of Neurological Disorders and Stroke (NINDS),United States
106,,1107.0,NCT00340834,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase,Novartis,United States
106,,1107.0,NCT00340834,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase,Novartis,Argentina
106,,1107.0,NCT00340834,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase,Novartis,Australia
106,,1107.0,NCT00340834,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase,Novartis,Austria
106,,1107.0,NCT00340834,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase,Novartis,Belgium
106,,1107.0,NCT00340834,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase,Novartis,Brazil
106,,1107.0,NCT00340834,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase,Novartis,Canada
106,,1107.0,NCT00340834,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase,Novartis,Egypt
106,,1107.0,NCT00340834,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase,Novartis,France
106,,1107.0,NCT00340834,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase,Novartis,Germany
106,,1107.0,NCT00340834,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase,Novartis,Greece
106,,1107.0,NCT00340834,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase,Novartis,Hungary
106,,1107.0,NCT00340834,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase,Novartis,Italy
106,,1107.0,NCT00340834,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase,Novartis,"Korea, Republic of"
106,,1107.0,NCT00340834,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase,Novartis,Portugal
106,,1107.0,NCT00340834,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase,Novartis,Spain
106,,1107.0,NCT00340834,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase,Novartis,Switzerland
106,,1107.0,NCT00340834,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase,Novartis,United Kingdom
107,,1108.0,NCT00338741,Rebif® Pregnancy Registry,EMD Serono,United States
108,,1109.0,NCT00336557,Determine Impact of Multiple NAb Tests on Treatment Compared to Usual Care of MS Patients on High-dose IFN Therapy,Teva Pharmaceutical Industries,United States
109,,1110.0,NCT00334100,Treadmill Training in Chronic MS: Efficacy and Cost-effectiveness,US Department of Veterans Affairs,United States
110,,1111.0,NCT00333138,Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis,Novartis,Canada
110,,1111.0,NCT00333138,Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis,Novartis,Denmark
110,,1111.0,NCT00333138,Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis,Novartis,Finland
110,,1111.0,NCT00333138,Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis,Novartis,France
110,,1111.0,NCT00333138,Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis,Novartis,Germany
110,,1111.0,NCT00333138,Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis,Novartis,Italy
110,,1111.0,NCT00333138,Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis,Novartis,Poland
110,,1111.0,NCT00333138,Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis,Novartis,Portugal
110,,1111.0,NCT00333138,Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis,Novartis,Spain
110,,1111.0,NCT00333138,Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis,Novartis,Switzerland
110,,1111.0,NCT00333138,Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis,Novartis,United Kingdom
111,,1112.0,NCT00331747,Gait Evaluation in Multiple Sclerosis Patients Treated With Glatiramer Acetate,Sheba Medical Center,Israel
112,,1113.0,NCT00325988,Biomarkers in Multiple Sclerosis,National Institute of Neurological Disorders and Stroke (NINDS),United States
113,,1114.0,NCT00324506,Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis,University of Texas Southwestern Medical Center,United States
114,,1115.0,NCT00323271,Cognitive-behavior Therapy for MS-Related Chronic Pain,US Department of Veterans Affairs,United States
115,,1116.0,NCT00321568,Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis,National Institute of Neurological Disorders and Stroke (NINDS),United States
116,,1117.0,NCT00313976,"Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)",Bayer,Denmark
116,,1117.0,NCT00313976,"Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)",Bayer,Sweden
120,,1121.0,NCT00288990,A Serologic Study to Correlate Beta-IFN NAb Titers to Beta-IFN Induced Biomarker Response in Patients With Multiple Sclerosis,Biogen,United States
122,,1123.0,NCT00276172,Open-Label Natalizumab Safety Extension Study,Biogen,United States
123,,1124.0,NCT00273364,Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study,Northwestern University,United States
124,,1125.0,NCT00270816,Interferon ß-1b Treatment by Cyclical Administration,S. Andrea Hospital,Italy
125,,1126.0,NCT00267319,FOCUS Fatigue Outcome in Copaxone USers,Sanofi,Czech Republic
126,,1127.0,NCT00262314,"Prospective, Open-label Tolerability and Safety Monitoring Study of Novantrone in a Selected Cohort of Multiple Sclerosis Patients",EMD Serono,United States
132,,1133.0,NCT00239993,A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone®,"Teva Neuroscience, Inc.",United States
134,,1135.0,NCT00230204,Infections and Autoimmunity: Autobodies Screening in Multiple Sclerosis,Sheba Medical Center,Israel
136,,1137.0,NCT00228228,TCV -01-002: T-Cell Vaccination in the Treatment of Probable Multiple Sclerosis,Sheba Medical Center,Israel
137,,1138.0,NCT00228163,Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses,Sanofi,Canada
137,,1138.0,NCT00228163,Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses,Sanofi,France
138,,1139.0,NCT00223457,Factors That Influence Compliance With Disease-Modifying Therapy in Multiple Sclerosis,University of Texas Southwestern Medical Center,United States
139,,1140.0,NCT00223301,Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis,University of Texas Southwestern Medical Center,United States
141,,1142.0,NCT00220428,T-Cell Vaccination in Multiple Sclerosis (MS),Sheba Medical Center,Israel
144,,1145.0,NCT00206635,Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis,Bayer,United States
144,,1145.0,NCT00206635,Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis,Bayer,Canada
145,,1146.0,NCT00202423,Use of Cannabinoids in Patients With Multiple Sclerosis,S. Andrea Hospital,Italy
146,,1147.0,NCT00202410,Efficacy of Anti-Tubercular Vaccination in Multiple Sclerosis,S. Andrea Hospital,Italy
147,,1148.0,NCT00202384,Gene Expression in MS Patients Before and During Treatment With Interferon-beta,S. Andrea Hospital,Italy
149,,1150.0,NCT00190268,"Efficacy of 3,4-DAP in Fatigue Associated With Multiple Sclerosis",Assistance Publique - Hôpitaux de Paris,France
150,,1151.0,NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,Bayer,Austria
150,,1151.0,NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,Bayer,Belgium
150,,1151.0,NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,Bayer,Canada
150,,1151.0,NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,Bayer,Czech Republic
150,,1151.0,NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,Bayer,Denmark
150,,1151.0,NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,Bayer,Finland
150,,1151.0,NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,Bayer,France
150,,1151.0,NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,Bayer,Germany
150,,1151.0,NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,Bayer,Hungary
150,,1151.0,NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,Bayer,Israel
150,,1151.0,NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,Bayer,Italy
150,,1151.0,NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,Bayer,Netherlands
150,,1151.0,NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,Bayer,Norway
150,,1151.0,NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,Bayer,Poland
150,,1151.0,NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,Bayer,Portugal
150,,1151.0,NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,Bayer,Slovenia
150,,1151.0,NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,Bayer,Spain
150,,1151.0,NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,Bayer,Sweden
150,,1151.0,NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,Bayer,Switzerland
150,,1151.0,NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,Bayer,United Kingdom
152,,1153.0,NCT00168701,Efficacy and Safety of BG00012 in MS,Biogen,Czech Republic
152,,1153.0,NCT00168701,Efficacy and Safety of BG00012 in MS,Biogen,Germany
152,,1153.0,NCT00168701,Efficacy and Safety of BG00012 in MS,Biogen,Hungary
152,,1153.0,NCT00168701,Efficacy and Safety of BG00012 in MS,Biogen,Netherlands
152,,1153.0,NCT00168701,Efficacy and Safety of BG00012 in MS,Biogen,Poland
152,,1153.0,NCT00168701,Efficacy and Safety of BG00012 in MS,Biogen,Russian Federation
152,,1153.0,NCT00168701,Efficacy and Safety of BG00012 in MS,Biogen,Sweden
152,,1153.0,NCT00168701,Efficacy and Safety of BG00012 in MS,Biogen,Switzerland
152,,1153.0,NCT00168701,Efficacy and Safety of BG00012 in MS,Biogen,Turkey
152,,1153.0,NCT00168701,Efficacy and Safety of BG00012 in MS,Biogen,United Kingdom
153,,1154.0,NCT00166283,Improving New Learning and Memory in Multiple Sclerosis,Kessler Foundation,United States
154,,1155.0,NCT00156676,Restoration of Walking in Multiple Sclerosis Using Treadmill Training.,US Department of Veterans Affairs,United States
155,,1156.0,NCT00151801,Safety and Tolerability of Interferon-Beta-1a and Estroprogestins Association in MS Patients,S. Andrea Hospital,Italy
156,,1157.0,NCT00147446,Stress Management for Patients With Multiple Sclerosis,Northwestern University,United States
158,,1159.0,NCT00142402,Modafinil in Multiple Sclerosis,Kessler Foundation,United States
162,,1163.0,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,Sanofi,United States
162,,1163.0,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,Sanofi,Austria
162,,1163.0,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,Sanofi,Canada
162,,1163.0,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,Sanofi,Chile
162,,1163.0,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,Sanofi,Czech Republic
162,,1163.0,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,Sanofi,Denmark
162,,1163.0,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,Sanofi,Estonia
162,,1163.0,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,Sanofi,Finland
162,,1163.0,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,Sanofi,France
162,,1163.0,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,Sanofi,Germany
162,,1163.0,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,Sanofi,Italy
162,,1163.0,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,Sanofi,Netherlands
162,,1163.0,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,Sanofi,Norway
162,,1163.0,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,Sanofi,Poland
162,,1163.0,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,Sanofi,Portugal
162,,1163.0,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,Sanofi,Russian Federation
162,,1163.0,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,Sanofi,Sweden
162,,1163.0,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,Sanofi,Switzerland
162,,1163.0,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,Sanofi,Turkey
162,,1163.0,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,Sanofi,Ukraine
162,,1163.0,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,Sanofi,United Kingdom
163,,1164.0,NCT00127530,Study of Oral Fampridine-SR in Multiple Sclerosis,Acorda Therapeutics,United States
163,,1164.0,NCT00127530,Study of Oral Fampridine-SR in Multiple Sclerosis,Acorda Therapeutics,Canada
164,,1165.0,NCT00127075,POPART'MUS: Prevention of Post Partum Relapses With Progestin and Estradiol in Multiple Sclerosis,Hospices Civils de Lyon,France
165,,1166.0,NCT00118547,Health Behavior Change in Chronic Disease Management,US Department of Veterans Affairs,United States
166,,1167.0,NCT00110396,Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis,EMD Serono,United States
168,,1169.0,NCT00104143,A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis.,Hoffmann-La Roche,Bulgaria
168,,1169.0,NCT00104143,A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis.,Hoffmann-La Roche,Canada
168,,1169.0,NCT00104143,A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis.,Hoffmann-La Roche,Czech Republic
168,,1169.0,NCT00104143,A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis.,Hoffmann-La Roche,Germany
168,,1169.0,NCT00104143,A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis.,Hoffmann-La Roche,Poland
168,,1169.0,NCT00104143,A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis.,Hoffmann-La Roche,Russian Federation
168,,1169.0,NCT00104143,A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis.,Hoffmann-La Roche,Slovakia
168,,1169.0,NCT00104143,A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis.,Hoffmann-La Roche,Spain
168,,1169.0,NCT00104143,A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis.,Hoffmann-La Roche,United Kingdom
170,,1171.0,NCT00099307,Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis,National Institute of Neurological Disorders and Stroke (NINDS),United States
171,,1172.0,NCT00097188,A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis,"Genentech, Inc.",United States
172,,1173.0,NCT00094172,Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple Sclerosis,National Institute of Allergy and Infectious Diseases (NIAID),United States
172,,1173.0,NCT00094172,Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple Sclerosis,National Institute of Allergy and Infectious Diseases (NIAID),Canada
179,,1180.0,NCT00053417,Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis,Acorda Therapeutics,United States
179,,1180.0,NCT00053417,Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis,Acorda Therapeutics,Canada
183,,1184.0,NCT00037947,Auditory Function in Patients With and Without Multiple Sclerosis,US Department of Veterans Affairs,United States
188,,1189.0,NCT00011375,Rolipram to Treat Multiple Sclerosis,National Institute of Neurological Disorders and Stroke (NINDS),United States
195,,1196.0,NCT00001934,Zenapax to Treat Multiple Sclerosis,National Institute of Neurological Disorders and Stroke (NINDS),United States
196,,1197.0,NCT00001781,"Safety, Tolerability, and Effectiveness of CGP77116 in Patients With Multiple Sclerosis (MS)",National Institute of Neurological Disorders and Stroke (NINDS),United States
197,,1198.0,NCT00001669,A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients,National Institute of Neurological Disorders and Stroke (NINDS),United States
198,,1199.0,NCT00001248,Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS),National Institute of Neurological Disorders and Stroke (NINDS),United States
199,,1200.0,NCT04856384,Effect of Variance on Error Correction During Coupling,Hasselt University,Belgium
201,,1202.0,NCT01442233,Plasma Exchanges in Multiple Sclerosis (MS) Relapses,"University Hospital, Bordeaux",France
204,,1205.0,NCT04756687,Real World Analysis on Lymphocyte Reconstitution After Lymphopenia in Participants Treated by Tecfidera,Biogen,France
205,,1206.0,NCT04655222,Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program,Biogen,Germany
208,,1209.0,NCT03963375,Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis,Washington University School of Medicine,United States
210,,1211.0,NCT02675413,Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS,Washington University School of Medicine,United States
211,,1212.0,NCT01143441,Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS),National Institute of Neurological Disorders and Stroke (NINDS),United States
212,,1213.0,NCT00461396,"Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron",Bayer,United States
213,,1214.0,NCT00076934,Safety of RG2077 in Patients With Multiple Sclerosis,National Institute of Allergy and Infectious Diseases (NIAID),United States
218,,1219.0,NCT01854359,Idebenone for Primary Progressive Multiple Sclerosis,National Institute of Allergy and Infectious Diseases (NIAID),United States
220,,1221.0,NCT02525874,Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).,Biogen,United States
220,,1221.0,NCT02525874,Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).,Biogen,Belgium
220,,1221.0,NCT02525874,Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).,Biogen,Bulgaria
220,,1221.0,NCT02525874,Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).,Biogen,Kuwait
220,,1221.0,NCT02525874,Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).,Biogen,Lithuania
220,,1221.0,NCT02525874,Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).,Biogen,Poland
220,,1221.0,NCT02525874,Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).,Biogen,Turkey
221,,1222.0,NCT02423083,Oral Guanabenz for Multiple Sclerosis,National Institute of Neurological Disorders and Stroke (NINDS),United States
224,,1225.0,NCT01930708,A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes,Biogen,Austria
224,,1225.0,NCT01930708,A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes,Biogen,Belgium
224,,1225.0,NCT01930708,A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes,Biogen,Canada
224,,1225.0,NCT01930708,A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes,Biogen,Czechia
224,,1225.0,NCT01930708,A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes,Biogen,France
224,,1225.0,NCT01930708,A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes,Biogen,Hungary
224,,1225.0,NCT01930708,A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes,Biogen,Italy
224,,1225.0,NCT01930708,A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes,Biogen,Portugal
224,,1225.0,NCT01930708,A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes,Biogen,Slovakia
224,,1225.0,NCT01930708,A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes,Biogen,Slovenia
224,,1225.0,NCT01930708,A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes,Biogen,Spain
225,,1226.0,NCT01838668,An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),Biogen,Czechia
225,,1226.0,NCT01838668,An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),Biogen,Japan
225,,1226.0,NCT01838668,An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),Biogen,"Korea, Republic of"
225,,1226.0,NCT01838668,An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),Biogen,Poland
225,,1226.0,NCT01838668,An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),Biogen,Taiwan
226,,1227.0,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,Biogen,United States
226,,1227.0,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,Biogen,Argentina
226,,1227.0,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,Biogen,Australia
226,,1227.0,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,Biogen,Brazil
226,,1227.0,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,Biogen,Canada
226,,1227.0,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,Biogen,Czechia
226,,1227.0,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,Biogen,Denmark
226,,1227.0,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,Biogen,France
226,,1227.0,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,Biogen,Georgia
226,,1227.0,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,Biogen,Germany
226,,1227.0,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,Biogen,Greece
226,,1227.0,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,Biogen,Hungary
226,,1227.0,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,Biogen,India
226,,1227.0,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,Biogen,Ireland
226,,1227.0,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,Biogen,Israel
226,,1227.0,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,Biogen,Italy
226,,1227.0,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,Biogen,Mexico
226,,1227.0,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,Biogen,"Moldova, Republic of"
226,,1227.0,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,Biogen,Poland
226,,1227.0,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,Biogen,Romania
226,,1227.0,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,Biogen,Russian Federation
226,,1227.0,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,Biogen,Serbia
226,,1227.0,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,Biogen,Spain
226,,1227.0,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,Biogen,Sweden
226,,1227.0,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,Biogen,Switzerland
226,,1227.0,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,Biogen,Ukraine
226,,1227.0,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,Biogen,United Kingdom
227,,1228.0,NCT01416155,Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis,Biogen,Japan
228,,1229.0,NCT01244139,Safety Study of BIIB033 in Subjects With Multiple Sclerosis,Biogen,United States
229,,1230.0,NCT01156311,BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis,Biogen,United States
236,,1237.0,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,Sanofi,United States
236,,1237.0,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,Sanofi,Argentina
236,,1237.0,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,Sanofi,Australia
236,,1237.0,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,Sanofi,Austria
236,,1237.0,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,Sanofi,Belgium
236,,1237.0,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,Sanofi,Brazil
236,,1237.0,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,Sanofi,Canada
236,,1237.0,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,Sanofi,Chile
236,,1237.0,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,Sanofi,Colombia
236,,1237.0,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,Sanofi,Denmark
236,,1237.0,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,Sanofi,Estonia
236,,1237.0,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,Sanofi,Finland
236,,1237.0,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,Sanofi,France
236,,1237.0,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,Sanofi,Germany
236,,1237.0,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,Sanofi,Greece
236,,1237.0,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,Sanofi,Hungary
236,,1237.0,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,Sanofi,Italy
236,,1237.0,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,Sanofi,"Korea, Republic of"
236,,1237.0,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,Sanofi,Lithuania
236,,1237.0,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,Sanofi,Netherlands
236,,1237.0,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,Sanofi,Norway
236,,1237.0,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,Sanofi,Portugal
236,,1237.0,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,Sanofi,Russian Federation
236,,1237.0,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,Sanofi,Slovakia
236,,1237.0,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,Sanofi,Spain
236,,1237.0,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,Sanofi,Sweden
236,,1237.0,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,Sanofi,Tunisia
236,,1237.0,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,Sanofi,United Kingdom
241,,1242.0,NCT04847596,A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab,Novartis Pharmaceuticals,United States
242,,1243.0,NCT04782466,ATOMIC (Active Teens Multiple Sclerosis) Physical Activity Research Program,The Hospital for Sick Children,United States
242,,1243.0,NCT04782466,ATOMIC (Active Teens Multiple Sclerosis) Physical Activity Research Program,The Hospital for Sick Children,Canada
243,,1244.0,NCT04667117,A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab,Novartis Pharmaceuticals,United States
246,,1247.0,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),Hoffmann-La Roche,United States
246,,1247.0,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),Hoffmann-La Roche,Austria
246,,1247.0,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),Hoffmann-La Roche,Brazil
246,,1247.0,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),Hoffmann-La Roche,Bulgaria
246,,1247.0,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),Hoffmann-La Roche,Canada
246,,1247.0,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),Hoffmann-La Roche,Denmark
246,,1247.0,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),Hoffmann-La Roche,France
246,,1247.0,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),Hoffmann-La Roche,Greece
246,,1247.0,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),Hoffmann-La Roche,Italy
246,,1247.0,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),Hoffmann-La Roche,"Korea, Republic of"
246,,1247.0,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),Hoffmann-La Roche,Mexico
246,,1247.0,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),Hoffmann-La Roche,Poland
246,,1247.0,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),Hoffmann-La Roche,Russian Federation
246,,1247.0,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),Hoffmann-La Roche,Turkey
247,,1248.0,NCT04586010,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),Hoffmann-La Roche,United States
247,,1248.0,NCT04586010,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),Hoffmann-La Roche,Argentina
247,,1248.0,NCT04586010,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),Hoffmann-La Roche,Finland
247,,1248.0,NCT04586010,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),Hoffmann-La Roche,Germany
247,,1248.0,NCT04586010,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),Hoffmann-La Roche,Hong Kong
247,,1248.0,NCT04586010,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),Hoffmann-La Roche,Italy
247,,1248.0,NCT04586010,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),Hoffmann-La Roche,Peru
247,,1248.0,NCT04586010,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),Hoffmann-La Roche,Portugal
247,,1248.0,NCT04586010,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),Hoffmann-La Roche,Russian Federation
247,,1248.0,NCT04586010,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),Hoffmann-La Roche,Spain
247,,1248.0,NCT04586010,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),Hoffmann-La Roche,Taiwan
247,,1248.0,NCT04586010,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),Hoffmann-La Roche,Ukraine
248,,1249.0,NCT04510220,9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis,Brigham and Women's Hospital,United States
249,,1250.0,NCT04486716,"A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis",Novartis Pharmaceuticals,United States
249,,1250.0,NCT04486716,"A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis",Novartis Pharmaceuticals,Puerto Rico
250,,1251.0,NCT04441229,Mobile Attentional Bias Modification Training in Pediatric MS,NYU Langone Health,United States
251,,1252.0,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,United States
251,,1252.0,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Argentina
251,,1252.0,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Belgium
251,,1252.0,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Brazil
251,,1252.0,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Canada
251,,1252.0,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Chile
251,,1252.0,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Croatia
251,,1252.0,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Czechia
251,,1252.0,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,France
251,,1252.0,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Germany
251,,1252.0,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Greece
251,,1252.0,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Hungary
251,,1252.0,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,India
251,,1252.0,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Israel
251,,1252.0,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,"Korea, Republic of"
251,,1252.0,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Latvia
251,,1252.0,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Netherlands
251,,1252.0,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Norway
251,,1252.0,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Portugal
251,,1252.0,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Puerto Rico
251,,1252.0,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Russian Federation
251,,1252.0,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Serbia
251,,1252.0,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Slovakia
251,,1252.0,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Spain
251,,1252.0,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Turkey
251,,1252.0,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Ukraine
251,,1252.0,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,United Kingdom
252,,1253.0,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,United States
252,,1253.0,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Belarus
252,,1253.0,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Bulgaria
252,,1253.0,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Canada
252,,1253.0,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,China
252,,1253.0,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Czechia
252,,1253.0,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Denmark
252,,1253.0,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Estonia
252,,1253.0,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Finland
252,,1253.0,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Germany
252,,1253.0,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Italy
252,,1253.0,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Japan
252,,1253.0,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Lithuania
252,,1253.0,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Poland
252,,1253.0,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Romania
252,,1253.0,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Russian Federation
252,,1253.0,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Spain
252,,1253.0,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Sweden
252,,1253.0,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Taiwan
252,,1253.0,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Turkey
252,,1253.0,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Ukraine
254,,1255.0,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,Novartis Pharmaceuticals,United States
254,,1255.0,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,Novartis Pharmaceuticals,Australia
254,,1255.0,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,Novartis Pharmaceuticals,Austria
254,,1255.0,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,Novartis Pharmaceuticals,Belgium
254,,1255.0,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,Novartis Pharmaceuticals,Bulgaria
254,,1255.0,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,Novartis Pharmaceuticals,Canada
254,,1255.0,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,Novartis Pharmaceuticals,Czechia
254,,1255.0,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,Novartis Pharmaceuticals,Germany
254,,1255.0,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,Novartis Pharmaceuticals,Greece
254,,1255.0,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,Novartis Pharmaceuticals,Hungary
254,,1255.0,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,Novartis Pharmaceuticals,Italy
254,,1255.0,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,Novartis Pharmaceuticals,Lebanon
254,,1255.0,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,Novartis Pharmaceuticals,Mexico
254,,1255.0,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,Novartis Pharmaceuticals,Norway
254,,1255.0,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,Novartis Pharmaceuticals,Poland
254,,1255.0,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,Novartis Pharmaceuticals,Portugal
254,,1255.0,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,Novartis Pharmaceuticals,Russian Federation
254,,1255.0,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,Novartis Pharmaceuticals,Saudi Arabia
254,,1255.0,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,Novartis Pharmaceuticals,Slovakia
254,,1255.0,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,Novartis Pharmaceuticals,Spain
254,,1255.0,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,Novartis Pharmaceuticals,Switzerland
254,,1255.0,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,Novartis Pharmaceuticals,Turkey
259,,1260.0,NCT03996291,Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis,Sanofi,United States
259,,1260.0,NCT03996291,Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis,Sanofi,Canada
259,,1260.0,NCT03996291,Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis,Sanofi,Czechia
259,,1260.0,NCT03996291,Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis,Sanofi,Estonia
259,,1260.0,NCT03996291,Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis,Sanofi,France
259,,1260.0,NCT03996291,Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis,Sanofi,Netherlands
259,,1260.0,NCT03996291,Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis,Sanofi,Russian Federation
259,,1260.0,NCT03996291,Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis,Sanofi,Spain
259,,1260.0,NCT03996291,Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis,Sanofi,Ukraine
260,,1261.0,NCT03889639,Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis,Sanofi,United States
260,,1261.0,NCT03889639,Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis,Sanofi,Canada
260,,1261.0,NCT03889639,Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis,Sanofi,Czechia
260,,1261.0,NCT03889639,Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis,Sanofi,Estonia
260,,1261.0,NCT03889639,Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis,Sanofi,France
260,,1261.0,NCT03889639,Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis,Sanofi,Netherlands
260,,1261.0,NCT03889639,Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis,Sanofi,Russian Federation
260,,1261.0,NCT03889639,Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis,Sanofi,Slovakia
260,,1261.0,NCT03889639,Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis,Sanofi,Spain
260,,1261.0,NCT03889639,Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis,Sanofi,Ukraine
261,,1262.0,NCT03856619,To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis,Sanofi,India
262,,1263.0,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",Novartis Pharmaceuticals,United States
262,,1263.0,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",Novartis Pharmaceuticals,Argentina
262,,1263.0,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",Novartis Pharmaceuticals,Australia
262,,1263.0,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",Novartis Pharmaceuticals,Austria
262,,1263.0,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",Novartis Pharmaceuticals,Belgium
262,,1263.0,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",Novartis Pharmaceuticals,Bulgaria
262,,1263.0,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",Novartis Pharmaceuticals,Canada
262,,1263.0,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",Novartis Pharmaceuticals,Croatia
262,,1263.0,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",Novartis Pharmaceuticals,Czechia
262,,1263.0,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",Novartis Pharmaceuticals,Denmark
262,,1263.0,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",Novartis Pharmaceuticals,Estonia
262,,1263.0,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",Novartis Pharmaceuticals,Finland
262,,1263.0,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",Novartis Pharmaceuticals,France
262,,1263.0,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",Novartis Pharmaceuticals,Germany
262,,1263.0,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",Novartis Pharmaceuticals,Greece
262,,1263.0,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",Novartis Pharmaceuticals,Hungary
262,,1263.0,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",Novartis Pharmaceuticals,India
262,,1263.0,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",Novartis Pharmaceuticals,Israel
262,,1263.0,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",Novartis Pharmaceuticals,Japan
262,,1263.0,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",Novartis Pharmaceuticals,Latvia
262,,1263.0,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",Novartis Pharmaceuticals,Lithuania
262,,1263.0,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",Novartis Pharmaceuticals,Mexico
262,,1263.0,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",Novartis Pharmaceuticals,Netherlands
262,,1263.0,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",Novartis Pharmaceuticals,Norway
262,,1263.0,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",Novartis Pharmaceuticals,Peru
262,,1263.0,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",Novartis Pharmaceuticals,Poland
262,,1263.0,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",Novartis Pharmaceuticals,Portugal
262,,1263.0,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",Novartis Pharmaceuticals,Russian Federation
262,,1263.0,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",Novartis Pharmaceuticals,Slovakia
262,,1263.0,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",Novartis Pharmaceuticals,South Africa
262,,1263.0,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",Novartis Pharmaceuticals,Spain
262,,1263.0,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",Novartis Pharmaceuticals,Sweden
262,,1263.0,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",Novartis Pharmaceuticals,Switzerland
262,,1263.0,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",Novartis Pharmaceuticals,Taiwan
262,,1263.0,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",Novartis Pharmaceuticals,Thailand
262,,1263.0,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",Novartis Pharmaceuticals,Turkey
262,,1263.0,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",Novartis Pharmaceuticals,United Kingdom
263,,1264.0,NCT03257358,A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod,Novartis Pharmaceuticals,United States
264,,1265.0,NCT03249714,Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab,Novartis Pharmaceuticals,Japan
264,,1265.0,NCT03249714,Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab,Novartis Pharmaceuticals,Russian Federation
265,,1266.0,NCT03137602,ATOMIC (Active Teens With MultIple sClerosis) Teens: A Feasibility Study,The Hospital for Sick Children,Canada
266,,1267.0,NCT03067025,"Sleep, Physical Activity and Multiple Sclerosis Symptoms in Pediatric Multiple Sclerosis",The Hospital for Sick Children,Canada
267,,1268.0,NCT03066752,Cognitive Dysfunction in MS: Using Altered Brain Oscillation to Link Molecular Mechanisms With Clinical Outcomes,The Hospital for Sick Children,Canada
268,,1269.0,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,Novartis Pharmaceuticals,United States
268,,1269.0,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,Novartis Pharmaceuticals,Argentina
268,,1269.0,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,Novartis Pharmaceuticals,Australia
268,,1269.0,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,Novartis Pharmaceuticals,Belgium
268,,1269.0,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,Novartis Pharmaceuticals,Bulgaria
268,,1269.0,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,Novartis Pharmaceuticals,Canada
268,,1269.0,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,Novartis Pharmaceuticals,Croatia
268,,1269.0,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,Novartis Pharmaceuticals,Czechia
268,,1269.0,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,Novartis Pharmaceuticals,Denmark
268,,1269.0,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,Novartis Pharmaceuticals,Estonia
268,,1269.0,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,Novartis Pharmaceuticals,France
268,,1269.0,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,Novartis Pharmaceuticals,Germany
268,,1269.0,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,Novartis Pharmaceuticals,Greece
268,,1269.0,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,Novartis Pharmaceuticals,Hungary
268,,1269.0,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,Novartis Pharmaceuticals,India
268,,1269.0,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,Novartis Pharmaceuticals,Israel
268,,1269.0,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,Novartis Pharmaceuticals,Italy
268,,1269.0,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,Novartis Pharmaceuticals,Mexico
268,,1269.0,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,Novartis Pharmaceuticals,Netherlands
268,,1269.0,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,Novartis Pharmaceuticals,Poland
268,,1269.0,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,Novartis Pharmaceuticals,Puerto Rico
268,,1269.0,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,Novartis Pharmaceuticals,Russian Federation
268,,1269.0,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,Novartis Pharmaceuticals,Slovakia
268,,1269.0,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,Novartis Pharmaceuticals,Spain
268,,1269.0,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,Novartis Pharmaceuticals,Sweden
268,,1269.0,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,Novartis Pharmaceuticals,Switzerland
268,,1269.0,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,Novartis Pharmaceuticals,Thailand
268,,1269.0,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,Novartis Pharmaceuticals,Turkey
268,,1269.0,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,Novartis Pharmaceuticals,United Kingdom
269,,1270.0,NCT02241785,Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies,Biogen,United States
271,,1272.0,NCT02142192,Natalizumab Subcutaneous Immunogenicity and Safety Study,Biogen,Belgium
273,,1274.0,NCT01939002,Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017),Biogen,United States
275,,1276.0,NCT01601119,Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients,"Merck KGaA, Darmstadt, Germany",United Kingdom
276,,1277.0,NCT01601080,"An Observational, Retrospective, UK & Ireland Audit of Patient Adherence to Rebif® Injections Using the RebiSmart™ Injection Device","Merck KGaA, Darmstadt, Germany",United Kingdom
277,,1278.0,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,United States
277,,1278.0,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Argentina
277,,1278.0,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Belarus
277,,1278.0,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Belgium
277,,1278.0,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Bosnia and Herzegovina
277,,1278.0,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Brazil
277,,1278.0,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Bulgaria
277,,1278.0,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Canada
277,,1278.0,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Croatia
277,,1278.0,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Czechia
277,,1278.0,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,France
277,,1278.0,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Germany
277,,1278.0,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Ireland
277,,1278.0,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Italy
277,,1278.0,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Mexico
277,,1278.0,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Norway
277,,1278.0,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Poland
277,,1278.0,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Russian Federation
277,,1278.0,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Slovakia
277,,1278.0,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Spain
277,,1278.0,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Sweden
277,,1278.0,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Turkey
277,,1278.0,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Ukraine
277,,1278.0,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,United Kingdom
279,,1280.0,NCT01396343,Environmental and Genetic Risk Factors for Pediatric Multiple Sclerosis,"University of California, San Francisco",United States
280,,1281.0,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,Biogen,United States
280,,1281.0,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,Biogen,Belgium
280,,1281.0,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,Biogen,Bulgaria
280,,1281.0,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,Biogen,Canada
280,,1281.0,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,Biogen,Chile
280,,1281.0,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,Biogen,Colombia
280,,1281.0,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,Biogen,Croatia
280,,1281.0,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,Biogen,Czech Republic
280,,1281.0,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,Biogen,Estonia
280,,1281.0,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,Biogen,France
280,,1281.0,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,Biogen,Georgia
280,,1281.0,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,Biogen,Germany
280,,1281.0,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,Biogen,Greece
280,,1281.0,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,Biogen,India
280,,1281.0,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,Biogen,Latvia
280,,1281.0,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,Biogen,Mexico
280,,1281.0,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,Biogen,Netherlands
280,,1281.0,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,Biogen,New Zealand
280,,1281.0,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,Biogen,Peru
280,,1281.0,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,Biogen,Poland
280,,1281.0,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,Biogen,Romania
280,,1281.0,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,Biogen,Russian Federation
280,,1281.0,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,Biogen,Serbia
280,,1281.0,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,Biogen,Spain
280,,1281.0,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,Biogen,Ukraine
280,,1281.0,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,Biogen,United Kingdom
281,,1282.0,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,United States
281,,1282.0,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Argentina
281,,1282.0,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Australia
281,,1282.0,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Austria
281,,1282.0,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Belgium
281,,1282.0,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Brazil
281,,1282.0,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Bulgaria
281,,1282.0,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Chile
281,,1282.0,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Czechia
281,,1282.0,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Estonia
281,,1282.0,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Finland
281,,1282.0,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,France
281,,1282.0,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Germany
281,,1282.0,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Hungary
281,,1282.0,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Israel
281,,1282.0,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Italy
281,,1282.0,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Latvia
281,,1282.0,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Lithuania
281,,1282.0,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Mexico
281,,1282.0,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Netherlands
281,,1282.0,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Peru
281,,1282.0,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Poland
281,,1282.0,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Portugal
281,,1282.0,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Russian Federation
281,,1282.0,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Serbia
281,,1282.0,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Slovakia
281,,1282.0,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,South Africa
281,,1282.0,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Spain
281,,1282.0,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Switzerland
281,,1282.0,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Tunisia
281,,1282.0,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,Ukraine
281,,1282.0,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,Hoffmann-La Roche,United Kingdom
282,,1283.0,NCT01199861,Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS),Novartis,Belgium
282,,1283.0,NCT01199861,Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS),Novartis,Canada
282,,1283.0,NCT01199861,Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS),Novartis,Finland
282,,1283.0,NCT01199861,Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS),Novartis,France
282,,1283.0,NCT01199861,Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS),Novartis,Guatemala
282,,1283.0,NCT01199861,Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS),Novartis,Poland
282,,1283.0,NCT01199861,Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS),Novartis,Spain
282,,1283.0,NCT01199861,Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS),Novartis,Switzerland
282,,1283.0,NCT01199861,Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS),Novartis,United Kingdom
283,,1284.0,NCT01127750,Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients,Novartis,Australia
283,,1284.0,NCT01127750,Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients,Novartis,Austria
283,,1284.0,NCT01127750,Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients,Novartis,Belgium
283,,1284.0,NCT01127750,Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients,Novartis,Canada
283,,1284.0,NCT01127750,Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients,Novartis,Czech Republic
283,,1284.0,NCT01127750,Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients,Novartis,Denmark
283,,1284.0,NCT01127750,Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients,Novartis,Finland
283,,1284.0,NCT01127750,Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients,Novartis,Germany
283,,1284.0,NCT01127750,Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients,Novartis,Greece
283,,1284.0,NCT01127750,Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients,Novartis,Hungary
283,,1284.0,NCT01127750,Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients,Novartis,Ireland
283,,1284.0,NCT01127750,Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients,Novartis,Italy
283,,1284.0,NCT01127750,Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients,Novartis,Netherlands
283,,1284.0,NCT01127750,Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients,Novartis,Norway
283,,1284.0,NCT01127750,Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients,Novartis,Poland
283,,1284.0,NCT01127750,Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients,Novartis,Portugal
283,,1284.0,NCT01127750,Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients,Novartis,Russian Federation
283,,1284.0,NCT01127750,Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients,Novartis,Slovakia
283,,1284.0,NCT01127750,Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients,Novartis,Spain
283,,1284.0,NCT01127750,Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients,Novartis,Sweden
283,,1284.0,NCT01127750,Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients,Novartis,Switzerland
283,,1284.0,NCT01127750,Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients,Novartis,Turkey
283,,1284.0,NCT01127750,Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients,Novartis,United Kingdom
284,,1285.0,NCT01070836,JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab,Biogen,United States
284,,1285.0,NCT01070836,JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab,Biogen,Puerto Rico
286,,1287.0,NCT01034579,The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial,EMD Serono,United States
287,,1288.0,NCT01006941,Trichuris Suis Ova Therapy for Relapsing Multiple Sclerosis - a Safety Study,"Rigshospitalet, Denmark",Denmark
289,,1290.0,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,Biogen,United States
289,,1290.0,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,Biogen,Belgium
289,,1290.0,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,Biogen,Bulgaria
289,,1290.0,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,Biogen,Canada
289,,1290.0,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,Biogen,Chile
289,,1290.0,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,Biogen,Colombia
289,,1290.0,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,Biogen,Croatia
289,,1290.0,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,Biogen,Czech Republic
289,,1290.0,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,Biogen,Estonia
289,,1290.0,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,Biogen,France
289,,1290.0,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,Biogen,Georgia
289,,1290.0,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,Biogen,Germany
289,,1290.0,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,Biogen,Greece
289,,1290.0,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,Biogen,India
289,,1290.0,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,Biogen,Latvia
289,,1290.0,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,Biogen,Mexico
289,,1290.0,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,Biogen,Netherlands
289,,1290.0,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,Biogen,New Zealand
289,,1290.0,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,Biogen,Peru
289,,1290.0,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,Biogen,Poland
289,,1290.0,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,Biogen,Romania
289,,1290.0,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,Biogen,Russian Federation
289,,1290.0,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,Biogen,Serbia
289,,1290.0,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,Biogen,Spain
289,,1290.0,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,Biogen,Ukraine
289,,1290.0,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,Biogen,United Kingdom
290,,1291.0,NCT00853762,"Atacicept in Multiple Sclerosis Extension Study, Phase II",EMD Serono,United States
290,,1291.0,NCT00853762,"Atacicept in Multiple Sclerosis Extension Study, Phase II",EMD Serono,Australia
290,,1291.0,NCT00853762,"Atacicept in Multiple Sclerosis Extension Study, Phase II",EMD Serono,Belgium
290,,1291.0,NCT00853762,"Atacicept in Multiple Sclerosis Extension Study, Phase II",EMD Serono,Canada
290,,1291.0,NCT00853762,"Atacicept in Multiple Sclerosis Extension Study, Phase II",EMD Serono,Czech Republic
290,,1291.0,NCT00853762,"Atacicept in Multiple Sclerosis Extension Study, Phase II",EMD Serono,France
290,,1291.0,NCT00853762,"Atacicept in Multiple Sclerosis Extension Study, Phase II",EMD Serono,Germany
290,,1291.0,NCT00853762,"Atacicept in Multiple Sclerosis Extension Study, Phase II",EMD Serono,Lebanon
290,,1291.0,NCT00853762,"Atacicept in Multiple Sclerosis Extension Study, Phase II",EMD Serono,Lithuania
290,,1291.0,NCT00853762,"Atacicept in Multiple Sclerosis Extension Study, Phase II",EMD Serono,Netherlands
290,,1291.0,NCT00853762,"Atacicept in Multiple Sclerosis Extension Study, Phase II",EMD Serono,New Caledonia
290,,1291.0,NCT00853762,"Atacicept in Multiple Sclerosis Extension Study, Phase II",EMD Serono,Russian Federation
290,,1291.0,NCT00853762,"Atacicept in Multiple Sclerosis Extension Study, Phase II",EMD Serono,Spain
290,,1291.0,NCT00853762,"Atacicept in Multiple Sclerosis Extension Study, Phase II",EMD Serono,Sweden
290,,1291.0,NCT00853762,"Atacicept in Multiple Sclerosis Extension Study, Phase II",EMD Serono,Switzerland
290,,1291.0,NCT00853762,"Atacicept in Multiple Sclerosis Extension Study, Phase II",EMD Serono,Ukraine
290,,1291.0,NCT00853762,"Atacicept in Multiple Sclerosis Extension Study, Phase II",EMD Serono,United Kingdom
292,,1293.0,NCT00642902,A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS),EMD Serono,United States
292,,1293.0,NCT00642902,A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS),EMD Serono,Australia
292,,1293.0,NCT00642902,A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS),EMD Serono,Austria
292,,1293.0,NCT00642902,A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS),EMD Serono,Belgium
292,,1293.0,NCT00642902,A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS),EMD Serono,Canada
292,,1293.0,NCT00642902,A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS),EMD Serono,Czech Republic
292,,1293.0,NCT00642902,A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS),EMD Serono,France
292,,1293.0,NCT00642902,A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS),EMD Serono,Germany
292,,1293.0,NCT00642902,A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS),EMD Serono,Lebanon
292,,1293.0,NCT00642902,A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS),EMD Serono,Lithuania
292,,1293.0,NCT00642902,A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS),EMD Serono,Netherlands
292,,1293.0,NCT00642902,A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS),EMD Serono,Russian Federation
292,,1293.0,NCT00642902,A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS),EMD Serono,Spain
292,,1293.0,NCT00642902,A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS),EMD Serono,Sweden
292,,1293.0,NCT00642902,A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS),EMD Serono,Switzerland
292,,1293.0,NCT00642902,A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS),EMD Serono,Ukraine
292,,1293.0,NCT00642902,A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS),EMD Serono,United Kingdom
293,,1294.0,NCT00619307,Transition to Rebif New Formulation,"Merck KGaA, Darmstadt, Germany",France
293,,1294.0,NCT00619307,Transition to Rebif New Formulation,"Merck KGaA, Darmstadt, Germany",Germany
294,,1295.0,NCT00472797,Rebif New Formulation (RNF) Quality of Life (QOL) Study,EMD Serono,United States
299,,1300.0,NCT03423121,A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis,Johns Hopkins University,United States
302,,1303.0,NCT02977533,A Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis,Sanofi,Germany
303,,1304.0,NCT02583594,A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis,"Genzyme, a Sanofi Company",Spain
305,,1306.0,NCT02313285,A Long-term Follow-up Study Of Multiple Sclerosis Patients Who Participated In Genzyme-sponsored Studies of GZ402668,"Genzyme, a Sanofi Company",Germany
306,,1307.0,NCT02282826,"A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis","Genzyme, a Sanofi Company",Germany
309,,1310.0,NCT01305837,Cyclic Oral Methylprednisolone Trial in Multiple Sclerosis,"Rigshospitalet, Denmark",Denmark
310,,1311.0,NCT04377555,Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab.,"Genentech, Inc.",United States
310,,1311.0,NCT04377555,Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab.,"Genentech, Inc.",Kenya
310,,1311.0,NCT04377555,Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab.,"Genentech, Inc.",Puerto Rico
316,,1317.0,NCT05058729,MS PATHS COVID-19 Questionnaire Data Linkage Sub-Study,Biogen,United States
320,,1321.0,NCT04203498,Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis,GW Pharmaceuticals Ltd.,United States
320,,1321.0,NCT04203498,Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis,GW Pharmaceuticals Ltd.,Czechia
320,,1321.0,NCT04203498,Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis,GW Pharmaceuticals Ltd.,Poland
321,,1322.0,NCT04121468,A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children With Multiple Sclerosis,The Hospital for Sick Children,Canada
322,,1323.0,NCT03972306,"A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis",Hoffmann-La Roche,United States
322,,1323.0,NCT03972306,"A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis",Hoffmann-La Roche,Canada
323,,1324.0,NCT03961204,Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS),"EMD Serono Research & Development Institute, Inc.",United States
323,,1324.0,NCT03961204,Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS),"EMD Serono Research & Development Institute, Inc.",Australia
323,,1324.0,NCT03961204,Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS),"EMD Serono Research & Development Institute, Inc.",Austria
323,,1324.0,NCT03961204,Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS),"EMD Serono Research & Development Institute, Inc.",Belgium
323,,1324.0,NCT03961204,Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS),"EMD Serono Research & Development Institute, Inc.",Bulgaria
323,,1324.0,NCT03961204,Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS),"EMD Serono Research & Development Institute, Inc.",Canada
323,,1324.0,NCT03961204,Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS),"EMD Serono Research & Development Institute, Inc.",Croatia
323,,1324.0,NCT03961204,Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS),"EMD Serono Research & Development Institute, Inc.",Czechia
323,,1324.0,NCT03961204,Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS),"EMD Serono Research & Development Institute, Inc.",Estonia
323,,1324.0,NCT03961204,Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS),"EMD Serono Research & Development Institute, Inc.",Finland
323,,1324.0,NCT03961204,Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS),"EMD Serono Research & Development Institute, Inc.",France
323,,1324.0,NCT03961204,Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS),"EMD Serono Research & Development Institute, Inc.",Georgia
323,,1324.0,NCT03961204,Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS),"EMD Serono Research & Development Institute, Inc.",Germany
323,,1324.0,NCT03961204,Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS),"EMD Serono Research & Development Institute, Inc.",Italy
323,,1324.0,NCT03961204,Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS),"EMD Serono Research & Development Institute, Inc.","Korea, Republic of"
323,,1324.0,NCT03961204,Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS),"EMD Serono Research & Development Institute, Inc.",Lebanon
323,,1324.0,NCT03961204,Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS),"EMD Serono Research & Development Institute, Inc.",Lithuania
323,,1324.0,NCT03961204,Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS),"EMD Serono Research & Development Institute, Inc.",Norway
323,,1324.0,NCT03961204,Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS),"EMD Serono Research & Development Institute, Inc.",Poland
323,,1324.0,NCT03961204,Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS),"EMD Serono Research & Development Institute, Inc.",Portugal
323,,1324.0,NCT03961204,Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS),"EMD Serono Research & Development Institute, Inc.",Romania
323,,1324.0,NCT03961204,Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS),"EMD Serono Research & Development Institute, Inc.",Russian Federation
323,,1324.0,NCT03961204,Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS),"EMD Serono Research & Development Institute, Inc.",Serbia
323,,1324.0,NCT03961204,Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS),"EMD Serono Research & Development Institute, Inc.",Spain
323,,1324.0,NCT03961204,Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS),"EMD Serono Research & Development Institute, Inc.",Sweden
323,,1324.0,NCT03961204,Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS),"EMD Serono Research & Development Institute, Inc.",Switzerland
323,,1324.0,NCT03961204,Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS),"EMD Serono Research & Development Institute, Inc.",Tunisia
323,,1324.0,NCT03961204,Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS),"EMD Serono Research & Development Institute, Inc.",Ukraine
323,,1324.0,NCT03961204,Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS),"EMD Serono Research & Development Institute, Inc.",United Kingdom
328,,1329.0,NCT03135249,Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis,University of Texas Southwestern Medical Center,United States
329,,1330.0,NCT02739542,Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS),University of Texas Southwestern Medical Center,United States
331,,1332.0,NCT02352194,Physical Capacity and Rehabilitation of Patients With Multiple Sclerosis,Assistance Publique - Hôpitaux de Paris,France
336,,1337.0,NCT01710228,Alternative Treatment Paradigm for Natalizumab Trial,University of Texas Southwestern Medical Center,United States
337,,1338.0,NCT04982991,Single Ascending Dose Study of SAR443820 in Healthy Adult Chinese and Japanese Female and Male Participants,Sanofi,United Kingdom
344,,1345.0,NCT04918225,Motor Asymmetry in Progressive Multiple Sclerosis Patients,Rennes University Hospital,France
349,,1350.0,NCT02323269,Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve),Biogen,Canada
350,,1351.0,NCT00220506,Fatigue Treatment Using Provigil,Sheba Medical Center,Israel
351,,1352.0,NCT00220493,Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients,Sheba Medical Center,Israel
356,,1357.0,NCT02253264,A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients,Johns Hopkins University,United States
357,,1358.0,NCT01077466,Natalizumab Treatment of Progressive Multiple Sclerosis,"Rigshospitalet, Denmark",Denmark
359,,1360.0,NCT00559702,Safety Study of Natalizumab to Treat Multiple Sclerosis (MS),Biogen,United States
363,,1364.0,NCT03185065,"Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis",Johns Hopkins University,United States
365,,1366.0,NCT01490840,Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis,Novartis Pharmaceuticals,Germany
366,,1367.0,NCT02398461,An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse,Acorda Therapeutics,United States
368,,1369.0,NCT04940065,Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen,Novartis Pharmaceuticals,Japan
370,,1371.0,NCT04972929,Effects of Chiropractic Care on Cytokine Levels in Multiple Sclerosis,University of Alabama at Birmingham,United States
371,,1372.0,NCT04885894,An Examination of Cognitive Fatigue Using Functional Neuroimaging,Kessler Foundation,United States
375,,1376.0,NCT04565431,Examining Effects of Tysabri on Cognitive Fatigue Using fMRI,Kessler Foundation,United States
377,,1378.0,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,United States
377,,1378.0,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Argentina
377,,1378.0,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Australia
377,,1378.0,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Austria
377,,1378.0,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Brazil
377,,1378.0,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Canada
377,,1378.0,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Denmark
377,,1378.0,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,France
377,,1378.0,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Greece
377,,1378.0,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Hungary
377,,1378.0,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Israel
377,,1378.0,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Mexico
377,,1378.0,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Peru
377,,1378.0,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Poland
377,,1378.0,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Portugal
377,,1378.0,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Puerto Rico
377,,1378.0,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Russian Federation
377,,1378.0,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Spain
377,,1378.0,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Turkey
377,,1378.0,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Ukraine
377,,1378.0,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,United Kingdom
380,,1381.0,NCT04450030,Immunoadsorption Versus High-dose Intravenous Corticosteroids in Relapsing Multiple Sclerosis,University Hospital Muenster,Germany
381,,1382.0,NCT04448977,Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI,Kessler Foundation,United States
383,,1384.0,NCT04261790,Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis,Johns Hopkins University,United States
385,,1386.0,NCT04233970,Development and Evaluation of a Web-based Programme on Relapse Management for People With Multiple Sclerosis,Universitätsklinikum Hamburg-Eppendorf,Germany
386,,1387.0,NCT04221191,"Dimethyl Fumarate (DMF, Tecfidera®) Persistence in RR-MS Patients Included in the French Patient Support Program OroSEP",Biogen,France
387,,1388.0,NCT04220814,Evaluation of the Impact of Lesions of the Motor and Proprioceptive Brain and Pan-medullary Pathways on Their Clinically and Electrophysiologically Assessed Function in Multiple Sclerosis,Rennes University Hospital,France
390,,1391.0,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,United States
390,,1391.0,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Australia
390,,1391.0,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Austria
390,,1391.0,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Belgium
390,,1391.0,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Bulgaria
390,,1391.0,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Canada
390,,1391.0,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Colombia
390,,1391.0,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Croatia
390,,1391.0,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Egypt
390,,1391.0,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,France
390,,1391.0,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Georgia
390,,1391.0,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Germany
390,,1391.0,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Hungary
390,,1391.0,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Ireland
390,,1391.0,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Italy
390,,1391.0,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Mexico
390,,1391.0,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,New Zealand
390,,1391.0,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Poland
390,,1391.0,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Portugal
390,,1391.0,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Romania
390,,1391.0,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Russian Federation
390,,1391.0,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Serbia
390,,1391.0,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Spain
390,,1391.0,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Ukraine
390,,1391.0,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,United Kingdom
393,,1394.0,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",Biogen,United States
393,,1394.0,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",Biogen,Argentina
393,,1394.0,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",Biogen,Australia
393,,1394.0,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",Biogen,Belgium
393,,1394.0,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",Biogen,Bulgaria
393,,1394.0,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",Biogen,Croatia
393,,1394.0,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",Biogen,Czechia
393,,1394.0,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",Biogen,France
393,,1394.0,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",Biogen,Germany
393,,1394.0,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",Biogen,Greece
393,,1394.0,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",Biogen,Hungary
393,,1394.0,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",Biogen,Israel
393,,1394.0,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",Biogen,Italy
393,,1394.0,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",Biogen,Kuwait
393,,1394.0,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",Biogen,Portugal
393,,1394.0,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",Biogen,Russian Federation
393,,1394.0,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",Biogen,Saudi Arabia
393,,1394.0,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",Biogen,Serbia
393,,1394.0,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",Biogen,Slovakia
393,,1394.0,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",Biogen,Spain
393,,1394.0,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",Biogen,Tunisia
393,,1394.0,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",Biogen,Turkey
395,,1396.0,NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,Biogen,United States
395,,1396.0,NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,Biogen,Colombia
395,,1396.0,NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,Biogen,Estonia
395,,1396.0,NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,Biogen,Hungary
395,,1396.0,NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,Biogen,Jordan
395,,1396.0,NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,Biogen,"Korea, Republic of"
395,,1396.0,NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,Biogen,Malaysia
395,,1396.0,NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,Biogen,Mexico
395,,1396.0,NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,Biogen,Saudi Arabia
395,,1396.0,NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,Biogen,Taiwan
395,,1396.0,NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,Biogen,Thailand
395,,1396.0,NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,Biogen,Tunisia
395,,1396.0,NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,Biogen,Turkey
397,,1398.0,NCT03768648,Cognition and MRI Markers in MS Patients With Aubagio® Treatment,"University Hospital, Bordeaux",France
400,,1401.0,NCT03689972,"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration",Biogen,United States
400,,1401.0,NCT03689972,"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration",Biogen,Australia
400,,1401.0,NCT03689972,"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration",Biogen,Belgium
400,,1401.0,NCT03689972,"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration",Biogen,Canada
400,,1401.0,NCT03689972,"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration",Biogen,France
400,,1401.0,NCT03689972,"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration",Biogen,Germany
400,,1401.0,NCT03689972,"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration",Biogen,Israel
400,,1401.0,NCT03689972,"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration",Biogen,Italy
400,,1401.0,NCT03689972,"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration",Biogen,Netherlands
400,,1401.0,NCT03689972,"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration",Biogen,Spain
400,,1401.0,NCT03689972,"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration",Biogen,United Kingdom
403,,1404.0,NCT03535298,Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS,The Cleveland Clinic,United States
403,,1404.0,NCT03535298,Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS,The Cleveland Clinic,United Kingdom
404,,1405.0,NCT03500328,Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial,Johns Hopkins University,United States
406,,1407.0,NCT03455582,Cognition Evolution and MRI Markers in PPMS Patients on 2 Years,"University Hospital, Bordeaux",France
407,,1408.0,NCT03387046,A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS),"Merck KGaA, Darmstadt, Germany",Italy
408,,1409.0,NCT03347370,A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis,Biogen,Germany
409,,1410.0,NCT03342638,Maximizing Outcome of Multiple Sclerosis Transplantation,Northwestern University,United States
412,,1413.0,NCT03205280,Clinical Decision Support System (CADIMS) for MS Diagnostic,Rennes University Hospital,France
415,,1416.0,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),Hoffmann-La Roche,United States
415,,1416.0,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),Hoffmann-La Roche,Argentina
415,,1416.0,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),Hoffmann-La Roche,Australia
415,,1416.0,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),Hoffmann-La Roche,Austria
415,,1416.0,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),Hoffmann-La Roche,Belgium
415,,1416.0,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),Hoffmann-La Roche,Brazil
415,,1416.0,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),Hoffmann-La Roche,Bulgaria
415,,1416.0,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),Hoffmann-La Roche,Canada
415,,1416.0,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),Hoffmann-La Roche,Croatia
415,,1416.0,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),Hoffmann-La Roche,Denmark
415,,1416.0,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),Hoffmann-La Roche,France
415,,1416.0,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),Hoffmann-La Roche,Germany
415,,1416.0,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),Hoffmann-La Roche,Hungary
415,,1416.0,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),Hoffmann-La Roche,Italy
415,,1416.0,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),Hoffmann-La Roche,Kuwait
415,,1416.0,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),Hoffmann-La Roche,Lebanon
415,,1416.0,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),Hoffmann-La Roche,Mexico
415,,1416.0,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),Hoffmann-La Roche,Netherlands
415,,1416.0,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),Hoffmann-La Roche,Norway
415,,1416.0,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),Hoffmann-La Roche,Poland
415,,1416.0,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),Hoffmann-La Roche,Portugal
415,,1416.0,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),Hoffmann-La Roche,Romania
415,,1416.0,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),Hoffmann-La Roche,Slovakia
415,,1416.0,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),Hoffmann-La Roche,Slovenia
415,,1416.0,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),Hoffmann-La Roche,Spain
415,,1416.0,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),Hoffmann-La Roche,Sweden
415,,1416.0,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),Hoffmann-La Roche,Switzerland
415,,1416.0,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),Hoffmann-La Roche,Turkey
415,,1416.0,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),Hoffmann-La Roche,United Kingdom
417,,1418.0,NCT02913157,Hydroxychloroquine in Primary Progressive Multiple Sclerosis,University of Calgary,Canada
419,,1420.0,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),Hoffmann-La Roche,Australia
419,,1420.0,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),Hoffmann-La Roche,Belgium
419,,1420.0,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),Hoffmann-La Roche,Czechia
419,,1420.0,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),Hoffmann-La Roche,Denmark
419,,1420.0,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),Hoffmann-La Roche,Estonia
419,,1420.0,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),Hoffmann-La Roche,Finland
419,,1420.0,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),Hoffmann-La Roche,France
419,,1420.0,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),Hoffmann-La Roche,Germany
419,,1420.0,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),Hoffmann-La Roche,Ireland
419,,1420.0,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),Hoffmann-La Roche,Italy
419,,1420.0,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),Hoffmann-La Roche,Netherlands
419,,1420.0,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),Hoffmann-La Roche,Norway
419,,1420.0,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),Hoffmann-La Roche,Spain
419,,1420.0,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),Hoffmann-La Roche,Sweden
419,,1420.0,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),Hoffmann-La Roche,Switzerland
419,,1420.0,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),Hoffmann-La Roche,Turkey
419,,1420.0,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),Hoffmann-La Roche,United Kingdom
425,,1426.0,NCT02652091,Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction,Bayer,United States
427,,1428.0,NCT02637856,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),"Genentech, Inc.",United States
427,,1428.0,NCT02637856,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),"Genentech, Inc.",Canada
429,,1430.0,NCT02598167,Participants Preferences to Disease Modifying Agents in Relapsing Remitting Multiple Sclerosis Condition,Hoffmann-La Roche,Spain
432,,1433.0,NCT02579681,Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012,Biogen,Italy
433,,1434.0,NCT02555215,Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),Biogen,United States
433,,1434.0,NCT02555215,Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),Biogen,Belgium
433,,1434.0,NCT02555215,Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),Biogen,Bulgaria
433,,1434.0,NCT02555215,Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),Biogen,Czechia
433,,1434.0,NCT02555215,Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),Biogen,Germany
433,,1434.0,NCT02555215,Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),Biogen,Kuwait
433,,1434.0,NCT02555215,Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),Biogen,Latvia
433,,1434.0,NCT02555215,Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),Biogen,Lebanon
433,,1434.0,NCT02555215,Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),Biogen,Poland
433,,1434.0,NCT02555215,Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),Biogen,Turkey
434,,1435.0,NCT02545868,A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis,Hoffmann-La Roche,United States
434,,1435.0,NCT02545868,A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis,Hoffmann-La Roche,Canada
437,,1438.0,NCT02493049,Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis (RRMS),University of Calgary,Canada
438,,1439.0,NCT02471560,Tecfidera and the Gut Microbiota,Biogen,Norway
439,,1440.0,NCT02461069,Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis,University Hospital Muenster,Germany
441,,1442.0,NCT02419378,Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential,University Hospital Muenster,Germany
443,,1444.0,NCT02410200,Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS,Biogen,United States
443,,1444.0,NCT02410200,Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS,Biogen,Belgium
443,,1444.0,NCT02410200,Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS,Biogen,Bulgaria
443,,1444.0,NCT02410200,Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS,Biogen,Czechia
443,,1444.0,NCT02410200,Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS,Biogen,Germany
443,,1444.0,NCT02410200,Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS,Biogen,Kuwait
443,,1444.0,NCT02410200,Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS,Biogen,Latvia
443,,1444.0,NCT02410200,Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS,Biogen,Lebanon
443,,1444.0,NCT02410200,Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS,Biogen,Poland
443,,1444.0,NCT02410200,Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS,Biogen,Turkey
444,,1445.0,NCT02394782,Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL),"Merck KGaA, Darmstadt, Germany",Germany
446,,1447.0,NCT02315872,ACTH for Fatigue in Multiple Sclerosis Patients,Providence Health & Services,United States
449,,1450.0,NCT02247310,BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon,Bayer,Austria
449,,1450.0,NCT02247310,BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon,Bayer,Belgium
449,,1450.0,NCT02247310,BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon,Bayer,Bosnia and Herzegovina
449,,1450.0,NCT02247310,BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon,Bayer,Croatia
449,,1450.0,NCT02247310,BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon,Bayer,Czechia
449,,1450.0,NCT02247310,BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon,Bayer,France
449,,1450.0,NCT02247310,BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon,Bayer,Greece
449,,1450.0,NCT02247310,BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon,Bayer,Hungary
449,,1450.0,NCT02247310,BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon,Bayer,Italy
449,,1450.0,NCT02247310,BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon,Bayer,Spain
449,,1450.0,NCT02247310,BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon,Bayer,Switzerland
450,,1451.0,NCT02064816,A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis,"Merck KGaA, Darmstadt, Germany",Germany
451,,1452.0,NCT02040298,Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis,"University of California, San Francisco",United States
452,,1453.0,NCT02019550,Rebif® Rebidose® Versus Rebiject II® Ease-of-Use,EMD Serono,United States
453,,1454.0,NCT01909492,Relaxin in Multiple Sclerosis (MS),Providence Health & Services,United States
454,,1455.0,NCT01808482,"A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS)",GlaxoSmithKline,United Kingdom
455,,1456.0,NCT01772199,Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis,GlaxoSmithKline,Bulgaria
455,,1456.0,NCT01772199,Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis,GlaxoSmithKline,Canada
455,,1456.0,NCT01772199,Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis,GlaxoSmithKline,Czech Republic
455,,1456.0,NCT01772199,Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis,GlaxoSmithKline,Germany
455,,1456.0,NCT01772199,Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis,GlaxoSmithKline,Spain
455,,1456.0,NCT01772199,Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis,GlaxoSmithKline,Sweden
455,,1456.0,NCT01772199,Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis,GlaxoSmithKline,Ukraine
455,,1456.0,NCT01772199,Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis,GlaxoSmithKline,United Kingdom
456,,1457.0,NCT01667796,Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health,Johns Hopkins University,United States
460,,1461.0,NCT01466322,"A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers.",GlaxoSmithKline,Australia
462,,1463.0,NCT01436838,"China Betaferon Adherence, Coping and Nurse Support Study",Bayer,China
463,,1464.0,NCT01435993,Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis,GlaxoSmithKline,Italy
463,,1464.0,NCT01435993,Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis,GlaxoSmithKline,Norway
464,,1465.0,NCT01431937,Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers,GlaxoSmithKline,Australia
465,,1466.0,NCT01424462,Healthy Volunteer Pilot Study Using 3 Types of Modified Release Formulations of Firategrast to Investigate How Quickly Absorption From the Digestive System Takes Place.,GlaxoSmithKline,Australia
466,,1467.0,NCT01420055,Fingolimod -Response According to Coping - Evaluation,Novartis Pharmaceuticals,France
467,,1468.0,NCT01417312,Metabolic Effects of a Green Tea Extract in Multiple Sclerosis Patients,"Charite University, Berlin, Germany",Germany
468,,1469.0,NCT01416363,Healthy Volunteer Study Using 3 Different Formulations of Firategrast,GlaxoSmithKline,Australia
471,,1472.0,NCT01279876,Melatonin in Relapsing-Remitting Multiple Sclerosis Patients,Tehran University of Medical Sciences,"Iran, Islamic Republic of"
472,,1473.0,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,United States
472,,1473.0,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Australia
472,,1473.0,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Austria
472,,1473.0,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Belgium
472,,1473.0,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Brazil
472,,1473.0,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Bulgaria
472,,1473.0,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Canada
472,,1473.0,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Czechia
472,,1473.0,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Finland
472,,1473.0,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,France
472,,1473.0,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Germany
472,,1473.0,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Greece
472,,1473.0,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Hungary
472,,1473.0,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Israel
472,,1473.0,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Italy
472,,1473.0,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Lithuania
472,,1473.0,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Mexico
472,,1473.0,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Netherlands
472,,1473.0,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,New Zealand
472,,1473.0,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Norway
472,,1473.0,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Peru
472,,1473.0,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Poland
472,,1473.0,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Portugal
472,,1473.0,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Romania
472,,1473.0,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Russian Federation
472,,1473.0,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Spain
472,,1473.0,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Switzerland
472,,1473.0,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Ukraine
472,,1473.0,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,United Kingdom
472,,1473.0,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,Hoffmann-La Roche,Uruguay
473,,1474.0,NCT01188811,Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS),VA Office of Research and Development,United States
474,,1475.0,NCT01158183,Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis,Bayer,United States
478,,1479.0,NCT01134627,Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS],"Merck KGaA, Darmstadt, Germany",Denmark
479,,1480.0,NCT01116427,A Cooperative Clinical Study of Abatacept in Multiple Sclerosis,National Institute of Allergy and Infectious Diseases (NIAID),United States
479,,1480.0,NCT01116427,A Cooperative Clinical Study of Abatacept in Multiple Sclerosis,National Institute of Allergy and Infectious Diseases (NIAID),Canada
480,,1481.0,NCT01112345,An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters,"Merck KGaA, Darmstadt, Germany",Greece
481,,1482.0,NCT01110993,An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF),"Merck KGaA, Darmstadt, Germany",Poland
482,,1483.0,NCT01108887,"An Observational Study for the Assessment of Adherence, Effectiveness and Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart™.","Merck KGaA, Darmstadt, Germany",Netherlands
483,,1484.0,NCT01080053,"Sexual Dysfunction, Disability and Quality of Life in Patients With Multiple Sclerosis (MS)","Merck KGaA, Darmstadt, Germany",Argentina
484,,1485.0,NCT01080040,To Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Multiple Sclerosis Patients,"Merck KGaA, Darmstadt, Germany",Argentina
485,,1486.0,NCT01080027,"Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)","Merck KGaA, Darmstadt, Germany",Greece
486,,1487.0,NCT01080001,"A Observational, Prospective Study to Assess the Impact of Fatigue in the Quality of Life of Patients With Multiple Sclerosis in Argentina","Merck KGaA, Darmstadt, Germany",Argentina
487,,1488.0,NCT01075880,Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®,"Merck KGaA, Darmstadt, Germany",Czech Republic
488,,1489.0,NCT01071694,QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea,Bayer,"Korea, Republic of"
489,,1490.0,NCT00984984,Efficacy and Safety of Methylprednisolone Per os Versus IV for the Treatment of Multiple Sclerosis (MS) Relapses,Rennes University Hospital,France
490,,1491.0,NCT00930553,An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab,"Genzyme, a Sanofi Company",United States
490,,1491.0,NCT00930553,An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab,"Genzyme, a Sanofi Company",Argentina
490,,1491.0,NCT00930553,An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab,"Genzyme, a Sanofi Company",Australia
490,,1491.0,NCT00930553,An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab,"Genzyme, a Sanofi Company",Austria
490,,1491.0,NCT00930553,An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab,"Genzyme, a Sanofi Company",Belgium
490,,1491.0,NCT00930553,An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab,"Genzyme, a Sanofi Company",Brazil
490,,1491.0,NCT00930553,An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab,"Genzyme, a Sanofi Company",Canada
490,,1491.0,NCT00930553,An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab,"Genzyme, a Sanofi Company",Croatia
490,,1491.0,NCT00930553,An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab,"Genzyme, a Sanofi Company",Czechia
490,,1491.0,NCT00930553,An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab,"Genzyme, a Sanofi Company",Denmark
490,,1491.0,NCT00930553,An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab,"Genzyme, a Sanofi Company",France
490,,1491.0,NCT00930553,An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab,"Genzyme, a Sanofi Company",Germany
490,,1491.0,NCT00930553,An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab,"Genzyme, a Sanofi Company",Israel
490,,1491.0,NCT00930553,An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab,"Genzyme, a Sanofi Company",Italy
490,,1491.0,NCT00930553,An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab,"Genzyme, a Sanofi Company",Mexico
490,,1491.0,NCT00930553,An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab,"Genzyme, a Sanofi Company",Netherlands
490,,1491.0,NCT00930553,An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab,"Genzyme, a Sanofi Company",Poland
490,,1491.0,NCT00930553,An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab,"Genzyme, a Sanofi Company",Russian Federation
490,,1491.0,NCT00930553,An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab,"Genzyme, a Sanofi Company",Serbia
490,,1491.0,NCT00930553,An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab,"Genzyme, a Sanofi Company",Spain
490,,1491.0,NCT00930553,An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab,"Genzyme, a Sanofi Company",Sweden
490,,1491.0,NCT00930553,An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab,"Genzyme, a Sanofi Company",Ukraine
490,,1491.0,NCT00930553,An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab,"Genzyme, a Sanofi Company",United Kingdom
492,,1493.0,NCT00780455,Rehabilitation Study in MS Patients,Bayer,France
493,,1494.0,NCT00676715,A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis,"Genentech, Inc.",United States
493,,1494.0,NCT00676715,A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis,"Genentech, Inc.",Belgium
493,,1494.0,NCT00676715,A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis,"Genentech, Inc.",Bulgaria
493,,1494.0,NCT00676715,A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis,"Genentech, Inc.",Canada
493,,1494.0,NCT00676715,A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis,"Genentech, Inc.",Czechia
493,,1494.0,NCT00676715,A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis,"Genentech, Inc.",Denmark
493,,1494.0,NCT00676715,A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis,"Genentech, Inc.",France
493,,1494.0,NCT00676715,A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis,"Genentech, Inc.",Germany
493,,1494.0,NCT00676715,A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis,"Genentech, Inc.",Italy
493,,1494.0,NCT00676715,A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis,"Genentech, Inc.",Mexico
493,,1494.0,NCT00676715,A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis,"Genentech, Inc.",Romania
493,,1494.0,NCT00676715,A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis,"Genentech, Inc.",Russian Federation
493,,1494.0,NCT00676715,A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis,"Genentech, Inc.",Serbia
493,,1494.0,NCT00676715,A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis,"Genentech, Inc.",Slovakia
493,,1494.0,NCT00676715,A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis,"Genentech, Inc.",Spain
493,,1494.0,NCT00676715,A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis,"Genentech, Inc.",Switzerland
493,,1494.0,NCT00676715,A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis,"Genentech, Inc.",Ukraine
493,,1494.0,NCT00676715,A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis,"Genentech, Inc.",United Kingdom
494,,1495.0,NCT00675883,COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS,Biogen,Canada
495,,1496.0,NCT00548405,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two","Genzyme, a Sanofi Company",United States
495,,1496.0,NCT00548405,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two","Genzyme, a Sanofi Company",Argentina
495,,1496.0,NCT00548405,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two","Genzyme, a Sanofi Company",Australia
495,,1496.0,NCT00548405,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two","Genzyme, a Sanofi Company",Austria
495,,1496.0,NCT00548405,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two","Genzyme, a Sanofi Company",Belgium
495,,1496.0,NCT00548405,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two","Genzyme, a Sanofi Company",Brazil
495,,1496.0,NCT00548405,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two","Genzyme, a Sanofi Company",Canada
495,,1496.0,NCT00548405,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two","Genzyme, a Sanofi Company",Croatia
495,,1496.0,NCT00548405,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two","Genzyme, a Sanofi Company",Czech Republic
495,,1496.0,NCT00548405,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two","Genzyme, a Sanofi Company",Denmark
495,,1496.0,NCT00548405,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two","Genzyme, a Sanofi Company",France
495,,1496.0,NCT00548405,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two","Genzyme, a Sanofi Company",Germany
495,,1496.0,NCT00548405,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two","Genzyme, a Sanofi Company",Israel
495,,1496.0,NCT00548405,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two","Genzyme, a Sanofi Company",Italy
495,,1496.0,NCT00548405,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two","Genzyme, a Sanofi Company",Mexico
495,,1496.0,NCT00548405,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two","Genzyme, a Sanofi Company",Netherlands
495,,1496.0,NCT00548405,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two","Genzyme, a Sanofi Company",Poland
495,,1496.0,NCT00548405,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two","Genzyme, a Sanofi Company",Russian Federation
495,,1496.0,NCT00548405,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two","Genzyme, a Sanofi Company",Serbia
495,,1496.0,NCT00548405,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two","Genzyme, a Sanofi Company",Spain
495,,1496.0,NCT00548405,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two","Genzyme, a Sanofi Company",Sweden
495,,1496.0,NCT00548405,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two","Genzyme, a Sanofi Company",Ukraine
495,,1496.0,NCT00548405,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two","Genzyme, a Sanofi Company",United Kingdom
496,,1497.0,NCT00530348,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One","Genzyme, a Sanofi Company",United States
496,,1497.0,NCT00530348,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One","Genzyme, a Sanofi Company",Argentina
496,,1497.0,NCT00530348,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One","Genzyme, a Sanofi Company",Australia
496,,1497.0,NCT00530348,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One","Genzyme, a Sanofi Company",Brazil
496,,1497.0,NCT00530348,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One","Genzyme, a Sanofi Company",Canada
496,,1497.0,NCT00530348,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One","Genzyme, a Sanofi Company",Croatia
496,,1497.0,NCT00530348,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One","Genzyme, a Sanofi Company",Czech Republic
496,,1497.0,NCT00530348,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One","Genzyme, a Sanofi Company",France
496,,1497.0,NCT00530348,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One","Genzyme, a Sanofi Company",Germany
496,,1497.0,NCT00530348,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One","Genzyme, a Sanofi Company",Mexico
496,,1497.0,NCT00530348,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One","Genzyme, a Sanofi Company",Poland
496,,1497.0,NCT00530348,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One","Genzyme, a Sanofi Company",Russian Federation
496,,1497.0,NCT00530348,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One","Genzyme, a Sanofi Company",Serbia
496,,1497.0,NCT00530348,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One","Genzyme, a Sanofi Company",Sweden
496,,1497.0,NCT00530348,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One","Genzyme, a Sanofi Company",Ukraine
496,,1497.0,NCT00530348,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One","Genzyme, a Sanofi Company",United Kingdom
497,,1498.0,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,Bayer,United States
497,,1498.0,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,Bayer,Argentina
497,,1498.0,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,Bayer,Australia
497,,1498.0,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,Bayer,Austria
497,,1498.0,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,Bayer,Belgium
497,,1498.0,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,Bayer,Brazil
497,,1498.0,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,Bayer,Canada
497,,1498.0,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,Bayer,Denmark
497,,1498.0,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,Bayer,Finland
497,,1498.0,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,Bayer,France
497,,1498.0,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,Bayer,Germany
497,,1498.0,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,Bayer,Greece
497,,1498.0,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,Bayer,Hungary
497,,1498.0,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,Bayer,Ireland
497,,1498.0,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,Bayer,Israel
497,,1498.0,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,Bayer,Italy
497,,1498.0,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,Bayer,Latvia
497,,1498.0,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,Bayer,Netherlands
497,,1498.0,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,Bayer,Norway
497,,1498.0,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,Bayer,Poland
497,,1498.0,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,Bayer,Russian Federation
497,,1498.0,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,Bayer,Slovenia
497,,1498.0,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,Bayer,Spain
497,,1498.0,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,Bayer,Sweden
497,,1498.0,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,Bayer,Switzerland
497,,1498.0,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,Bayer,Ukraine
499,,1500.0,NCT00306592,Natalizumab Re-Initiation of Dosing,Biogen,United States
499,,1500.0,NCT00306592,Natalizumab Re-Initiation of Dosing,Biogen,Canada
504,,1505.0,NCT00241254,Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis,"University Hospital, Bordeaux",France
505,,1506.0,NCT00235989,Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis,Bayer,United States
509,,1510.0,NCT00206648,An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS,Bayer,United States
509,,1510.0,NCT00206648,An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS,Bayer,Canada
510,,1511.0,NCT00112034,"AVONEX® Combination Trial - ""ACT""",Biogen,United States
511,,1512.0,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,Bayer,United States
511,,1512.0,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,Bayer,Argentina
511,,1512.0,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,Bayer,Australia
511,,1512.0,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,Bayer,Austria
511,,1512.0,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,Bayer,Belgium
511,,1512.0,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,Bayer,Brazil
511,,1512.0,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,Bayer,Canada
511,,1512.0,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,Bayer,Denmark
511,,1512.0,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,Bayer,Finland
511,,1512.0,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,Bayer,France
511,,1512.0,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,Bayer,Germany
511,,1512.0,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,Bayer,Greece
511,,1512.0,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,Bayer,Hungary
511,,1512.0,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,Bayer,Ireland
511,,1512.0,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,Bayer,Israel
511,,1512.0,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,Bayer,Italy
511,,1512.0,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,Bayer,Latvia
511,,1512.0,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,Bayer,Netherlands
511,,1512.0,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,Bayer,Norway
511,,1512.0,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,Bayer,Poland
511,,1512.0,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,Bayer,Russian Federation
511,,1512.0,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,Bayer,Slovenia
511,,1512.0,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,Bayer,Spain
511,,1512.0,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,Bayer,Sweden
511,,1512.0,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,Bayer,Switzerland
511,,1512.0,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,Bayer,Ukraine
513,,1514.0,NCT00097331,Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis,GlaxoSmithKline,Belgium
513,,1514.0,NCT00097331,Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis,GlaxoSmithKline,Germany
513,,1514.0,NCT00097331,Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis,GlaxoSmithKline,Poland
513,,1514.0,NCT00097331,Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis,GlaxoSmithKline,Russian Federation
513,,1514.0,NCT00097331,Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis,GlaxoSmithKline,Spain
514,,1515.0,NCT00071838,Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis,National Institute of Neurological Disorders and Stroke (NINDS),United States
516,,1517.0,NCT00050778,"A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis","Genzyme, a Sanofi Company",United States
516,,1517.0,NCT00050778,"A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis","Genzyme, a Sanofi Company",Croatia
516,,1517.0,NCT00050778,"A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis","Genzyme, a Sanofi Company",Poland
516,,1517.0,NCT00050778,"A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis","Genzyme, a Sanofi Company",Russian Federation
516,,1517.0,NCT00050778,"A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis","Genzyme, a Sanofi Company",United Kingdom
517,,1518.0,NCT00030966,Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis,Biogen,United States
517,,1518.0,NCT00030966,Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis,Biogen,Austria
517,,1518.0,NCT00030966,Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis,Biogen,Belgium
517,,1518.0,NCT00030966,Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis,Biogen,France
517,,1518.0,NCT00030966,Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis,Biogen,Germany
517,,1518.0,NCT00030966,Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis,Biogen,Israel
517,,1518.0,NCT00030966,Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis,Biogen,Italy
518,,1519.0,NCT00027300,Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis,Biogen,United States
518,,1519.0,NCT00027300,Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis,Biogen,Belgium
518,,1519.0,NCT00027300,Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis,Biogen,Canada
518,,1519.0,NCT00027300,Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis,Biogen,Czech Republic
518,,1519.0,NCT00027300,Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis,Biogen,France
518,,1519.0,NCT00027300,Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis,Biogen,Germany
518,,1519.0,NCT00027300,Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis,Biogen,Netherlands
518,,1519.0,NCT00027300,Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis,Biogen,United Kingdom
522,,1523.0,NCT00872053,Effect of Robot-assisted Training on Foot Drop in Multiple Sclerosis,US Department of Veterans Affairs,United States
525,,1526.0,NCT02430532,BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis,Biogen,United States
525,,1526.0,NCT02430532,BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis,Biogen,Belgium
525,,1526.0,NCT02430532,BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis,Biogen,Czech Republic
525,,1526.0,NCT02430532,BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis,Biogen,Netherlands
525,,1526.0,NCT02430532,BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis,Biogen,Poland
525,,1526.0,NCT02430532,BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis,Biogen,Slovakia
526,,1527.0,NCT02308137,Domperidone in Secondary Progressive Multiple Sclerosis (SPMS),University of Calgary,Canada
529,,1530.0,NCT02038049,A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis,Novartis Pharmaceuticals,United States
529,,1530.0,NCT02038049,A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis,Novartis Pharmaceuticals,Czechia
529,,1530.0,NCT02038049,A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis,Novartis Pharmaceuticals,Ukraine
533,,1534.0,NCT00202982,"A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose",Teva Pharmaceutical Industries,United States
536,,1537.0,NCT04971005,Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial,Universitätsklinikum Hamburg-Eppendorf,Germany
539,,1540.0,NCT04832399,Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants,Biogen,Portugal
545,,1546.0,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,United States
545,,1546.0,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Argentina
545,,1546.0,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Australia
545,,1546.0,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Austria
545,,1546.0,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Belarus
545,,1546.0,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Belgium
545,,1546.0,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Bulgaria
545,,1546.0,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Canada
545,,1546.0,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Chile
545,,1546.0,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,China
545,,1546.0,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Colombia
545,,1546.0,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Croatia
545,,1546.0,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Czechia
545,,1546.0,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Denmark
545,,1546.0,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Estonia
545,,1546.0,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,France
545,,1546.0,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Germany
545,,1546.0,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Greece
545,,1546.0,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Hungary
545,,1546.0,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,India
545,,1546.0,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Israel
545,,1546.0,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Italy
545,,1546.0,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Japan
545,,1546.0,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Latvia
545,,1546.0,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Netherlands
545,,1546.0,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Norway
545,,1546.0,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Poland
545,,1546.0,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Portugal
545,,1546.0,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Romania
545,,1546.0,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Russian Federation
545,,1546.0,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Serbia
545,,1546.0,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Spain
545,,1546.0,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Sweden
545,,1546.0,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Switzerland
545,,1546.0,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Turkey
545,,1546.0,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Ukraine
545,,1546.0,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,United Kingdom
547,,1548.0,NCT04032171,Study of Evobrutinib in Participants With RMS,"EMD Serono Research & Development Institute, Inc.",United States
547,,1548.0,NCT04032171,Study of Evobrutinib in Participants With RMS,"EMD Serono Research & Development Institute, Inc.",Germany
548,,1549.0,NCT04032158,Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS),"EMD Serono Research & Development Institute, Inc.",United States
548,,1549.0,NCT04032158,Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS),"EMD Serono Research & Development Institute, Inc.",Germany
552,,1553.0,NCT03539094,Intermittent Fasting in Multiple Sclerosis,Washington University School of Medicine,United States
553,,1554.0,NCT03498131,Melatonin in Patients With Multiple Sclerosis (MS).,Providence Health & Services,United States
559,,1560.0,NCT03284970,Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes,"EMD Serono Research & Development Institute, Inc.",United States
562,,1563.0,NCT03177083,Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy,Biogen,Portugal
563,,1564.0,NCT03157830,Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab,Providence Health & Services,United States
564,,1565.0,NCT03093324,A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2,Biogen,United States
564,,1565.0,NCT03093324,A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2,Biogen,Germany
564,,1565.0,NCT03093324,A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2,Biogen,Poland
565,,1566.0,NCT03091569,Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy,Biogen,Italy
566,,1567.0,NCT02975349,A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis,"EMD Serono Research & Development Institute, Inc.",Bulgaria
566,,1567.0,NCT02975349,A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis,"EMD Serono Research & Development Institute, Inc.",Czechia
566,,1567.0,NCT02975349,A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis,"EMD Serono Research & Development Institute, Inc.",Poland
566,,1567.0,NCT02975349,A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis,"EMD Serono Research & Development Institute, Inc.",Russian Federation
566,,1567.0,NCT02975349,A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis,"EMD Serono Research & Development Institute, Inc.",Serbia
566,,1567.0,NCT02975349,A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis,"EMD Serono Research & Development Institute, Inc.",Slovakia
566,,1567.0,NCT02975349,A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis,"EMD Serono Research & Development Institute, Inc.",Spain
566,,1567.0,NCT02975349,A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis,"EMD Serono Research & Development Institute, Inc.",Ukraine
567,,1568.0,NCT02959658,Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis,"Rigshospitalet, Denmark",Denmark
571,,1572.0,NCT02720107,Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01),Novartis Pharmaceuticals,Germany
574,,1575.0,NCT02677077,Clinical Disease Activity With Long Term Natalizumab Treatment,Biogen,Belgium
574,,1575.0,NCT02677077,Clinical Disease Activity With Long Term Natalizumab Treatment,Biogen,Czechia
575,,1576.0,NCT02647502,A Pilot Study of Intermittent Calorie Restriction in Multiple Sclerosis,Johns Hopkins University,United States
578,,1579.0,NCT02424396,Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis,Assistance Publique - Hôpitaux de Paris,France
579,,1580.0,NCT02373098,Fingolimod Effect on Cytokine and Chemokine Levels,Novartis Pharmaceuticals,Turkey
581,,1582.0,NCT02342704,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,Biogen,United States
581,,1582.0,NCT02342704,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,Biogen,Australia
581,,1582.0,NCT02342704,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,Biogen,Czechia
581,,1582.0,NCT02342704,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,Biogen,France
581,,1582.0,NCT02342704,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,Biogen,Germany
581,,1582.0,NCT02342704,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,Biogen,Italy
581,,1582.0,NCT02342704,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,Biogen,Spain
581,,1582.0,NCT02342704,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,Biogen,Sweden
581,,1582.0,NCT02342704,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,Biogen,United Kingdom
582,,1583.0,NCT02335892,PROFILE - Evaluation of QoL and PRO Outcomes in Patients Taking Fingolimod,Novartis Pharmaceuticals,United Kingdom
583,,1584.0,NCT02325440,Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya,University Hospital Muenster,Germany
584,,1585.0,NCT02310048,Comparative Oral Bioavailability Study of MT-1303,Mitsubishi Tanabe Pharma Corporation,United Kingdom
585,,1586.0,NCT02306811,Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839,"Genzyme, a Sanofi Company",United States
585,,1586.0,NCT02306811,Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839,"Genzyme, a Sanofi Company",Canada
585,,1586.0,NCT02306811,Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839,"Genzyme, a Sanofi Company",Poland
585,,1586.0,NCT02306811,Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839,"Genzyme, a Sanofi Company",Russian Federation
586,,1587.0,NCT02293967,Mass Balance Study of MT-1303,Mitsubishi Tanabe Pharma Corporation,United Kingdom
588,,1589.0,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),Biogen,United States
588,,1589.0,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),Biogen,Belgium
588,,1589.0,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),Biogen,Bulgaria
588,,1589.0,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),Biogen,Canada
588,,1589.0,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),Biogen,Czechia
588,,1589.0,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),Biogen,Denmark
588,,1589.0,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),Biogen,France
588,,1589.0,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),Biogen,Germany
588,,1589.0,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),Biogen,Hungary
588,,1589.0,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),Biogen,Israel
588,,1589.0,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),Biogen,Italy
588,,1589.0,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),Biogen,Kuwait
588,,1589.0,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),Biogen,Poland
588,,1589.0,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),Biogen,Serbia
588,,1589.0,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),Biogen,Spain
588,,1589.0,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),Biogen,Sweden
588,,1589.0,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),Biogen,Turkey
588,,1589.0,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),Biogen,United Kingdom
591,,1592.0,NCT02255656,Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409,"Genzyme, a Sanofi Company",United States
591,,1592.0,NCT02255656,Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409,"Genzyme, a Sanofi Company",Argentina
591,,1592.0,NCT02255656,Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409,"Genzyme, a Sanofi Company",Australia
591,,1592.0,NCT02255656,Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409,"Genzyme, a Sanofi Company",Belgium
591,,1592.0,NCT02255656,Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409,"Genzyme, a Sanofi Company",Brazil
591,,1592.0,NCT02255656,Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409,"Genzyme, a Sanofi Company",Canada
591,,1592.0,NCT02255656,Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409,"Genzyme, a Sanofi Company",Czechia
591,,1592.0,NCT02255656,Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409,"Genzyme, a Sanofi Company",Denmark
591,,1592.0,NCT02255656,Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409,"Genzyme, a Sanofi Company",Germany
591,,1592.0,NCT02255656,Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409,"Genzyme, a Sanofi Company",Israel
591,,1592.0,NCT02255656,Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409,"Genzyme, a Sanofi Company",Italy
591,,1592.0,NCT02255656,Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409,"Genzyme, a Sanofi Company",Mexico
591,,1592.0,NCT02255656,Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409,"Genzyme, a Sanofi Company",Netherlands
591,,1592.0,NCT02255656,Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409,"Genzyme, a Sanofi Company",Poland
591,,1592.0,NCT02255656,Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409,"Genzyme, a Sanofi Company",Russian Federation
591,,1592.0,NCT02255656,Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409,"Genzyme, a Sanofi Company",Spain
591,,1592.0,NCT02255656,Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409,"Genzyme, a Sanofi Company",Sweden
591,,1592.0,NCT02255656,Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409,"Genzyme, a Sanofi Company",Ukraine
591,,1592.0,NCT02255656,Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409,"Genzyme, a Sanofi Company",United Kingdom
592,,1593.0,NCT02222948,Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis,"Genzyme, a Sanofi Company",United States
592,,1593.0,NCT02222948,Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis,"Genzyme, a Sanofi Company",Canada
592,,1593.0,NCT02222948,Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis,"Genzyme, a Sanofi Company",Poland
592,,1593.0,NCT02222948,Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis,"Genzyme, a Sanofi Company",Russian Federation
592,,1593.0,NCT02222948,Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis,"Genzyme, a Sanofi Company",Sweden
594,,1595.0,NCT02205489,Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA,"Genzyme, a Sanofi Company",Belgium
594,,1595.0,NCT02205489,Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA,"Genzyme, a Sanofi Company",France
594,,1595.0,NCT02205489,Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA,"Genzyme, a Sanofi Company",Netherlands
594,,1595.0,NCT02205489,Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA,"Genzyme, a Sanofi Company",Spain
595,,1596.0,NCT02193217,A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303,Mitsubishi Tanabe Pharma Corporation,United Kingdom
596,,1597.0,NCT02159573,"Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)",Biogen,United States
597,,1598.0,NCT02142205,"Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)",Biogen,Russian Federation
598,,1599.0,NCT02125604,Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany,Biogen,Germany
600,,1601.0,NCT02090413,Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis,Biogen,Ireland
600,,1601.0,NCT02090413,Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis,Biogen,United Kingdom
601,,1602.0,NCT02016222,Tear Analysis in the Diagnosis of Multiple Sclerosis,Lille Catholic University,France
604,,1605.0,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",EMD Serono,United States
604,,1605.0,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",EMD Serono,Bulgaria
604,,1605.0,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",EMD Serono,Croatia
604,,1605.0,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",EMD Serono,Czech Republic
604,,1605.0,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",EMD Serono,Finland
604,,1605.0,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",EMD Serono,Greece
604,,1605.0,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",EMD Serono,Hungary
604,,1605.0,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",EMD Serono,Italy
604,,1605.0,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",EMD Serono,Mexico
604,,1605.0,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",EMD Serono,Poland
604,,1605.0,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",EMD Serono,Russian Federation
604,,1605.0,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",EMD Serono,Serbia
604,,1605.0,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",EMD Serono,South Africa
604,,1605.0,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",EMD Serono,Spain
604,,1605.0,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",EMD Serono,Turkey
604,,1605.0,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",EMD Serono,Ukraine
604,,1605.0,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",EMD Serono,United Kingdom
606,,1607.0,NCT01943526,Ireland Natalizumab (TYSABRI) Observational Program,Biogen,Ireland
608,,1609.0,NCT01890655,Extension Study of MT-1303,Mitsubishi Tanabe Pharma Corporation,Belgium
608,,1609.0,NCT01890655,Extension Study of MT-1303,Mitsubishi Tanabe Pharma Corporation,Bulgaria
608,,1609.0,NCT01890655,Extension Study of MT-1303,Mitsubishi Tanabe Pharma Corporation,Canada
608,,1609.0,NCT01890655,Extension Study of MT-1303,Mitsubishi Tanabe Pharma Corporation,Croatia
608,,1609.0,NCT01890655,Extension Study of MT-1303,Mitsubishi Tanabe Pharma Corporation,Czech Republic
608,,1609.0,NCT01890655,Extension Study of MT-1303,Mitsubishi Tanabe Pharma Corporation,Finland
608,,1609.0,NCT01890655,Extension Study of MT-1303,Mitsubishi Tanabe Pharma Corporation,Germany
608,,1609.0,NCT01890655,Extension Study of MT-1303,Mitsubishi Tanabe Pharma Corporation,Hungary
608,,1609.0,NCT01890655,Extension Study of MT-1303,Mitsubishi Tanabe Pharma Corporation,Italy
608,,1609.0,NCT01890655,Extension Study of MT-1303,Mitsubishi Tanabe Pharma Corporation,Lithuania
608,,1609.0,NCT01890655,Extension Study of MT-1303,Mitsubishi Tanabe Pharma Corporation,Poland
608,,1609.0,NCT01890655,Extension Study of MT-1303,Mitsubishi Tanabe Pharma Corporation,Russian Federation
608,,1609.0,NCT01890655,Extension Study of MT-1303,Mitsubishi Tanabe Pharma Corporation,Serbia
608,,1609.0,NCT01890655,Extension Study of MT-1303,Mitsubishi Tanabe Pharma Corporation,Spain
608,,1609.0,NCT01890655,Extension Study of MT-1303,Mitsubishi Tanabe Pharma Corporation,Turkey
608,,1609.0,NCT01890655,Extension Study of MT-1303,Mitsubishi Tanabe Pharma Corporation,Ukraine
608,,1609.0,NCT01890655,Extension Study of MT-1303,Mitsubishi Tanabe Pharma Corporation,United Kingdom
609,,1610.0,NCT01884935,PK and PD Study of Natalizumab in Pediatric Subjects With RRMS,Biogen,Italy
610,,1611.0,NCT01874145,Safety and Tolerability of Glatiramer Acetate,Teva Pharmaceutical Industries,United States
611,,1612.0,NCT01808885,Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta.,Hoffmann-La Roche,France
613,,1614.0,NCT01790269,Monitoring Natural Killer Cells in Multiple Sclerosis Patients Treated With Fingolimod,"Charite University, Berlin, Germany",Germany
617,,1618.0,NCT01742052,Dose-finding Study of MT-1303,Mitsubishi Tanabe Pharma Corporation,Belgium
617,,1618.0,NCT01742052,Dose-finding Study of MT-1303,Mitsubishi Tanabe Pharma Corporation,Bulgaria
617,,1618.0,NCT01742052,Dose-finding Study of MT-1303,Mitsubishi Tanabe Pharma Corporation,Canada
617,,1618.0,NCT01742052,Dose-finding Study of MT-1303,Mitsubishi Tanabe Pharma Corporation,Croatia
617,,1618.0,NCT01742052,Dose-finding Study of MT-1303,Mitsubishi Tanabe Pharma Corporation,Czech Republic
617,,1618.0,NCT01742052,Dose-finding Study of MT-1303,Mitsubishi Tanabe Pharma Corporation,Finland
617,,1618.0,NCT01742052,Dose-finding Study of MT-1303,Mitsubishi Tanabe Pharma Corporation,Germany
617,,1618.0,NCT01742052,Dose-finding Study of MT-1303,Mitsubishi Tanabe Pharma Corporation,Hungary
617,,1618.0,NCT01742052,Dose-finding Study of MT-1303,Mitsubishi Tanabe Pharma Corporation,Italy
617,,1618.0,NCT01742052,Dose-finding Study of MT-1303,Mitsubishi Tanabe Pharma Corporation,Lithuania
617,,1618.0,NCT01742052,Dose-finding Study of MT-1303,Mitsubishi Tanabe Pharma Corporation,Poland
617,,1618.0,NCT01742052,Dose-finding Study of MT-1303,Mitsubishi Tanabe Pharma Corporation,Russian Federation
617,,1618.0,NCT01742052,Dose-finding Study of MT-1303,Mitsubishi Tanabe Pharma Corporation,Serbia
617,,1618.0,NCT01742052,Dose-finding Study of MT-1303,Mitsubishi Tanabe Pharma Corporation,Spain
617,,1618.0,NCT01742052,Dose-finding Study of MT-1303,Mitsubishi Tanabe Pharma Corporation,Switzerland
617,,1618.0,NCT01742052,Dose-finding Study of MT-1303,Mitsubishi Tanabe Pharma Corporation,Turkey
617,,1618.0,NCT01742052,Dose-finding Study of MT-1303,Mitsubishi Tanabe Pharma Corporation,Ukraine
617,,1618.0,NCT01742052,Dose-finding Study of MT-1303,Mitsubishi Tanabe Pharma Corporation,United Kingdom
621,,1622.0,NCT01706107,Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants,Biogen,Canada
622,,1623.0,NCT01705457,Impact of Vitamin A on RAR Gene Expression in Multiple Sclerosis,Tehran University of Medical Sciences,"Iran, Islamic Republic of"
624,,1625.0,NCT01623596,Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.,Novartis Pharmaceuticals,United States
624,,1625.0,NCT01623596,Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.,Novartis Pharmaceuticals,Puerto Rico
625,,1626.0,NCT01578785,"An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)",Teva Pharmaceutical Industries,United States
625,,1626.0,NCT01578785,"An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)",Teva Pharmaceutical Industries,Albania
625,,1626.0,NCT01578785,"An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)",Teva Pharmaceutical Industries,Belarus
625,,1626.0,NCT01578785,"An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)",Teva Pharmaceutical Industries,Bosnia and Herzegovina
625,,1626.0,NCT01578785,"An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)",Teva Pharmaceutical Industries,Bulgaria
625,,1626.0,NCT01578785,"An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)",Teva Pharmaceutical Industries,Croatia
625,,1626.0,NCT01578785,"An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)",Teva Pharmaceutical Industries,Estonia
625,,1626.0,NCT01578785,"An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)",Teva Pharmaceutical Industries,Georgia
625,,1626.0,NCT01578785,"An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)",Teva Pharmaceutical Industries,Greece
625,,1626.0,NCT01578785,"An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)",Teva Pharmaceutical Industries,Latvia
625,,1626.0,NCT01578785,"An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)",Teva Pharmaceutical Industries,"Macedonia, The Former Yugoslav Republic of"
625,,1626.0,NCT01578785,"An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)",Teva Pharmaceutical Industries,Mexico
625,,1626.0,NCT01578785,"An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)",Teva Pharmaceutical Industries,"Moldova, Republic of"
625,,1626.0,NCT01578785,"An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)",Teva Pharmaceutical Industries,Montenegro
625,,1626.0,NCT01578785,"An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)",Teva Pharmaceutical Industries,Poland
625,,1626.0,NCT01578785,"An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)",Teva Pharmaceutical Industries,Romania
625,,1626.0,NCT01578785,"An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)",Teva Pharmaceutical Industries,Russian Federation
625,,1626.0,NCT01578785,"An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)",Teva Pharmaceutical Industries,Serbia
625,,1626.0,NCT01578785,"An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)",Teva Pharmaceutical Industries,Ukraine
628,,1629.0,NCT01538355,A Pilot Trial to Test the Feasibility of Prolonged Fasting and Ketogenic Diet in Relapsing-remitting Multiple Sclerosis,"Charite University, Berlin, Germany",Germany
629,,1630.0,NCT01534182,Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC),Novartis Pharmaceuticals,Russian Federation
630,,1631.0,NCT01498887,Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy,Novartis Pharmaceuticals,Australia
630,,1631.0,NCT01498887,Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy,Novartis Pharmaceuticals,Spain
631,,1632.0,NCT01490502,Vitamin D Supplementation in Multiple Sclerosis,Johns Hopkins University,United States
632,,1633.0,NCT01485003,Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants,Biogen,United States
634,,1635.0,NCT01462318,An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis,Biogen,United States
634,,1635.0,NCT01462318,An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis,Biogen,Czech Republic
634,,1635.0,NCT01462318,An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis,Biogen,Hungary
634,,1635.0,NCT01462318,An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis,Biogen,Poland
636,,1637.0,NCT01450124,"Safety, Tolerability And Mechanism Of Action Of Boswellic Acids (BA) In Multiple Sclerosis (SABA)",Universitätsklinikum Hamburg-Eppendorf,Germany
638,,1639.0,NCT01417273,Impact of Vitamin A on Multiple Sclerosis (MS),Tehran University of Medical Sciences,"Iran, Islamic Republic of"
639,,1640.0,NCT01407211,"Impact of Vitamin A on Gene Expression, in Multiple Sclerosis Patient",Tehran University of Medical Sciences,"Iran, Islamic Republic of"
640,,1641.0,NCT01405820,"Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)",Biogen,Belgium
640,,1641.0,NCT01405820,"Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)",Biogen,France
640,,1641.0,NCT01405820,"Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)",Biogen,Germany
640,,1641.0,NCT01405820,"Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)",Biogen,Italy
640,,1641.0,NCT01405820,"Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)",Biogen,Spain
642,,1643.0,NCT01317004,Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change,Novartis Pharmaceuticals,Italy
643,,1644.0,NCT01310166,Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,Novartis Pharmaceuticals,Germany
645,,1646.0,NCT01285401,Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment,"Merck KGaA, Darmstadt, Germany",Austria
645,,1646.0,NCT01285401,Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment,"Merck KGaA, Darmstadt, Germany",Denmark
645,,1646.0,NCT01285401,Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment,"Merck KGaA, Darmstadt, Germany",Estonia
645,,1646.0,NCT01285401,Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment,"Merck KGaA, Darmstadt, Germany",Finland
645,,1646.0,NCT01285401,Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment,"Merck KGaA, Darmstadt, Germany",Germany
645,,1646.0,NCT01285401,Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment,"Merck KGaA, Darmstadt, Germany",Italy
645,,1646.0,NCT01285401,Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment,"Merck KGaA, Darmstadt, Germany",Latvia
645,,1646.0,NCT01285401,Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment,"Merck KGaA, Darmstadt, Germany",Lithuania
645,,1646.0,NCT01285401,Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment,"Merck KGaA, Darmstadt, Germany",Netherlands
645,,1646.0,NCT01285401,Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment,"Merck KGaA, Darmstadt, Germany",Norway
645,,1646.0,NCT01285401,Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment,"Merck KGaA, Darmstadt, Germany",Portugal
645,,1646.0,NCT01285401,Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment,"Merck KGaA, Darmstadt, Germany",Switzerland
647,,1648.0,NCT01225289,Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients,Tehran University of Medical Sciences,"Iran, Islamic Republic of"
648,,1649.0,NCT01185821,"Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis",Novartis Pharmaceuticals,United States
648,,1649.0,NCT01185821,"Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis",Novartis Pharmaceuticals,Canada
648,,1649.0,NCT01185821,"Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis",Novartis Pharmaceuticals,Finland
648,,1649.0,NCT01185821,"Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis",Novartis Pharmaceuticals,Germany
648,,1649.0,NCT01185821,"Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis",Novartis Pharmaceuticals,Hungary
648,,1649.0,NCT01185821,"Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis",Novartis Pharmaceuticals,Italy
648,,1649.0,NCT01185821,"Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis",Novartis Pharmaceuticals,Norway
648,,1649.0,NCT01185821,"Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis",Novartis Pharmaceuticals,Poland
648,,1649.0,NCT01185821,"Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis",Novartis Pharmaceuticals,Russian Federation
648,,1649.0,NCT01185821,"Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis",Novartis Pharmaceuticals,Spain
648,,1649.0,NCT01185821,"Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis",Novartis Pharmaceuticals,Switzerland
648,,1649.0,NCT01185821,"Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis",Novartis Pharmaceuticals,Turkey
655,,1656.0,NCT01071083,Treatment Interruption of Natalizumab,Biogen,United States
655,,1656.0,NCT01071083,Treatment Interruption of Natalizumab,Biogen,Germany
655,,1656.0,NCT01071083,Treatment Interruption of Natalizumab,Biogen,Spain
657,,1658.0,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,Biogen,United States
657,,1658.0,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,Biogen,Argentina
657,,1658.0,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,Biogen,Australia
657,,1658.0,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,Biogen,Brazil
657,,1658.0,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,Biogen,Canada
657,,1658.0,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,Biogen,Czech Republic
657,,1658.0,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,Biogen,Denmark
657,,1658.0,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,Biogen,Finland
657,,1658.0,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,Biogen,France
657,,1658.0,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,Biogen,Georgia
657,,1658.0,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,Biogen,Germany
657,,1658.0,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,Biogen,Greece
657,,1658.0,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,Biogen,Hungary
657,,1658.0,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,Biogen,India
657,,1658.0,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,Biogen,Ireland
657,,1658.0,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,Biogen,Israel
657,,1658.0,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,Biogen,Italy
657,,1658.0,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,Biogen,Mexico
657,,1658.0,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,Biogen,"Moldova, Republic of"
657,,1658.0,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,Biogen,Poland
657,,1658.0,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,Biogen,Romania
657,,1658.0,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,Biogen,Russian Federation
657,,1658.0,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,Biogen,Serbia
657,,1658.0,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,Biogen,Spain
657,,1658.0,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,Biogen,Sweden
657,,1658.0,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,Biogen,Switzerland
657,,1658.0,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,Biogen,Ukraine
657,,1658.0,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,Biogen,United Kingdom
658,,1659.0,NCT01058005,"Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis",Biogen,United States
658,,1659.0,NCT01058005,"Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis",Biogen,Australia
658,,1659.0,NCT01058005,"Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis",Biogen,Canada
658,,1659.0,NCT01058005,"Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis",Biogen,Czech Republic
658,,1659.0,NCT01058005,"Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis",Biogen,Finland
658,,1659.0,NCT01058005,"Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis",Biogen,France
658,,1659.0,NCT01058005,"Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis",Biogen,Hungary
658,,1659.0,NCT01058005,"Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis",Biogen,Italy
658,,1659.0,NCT01058005,"Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis",Biogen,Latvia
658,,1659.0,NCT01058005,"Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis",Biogen,Poland
658,,1659.0,NCT01058005,"Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis",Biogen,Slovenia
658,,1659.0,NCT01058005,"Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis",Biogen,Spain
658,,1659.0,NCT01058005,"Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis",Biogen,Sweden
659,,1660.0,NCT01051349,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis,Biogen,Czechia
659,,1660.0,NCT01051349,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis,Biogen,Germany
659,,1660.0,NCT01051349,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis,Biogen,Hungary
659,,1660.0,NCT01051349,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis,Biogen,India
659,,1660.0,NCT01051349,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis,Biogen,Poland
659,,1660.0,NCT01051349,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis,Biogen,Russian Federation
659,,1660.0,NCT01051349,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis,Biogen,Ukraine
659,,1660.0,NCT01051349,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis,Biogen,United Kingdom
662,,1663.0,NCT00950248,Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS),National Institute of Allergy and Infectious Diseases (NIAID),United States
664,,1665.0,NCT00939549,High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis,Johns Hopkins University,United States
668,,1669.0,NCT00902135,"Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)",Bayer,Germany
669,,1670.0,NCT00882999,A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS),Eli Lilly and Company,United States
669,,1670.0,NCT00882999,A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS),Eli Lilly and Company,Bulgaria
669,,1670.0,NCT00882999,A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS),Eli Lilly and Company,Czechia
669,,1670.0,NCT00882999,A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS),Eli Lilly and Company,France
669,,1670.0,NCT00882999,A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS),Eli Lilly and Company,Germany
669,,1670.0,NCT00882999,A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS),Eli Lilly and Company,Hungary
669,,1670.0,NCT00882999,A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS),Eli Lilly and Company,Israel
669,,1670.0,NCT00882999,A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS),Eli Lilly and Company,Poland
669,,1670.0,NCT00882999,A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS),Eli Lilly and Company,Romania
669,,1670.0,NCT00882999,A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS),Eli Lilly and Company,Russian Federation
669,,1670.0,NCT00882999,A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS),Eli Lilly and Company,Serbia
669,,1670.0,NCT00882999,A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS),Eli Lilly and Company,Slovakia
669,,1670.0,NCT00882999,A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS),Eli Lilly and Company,Ukraine
670,,1671.0,NCT00879658,"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",Novartis Pharmaceuticals,United States
670,,1671.0,NCT00879658,"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",Novartis Pharmaceuticals,Canada
670,,1671.0,NCT00879658,"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",Novartis Pharmaceuticals,Finland
670,,1671.0,NCT00879658,"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",Novartis Pharmaceuticals,Germany
670,,1671.0,NCT00879658,"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",Novartis Pharmaceuticals,Hungary
670,,1671.0,NCT00879658,"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",Novartis Pharmaceuticals,Italy
670,,1671.0,NCT00879658,"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",Novartis Pharmaceuticals,Norway
670,,1671.0,NCT00879658,"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",Novartis Pharmaceuticals,Poland
670,,1671.0,NCT00879658,"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",Novartis Pharmaceuticals,Russian Federation
670,,1671.0,NCT00879658,"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",Novartis Pharmaceuticals,Spain
670,,1671.0,NCT00879658,"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",Novartis Pharmaceuticals,Switzerland
670,,1671.0,NCT00879658,"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",Novartis Pharmaceuticals,Turkey
671,,1672.0,NCT00870740,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis,Biogen,Czech Republic
671,,1672.0,NCT00870740,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis,Biogen,Germany
671,,1672.0,NCT00870740,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis,Biogen,Hungary
671,,1672.0,NCT00870740,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis,Biogen,India
671,,1672.0,NCT00870740,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis,Biogen,Poland
671,,1672.0,NCT00870740,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis,Biogen,Russian Federation
671,,1672.0,NCT00870740,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis,Biogen,Ukraine
671,,1672.0,NCT00870740,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis,Biogen,United Kingdom
672,,1673.0,NCT00869986,A Study for Patients With Relapsing Remitting Multiple Sclerosis,Eli Lilly and Company,Bulgaria
672,,1673.0,NCT00869986,A Study for Patients With Relapsing Remitting Multiple Sclerosis,Eli Lilly and Company,Poland
672,,1673.0,NCT00869986,A Study for Patients With Relapsing Remitting Multiple Sclerosis,Eli Lilly and Company,Russian Federation
672,,1673.0,NCT00869986,A Study for Patients With Relapsing Remitting Multiple Sclerosis,Eli Lilly and Company,Serbia
672,,1673.0,NCT00869986,A Study for Patients With Relapsing Remitting Multiple Sclerosis,Eli Lilly and Company,Slovakia
672,,1673.0,NCT00869986,A Study for Patients With Relapsing Remitting Multiple Sclerosis,Eli Lilly and Company,Ukraine
673,,1674.0,NCT00837785,A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS,Biogen,Germany
674,,1675.0,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),Biogen,United States
674,,1675.0,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),Biogen,Australia
674,,1675.0,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),Biogen,Austria
674,,1675.0,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),Biogen,Belarus
674,,1675.0,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),Biogen,Belgium
674,,1675.0,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),Biogen,Bosnia and Herzegovina
674,,1675.0,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),Biogen,Bulgaria
674,,1675.0,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),Biogen,Canada
674,,1675.0,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),Biogen,Croatia
674,,1675.0,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),Biogen,Czechia
674,,1675.0,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),Biogen,Estonia
674,,1675.0,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),Biogen,France
674,,1675.0,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),Biogen,Germany
674,,1675.0,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),Biogen,Greece
674,,1675.0,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),Biogen,India
674,,1675.0,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),Biogen,Ireland
674,,1675.0,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),Biogen,Israel
674,,1675.0,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),Biogen,Italy
674,,1675.0,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),Biogen,Latvia
674,,1675.0,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),Biogen,Mexico
674,,1675.0,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),Biogen,"Moldova, Republic of"
674,,1675.0,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),Biogen,Netherlands
674,,1675.0,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),Biogen,New Zealand
674,,1675.0,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),Biogen,North Macedonia
674,,1675.0,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),Biogen,Poland
674,,1675.0,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),Biogen,Puerto Rico
674,,1675.0,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),Biogen,Romania
674,,1675.0,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),Biogen,Serbia
674,,1675.0,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),Biogen,Slovakia
674,,1675.0,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),Biogen,South Africa
674,,1675.0,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),Biogen,Spain
674,,1675.0,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),Biogen,Switzerland
674,,1675.0,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),Biogen,Ukraine
674,,1675.0,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),Biogen,United Kingdom
678,,1679.0,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",Novartis Pharmaceuticals,United States
678,,1679.0,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",Novartis Pharmaceuticals,Australia
678,,1679.0,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",Novartis Pharmaceuticals,Belgium
678,,1679.0,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",Novartis Pharmaceuticals,Canada
678,,1679.0,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",Novartis Pharmaceuticals,Czechia
678,,1679.0,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",Novartis Pharmaceuticals,Denmark
678,,1679.0,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",Novartis Pharmaceuticals,Finland
678,,1679.0,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",Novartis Pharmaceuticals,France
678,,1679.0,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",Novartis Pharmaceuticals,Germany
678,,1679.0,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",Novartis Pharmaceuticals,Hungary
678,,1679.0,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",Novartis Pharmaceuticals,Italy
678,,1679.0,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",Novartis Pharmaceuticals,Netherlands
678,,1679.0,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",Novartis Pharmaceuticals,Poland
678,,1679.0,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",Novartis Pharmaceuticals,Spain
678,,1679.0,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",Novartis Pharmaceuticals,Sweden
678,,1679.0,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",Novartis Pharmaceuticals,Switzerland
678,,1679.0,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",Novartis Pharmaceuticals,Turkey
678,,1679.0,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",Novartis Pharmaceuticals,United Kingdom
679,,1680.0,NCT00668343,Simvastatin in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Using Avonex Compared to Placebo,Tehran University of Medical Sciences,"Iran, Islamic Republic of"
681,,1682.0,NCT00641537,CLARITY Extension Study,"EMD Serono Research & Development Institute, Inc.",United States
681,,1682.0,NCT00641537,CLARITY Extension Study,"EMD Serono Research & Development Institute, Inc.",Australia
681,,1682.0,NCT00641537,CLARITY Extension Study,"EMD Serono Research & Development Institute, Inc.",Austria
681,,1682.0,NCT00641537,CLARITY Extension Study,"EMD Serono Research & Development Institute, Inc.",Belgium
681,,1682.0,NCT00641537,CLARITY Extension Study,"EMD Serono Research & Development Institute, Inc.",Brazil
681,,1682.0,NCT00641537,CLARITY Extension Study,"EMD Serono Research & Development Institute, Inc.",Bulgaria
681,,1682.0,NCT00641537,CLARITY Extension Study,"EMD Serono Research & Development Institute, Inc.",Canada
681,,1682.0,NCT00641537,CLARITY Extension Study,"EMD Serono Research & Development Institute, Inc.",Croatia
681,,1682.0,NCT00641537,CLARITY Extension Study,"EMD Serono Research & Development Institute, Inc.",Czechia
681,,1682.0,NCT00641537,CLARITY Extension Study,"EMD Serono Research & Development Institute, Inc.",Denmark
681,,1682.0,NCT00641537,CLARITY Extension Study,"EMD Serono Research & Development Institute, Inc.",Estonia
681,,1682.0,NCT00641537,CLARITY Extension Study,"EMD Serono Research & Development Institute, Inc.",Finland
681,,1682.0,NCT00641537,CLARITY Extension Study,"EMD Serono Research & Development Institute, Inc.",France
681,,1682.0,NCT00641537,CLARITY Extension Study,"EMD Serono Research & Development Institute, Inc.",Germany
681,,1682.0,NCT00641537,CLARITY Extension Study,"EMD Serono Research & Development Institute, Inc.",Greece
681,,1682.0,NCT00641537,CLARITY Extension Study,"EMD Serono Research & Development Institute, Inc.",Italy
681,,1682.0,NCT00641537,CLARITY Extension Study,"EMD Serono Research & Development Institute, Inc.",Latvia
681,,1682.0,NCT00641537,CLARITY Extension Study,"EMD Serono Research & Development Institute, Inc.",Lebanon
681,,1682.0,NCT00641537,CLARITY Extension Study,"EMD Serono Research & Development Institute, Inc.",Lithuania
681,,1682.0,NCT00641537,CLARITY Extension Study,"EMD Serono Research & Development Institute, Inc.",Morocco
681,,1682.0,NCT00641537,CLARITY Extension Study,"EMD Serono Research & Development Institute, Inc.",Netherlands
681,,1682.0,NCT00641537,CLARITY Extension Study,"EMD Serono Research & Development Institute, Inc.",Poland
681,,1682.0,NCT00641537,CLARITY Extension Study,"EMD Serono Research & Development Institute, Inc.",Portugal
681,,1682.0,NCT00641537,CLARITY Extension Study,"EMD Serono Research & Development Institute, Inc.",Russian Federation
681,,1682.0,NCT00641537,CLARITY Extension Study,"EMD Serono Research & Development Institute, Inc.",Saudi Arabia
681,,1682.0,NCT00641537,CLARITY Extension Study,"EMD Serono Research & Development Institute, Inc.",Serbia
681,,1682.0,NCT00641537,CLARITY Extension Study,"EMD Serono Research & Development Institute, Inc.",Switzerland
681,,1682.0,NCT00641537,CLARITY Extension Study,"EMD Serono Research & Development Institute, Inc.",Tunisia
681,,1682.0,NCT00641537,CLARITY Extension Study,"EMD Serono Research & Development Institute, Inc.",Turkey
681,,1682.0,NCT00641537,CLARITY Extension Study,"EMD Serono Research & Development Institute, Inc.",Ukraine
681,,1682.0,NCT00641537,CLARITY Extension Study,"EMD Serono Research & Development Institute, Inc.",United Kingdom
682,,1683.0,NCT00623415,Flupirtine as Oral Treatment in Multiple Sclerosis,"Charite University, Berlin, Germany",Germany
684,,1685.0,NCT00574041,How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose,Biogen,Australia
685,,1686.0,NCT00534261,Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a?,Biogen,Belgium
685,,1686.0,NCT00534261,Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a?,Biogen,Luxembourg
685,,1686.0,NCT00534261,Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a?,Biogen,United Kingdom
686,,1687.0,NCT00525668,Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study),"Charite University, Berlin, Germany",Germany
687,,1688.0,NCT00493298,Tysabri Observational Program,Biogen,Argentina
687,,1688.0,NCT00493298,Tysabri Observational Program,Biogen,Australia
687,,1688.0,NCT00493298,Tysabri Observational Program,Biogen,Belgium
687,,1688.0,NCT00493298,Tysabri Observational Program,Biogen,Brazil
687,,1688.0,NCT00493298,Tysabri Observational Program,Biogen,Canada
687,,1688.0,NCT00493298,Tysabri Observational Program,Biogen,Czechia
687,,1688.0,NCT00493298,Tysabri Observational Program,Biogen,Finland
687,,1688.0,NCT00493298,Tysabri Observational Program,Biogen,France
687,,1688.0,NCT00493298,Tysabri Observational Program,Biogen,Germany
687,,1688.0,NCT00493298,Tysabri Observational Program,Biogen,Greece
687,,1688.0,NCT00493298,Tysabri Observational Program,Biogen,Italy
687,,1688.0,NCT00493298,Tysabri Observational Program,Biogen,Mexico
687,,1688.0,NCT00493298,Tysabri Observational Program,Biogen,Netherlands
687,,1688.0,NCT00493298,Tysabri Observational Program,Biogen,Norway
687,,1688.0,NCT00493298,Tysabri Observational Program,Biogen,Portugal
687,,1688.0,NCT00493298,Tysabri Observational Program,Biogen,Slovakia
687,,1688.0,NCT00493298,Tysabri Observational Program,Biogen,Spain
687,,1688.0,NCT00493298,Tysabri Observational Program,Biogen,United Kingdom
688,,1689.0,NCT00493116,Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta,Biogen,Australia
688,,1689.0,NCT00493116,Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta,Biogen,New Zealand
690,,1691.0,NCT00492466,Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies,Biogen,Finland
691,,1692.0,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,Biogen,United States
691,,1692.0,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,Biogen,Belarus
691,,1692.0,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,Biogen,Belgium
691,,1692.0,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,Biogen,Bosnia and Herzegovina
691,,1692.0,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,Biogen,Bulgaria
691,,1692.0,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,Biogen,Canada
691,,1692.0,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,Biogen,Costa Rica
691,,1692.0,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,Biogen,Croatia
691,,1692.0,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,Biogen,Czech Republic
691,,1692.0,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,Biogen,Estonia
691,,1692.0,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,Biogen,France
691,,1692.0,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,Biogen,Germany
691,,1692.0,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,Biogen,Greece
691,,1692.0,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,Biogen,India
691,,1692.0,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,Biogen,Ireland
691,,1692.0,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,Biogen,Israel
691,,1692.0,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,Biogen,Latvia
691,,1692.0,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,Biogen,"Macedonia, The Former Yugoslav Republic of"
691,,1692.0,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,Biogen,Mexico
691,,1692.0,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,Biogen,"Moldova, Republic of"
691,,1692.0,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,Biogen,New Zealand
691,,1692.0,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,Biogen,Poland
691,,1692.0,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,Biogen,Puerto Rico
691,,1692.0,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,Biogen,Romania
691,,1692.0,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,Biogen,Serbia
691,,1692.0,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,Biogen,Slovakia
691,,1692.0,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,Biogen,Spain
691,,1692.0,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,Biogen,Ukraine
694,,1695.0,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,Biogen,United States
694,,1695.0,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,Biogen,Australia
694,,1695.0,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,Biogen,Austria
694,,1695.0,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,Biogen,Belgium
694,,1695.0,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,Biogen,Bosnia and Herzegovina
694,,1695.0,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,Biogen,Canada
694,,1695.0,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,Biogen,Croatia
694,,1695.0,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,Biogen,Czech Republic
694,,1695.0,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,Biogen,France
694,,1695.0,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,Biogen,Germany
694,,1695.0,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,Biogen,Greece
694,,1695.0,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,Biogen,Guatemala
694,,1695.0,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,Biogen,India
694,,1695.0,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,Biogen,Israel
694,,1695.0,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,Biogen,Italy
694,,1695.0,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,Biogen,"Macedonia, The Former Yugoslav Republic of"
694,,1695.0,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,Biogen,Mexico
694,,1695.0,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,Biogen,"Moldova, Republic of"
694,,1695.0,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,Biogen,Netherlands
694,,1695.0,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,Biogen,New Zealand
694,,1695.0,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,Biogen,Poland
694,,1695.0,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,Biogen,Romania
694,,1695.0,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,Biogen,Serbia
694,,1695.0,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,Biogen,Slovakia
694,,1695.0,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,Biogen,South Africa
694,,1695.0,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,Biogen,Switzerland
694,,1695.0,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,Biogen,Ukraine
694,,1695.0,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,Biogen,United Kingdom
694,,1695.0,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,Biogen,Virgin Islands (U.S.)
697,,1698.0,NCT00390221,Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis,Biogen,Czech Republic
697,,1698.0,NCT00390221,Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis,Biogen,Germany
697,,1698.0,NCT00390221,Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis,Biogen,Hungary
697,,1698.0,NCT00390221,Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis,Biogen,India
697,,1698.0,NCT00390221,Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis,Biogen,Poland
697,,1698.0,NCT00390221,Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis,Biogen,Russian Federation
697,,1698.0,NCT00390221,Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis,Biogen,Ukraine
697,,1698.0,NCT00390221,Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis,Biogen,United Kingdom
703,,1704.0,NCT00317941,Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif,Bayer,France
705,,1706.0,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,Biogen,Australia
705,,1706.0,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,Biogen,Belgium
705,,1706.0,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,Biogen,Canada
705,,1706.0,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,Biogen,Czech Republic
705,,1706.0,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,Biogen,Denmark
705,,1706.0,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,Biogen,Finland
705,,1706.0,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,Biogen,France
705,,1706.0,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,Biogen,Germany
705,,1706.0,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,Biogen,Greece
705,,1706.0,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,Biogen,Hungary
705,,1706.0,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,Biogen,Ireland
705,,1706.0,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,Biogen,Israel
705,,1706.0,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,Biogen,Italy
705,,1706.0,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,Biogen,Netherlands
705,,1706.0,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,Biogen,New Zealand
705,,1706.0,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,Biogen,Poland
705,,1706.0,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,Biogen,Spain
705,,1706.0,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,Biogen,Sweden
705,,1706.0,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,Biogen,Switzerland
705,,1706.0,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,Biogen,Turkey
705,,1706.0,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,Biogen,United Kingdom
706,,1707.0,NCT00289978,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,Australia
706,,1707.0,NCT00289978,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,Belgium
706,,1707.0,NCT00289978,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,Canada
706,,1707.0,NCT00289978,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,Czech Republic
706,,1707.0,NCT00289978,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,Finland
706,,1707.0,NCT00289978,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,France
706,,1707.0,NCT00289978,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,Germany
706,,1707.0,NCT00289978,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,Greece
706,,1707.0,NCT00289978,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,Israel
706,,1707.0,NCT00289978,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,Lithuania
706,,1707.0,NCT00289978,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,Netherlands
706,,1707.0,NCT00289978,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,Poland
706,,1707.0,NCT00289978,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,Russian Federation
706,,1707.0,NCT00289978,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,Slovakia
706,,1707.0,NCT00289978,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,South Africa
706,,1707.0,NCT00289978,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,Sweden
706,,1707.0,NCT00289978,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,Switzerland
706,,1707.0,NCT00289978,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,Turkey
706,,1707.0,NCT00289978,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis,Novartis,United Kingdom
707,,1708.0,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,National Institute of Allergy and Infectious Diseases (NIAID),United States
711,,1712.0,NCT00219908,Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis,Rennes University Hospital,France
711,,1712.0,NCT00219908,Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis,Rennes University Hospital,Italy
720,,1721.0,NCT00168766,Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS,Biogen,Belgium
720,,1721.0,NCT00168766,Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS,Biogen,Denmark
720,,1721.0,NCT00168766,Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS,Biogen,Finland
720,,1721.0,NCT00168766,Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS,Biogen,Netherlands
720,,1721.0,NCT00168766,Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS,Biogen,Norway
720,,1721.0,NCT00168766,Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS,Biogen,Sweden
720,,1721.0,NCT00168766,Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS,Biogen,Switzerland
720,,1721.0,NCT00168766,Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS,Biogen,United Kingdom
722,,1723.0,NCT00078338,Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis,EMD Serono,United States
722,,1723.0,NCT00078338,Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis,EMD Serono,Argentina
722,,1723.0,NCT00078338,Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis,EMD Serono,Austria
722,,1723.0,NCT00078338,Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis,EMD Serono,Brazil
722,,1723.0,NCT00078338,Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis,EMD Serono,France
722,,1723.0,NCT00078338,Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis,EMD Serono,Germany
722,,1723.0,NCT00078338,Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis,EMD Serono,Italy
722,,1723.0,NCT00078338,Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis,EMD Serono,Netherlands
722,,1723.0,NCT00078338,Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis,EMD Serono,Russian Federation
722,,1723.0,NCT00078338,Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis,EMD Serono,Spain
722,,1723.0,NCT00078338,Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis,EMD Serono,Switzerland
722,,1723.0,NCT00078338,Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis,EMD Serono,United Kingdom
725,,1726.0,NCT04792567,Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC),Novartis Pharmaceuticals,Germany
726,,1727.0,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,United States
726,,1727.0,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Argentina
726,,1727.0,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Australia
726,,1727.0,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Austria
726,,1727.0,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Belarus
726,,1727.0,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Belgium
726,,1727.0,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Bulgaria
726,,1727.0,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Canada
726,,1727.0,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,China
726,,1727.0,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Czechia
726,,1727.0,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Denmark
726,,1727.0,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Finland
726,,1727.0,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,France
726,,1727.0,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Germany
726,,1727.0,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Greece
726,,1727.0,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Hungary
726,,1727.0,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,India
726,,1727.0,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Israel
726,,1727.0,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Italy
726,,1727.0,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Japan
726,,1727.0,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Lithuania
726,,1727.0,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Netherlands
726,,1727.0,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Norway
726,,1727.0,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Poland
726,,1727.0,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Portugal
726,,1727.0,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Romania
726,,1727.0,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Russian Federation
726,,1727.0,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Spain
726,,1727.0,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Turkey
726,,1727.0,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,Ukraine
726,,1727.0,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Sanofi,United Kingdom
728,,1729.0,NCT03896217,Simvastatin in Secondary Progressive Multiple Sclerosis,"University College, London",United Kingdom
731,,1732.0,NCT02330965,Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis,National Institute of Allergy and Infectious Diseases (NIAID),United States
735,,1736.0,NCT01910259,MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial,"University College, London",United Kingdom
736,,1737.0,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),Novartis Pharmaceuticals,United States
736,,1737.0,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),Novartis Pharmaceuticals,Argentina
736,,1737.0,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),Novartis Pharmaceuticals,Australia
736,,1737.0,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),Novartis Pharmaceuticals,Austria
736,,1737.0,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),Novartis Pharmaceuticals,Belgium
736,,1737.0,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),Novartis Pharmaceuticals,Bulgaria
736,,1737.0,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),Novartis Pharmaceuticals,Canada
736,,1737.0,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),Novartis Pharmaceuticals,China
736,,1737.0,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),Novartis Pharmaceuticals,Czechia
736,,1737.0,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),Novartis Pharmaceuticals,Estonia
736,,1737.0,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),Novartis Pharmaceuticals,France
736,,1737.0,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),Novartis Pharmaceuticals,Germany
736,,1737.0,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),Novartis Pharmaceuticals,Greece
736,,1737.0,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),Novartis Pharmaceuticals,Hungary
736,,1737.0,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),Novartis Pharmaceuticals,Ireland
736,,1737.0,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),Novartis Pharmaceuticals,Israel
736,,1737.0,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),Novartis Pharmaceuticals,Italy
736,,1737.0,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),Novartis Pharmaceuticals,Japan
736,,1737.0,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),Novartis Pharmaceuticals,Latvia
736,,1737.0,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),Novartis Pharmaceuticals,Lithuania
736,,1737.0,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),Novartis Pharmaceuticals,Netherlands
736,,1737.0,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),Novartis Pharmaceuticals,Poland
736,,1737.0,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),Novartis Pharmaceuticals,Portugal
736,,1737.0,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),Novartis Pharmaceuticals,Romania
736,,1737.0,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),Novartis Pharmaceuticals,Russian Federation
736,,1737.0,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),Novartis Pharmaceuticals,Slovakia
736,,1737.0,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),Novartis Pharmaceuticals,Spain
736,,1737.0,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),Novartis Pharmaceuticals,Sweden
736,,1737.0,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),Novartis Pharmaceuticals,Switzerland
736,,1737.0,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),Novartis Pharmaceuticals,Turkey
736,,1737.0,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),Novartis Pharmaceuticals,United Kingdom
737,,1738.0,NCT01647321,Functional Electrical Stimulation for Individuals With Secondary Progressive Multiple Sclerosis,Johns Hopkins University,United States
738,,1739.0,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,Biogen,United States
738,,1739.0,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,Biogen,Belgium
738,,1739.0,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,Biogen,Canada
738,,1739.0,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,Biogen,Czechia
738,,1739.0,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,Biogen,Denmark
738,,1739.0,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,Biogen,Finland
738,,1739.0,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,Biogen,France
738,,1739.0,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,Biogen,Germany
738,,1739.0,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,Biogen,Ireland
738,,1739.0,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,Biogen,Israel
738,,1739.0,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,Biogen,Italy
738,,1739.0,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,Biogen,Netherlands
738,,1739.0,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,Biogen,Poland
738,,1739.0,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,Biogen,Russian Federation
738,,1739.0,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,Biogen,Spain
738,,1739.0,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,Biogen,Sweden
738,,1739.0,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,Biogen,United Kingdom
741,,1742.0,NCT00870155,A Study for Patients With Multiple Sclerosis,Eli Lilly and Company,Canada
741,,1742.0,NCT00870155,A Study for Patients With Multiple Sclerosis,Eli Lilly and Company,Denmark
741,,1742.0,NCT00870155,A Study for Patients With Multiple Sclerosis,Eli Lilly and Company,Estonia
741,,1742.0,NCT00870155,A Study for Patients With Multiple Sclerosis,Eli Lilly and Company,Finland
741,,1742.0,NCT00870155,A Study for Patients With Multiple Sclerosis,Eli Lilly and Company,Germany
741,,1742.0,NCT00870155,A Study for Patients With Multiple Sclerosis,Eli Lilly and Company,Latvia
741,,1742.0,NCT00870155,A Study for Patients With Multiple Sclerosis,Eli Lilly and Company,Netherlands
741,,1742.0,NCT00870155,A Study for Patients With Multiple Sclerosis,Eli Lilly and Company,Spain
741,,1742.0,NCT00870155,A Study for Patients With Multiple Sclerosis,Eli Lilly and Company,Sweden
741,,1742.0,NCT00870155,A Study for Patients With Multiple Sclerosis,Eli Lilly and Company,United Kingdom
742,,1743.0,NCT00869726,A Study for Patients With Secondary Progressive Multiple Sclerosis,Eli Lilly and Company,Canada
742,,1743.0,NCT00869726,A Study for Patients With Secondary Progressive Multiple Sclerosis,Eli Lilly and Company,Denmark
742,,1743.0,NCT00869726,A Study for Patients With Secondary Progressive Multiple Sclerosis,Eli Lilly and Company,Estonia
742,,1743.0,NCT00869726,A Study for Patients With Secondary Progressive Multiple Sclerosis,Eli Lilly and Company,Finland
742,,1743.0,NCT00869726,A Study for Patients With Secondary Progressive Multiple Sclerosis,Eli Lilly and Company,Germany
742,,1743.0,NCT00869726,A Study for Patients With Secondary Progressive Multiple Sclerosis,Eli Lilly and Company,Latvia
742,,1743.0,NCT00869726,A Study for Patients With Secondary Progressive Multiple Sclerosis,Eli Lilly and Company,Netherlands
742,,1743.0,NCT00869726,A Study for Patients With Secondary Progressive Multiple Sclerosis,Eli Lilly and Company,Spain
742,,1743.0,NCT00869726,A Study for Patients With Secondary Progressive Multiple Sclerosis,Eli Lilly and Company,Sweden
742,,1743.0,NCT00869726,A Study for Patients With Secondary Progressive Multiple Sclerosis,Eli Lilly and Company,United Kingdom
749,,1750.0,NCT04878211,A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab,Novartis Pharmaceuticals,United States
750,,1751.0,NCT04667949,Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients,Novartis Pharmaceuticals,China
752,,1753.0,NCT03745144,Effects of Cladribine Tablets on the PK of Microgynon®,"Merck KGaA, Darmstadt, Germany",Germany
752,,1753.0,NCT03745144,Effects of Cladribine Tablets on the PK of Microgynon®,"Merck KGaA, Darmstadt, Germany",Poland
755,,1756.0,NCT02921035,Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS),"Merck KGaA, Darmstadt, Germany",Algeria
755,,1756.0,NCT02921035,Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS),"Merck KGaA, Darmstadt, Germany",Argentina
755,,1756.0,NCT02921035,Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS),"Merck KGaA, Darmstadt, Germany",Bahrain
755,,1756.0,NCT02921035,Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS),"Merck KGaA, Darmstadt, Germany",Bulgaria
755,,1756.0,NCT02921035,Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS),"Merck KGaA, Darmstadt, Germany",Egypt
755,,1756.0,NCT02921035,Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS),"Merck KGaA, Darmstadt, Germany",Hungary
755,,1756.0,NCT02921035,Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS),"Merck KGaA, Darmstadt, Germany","Iran, Islamic Republic of"
755,,1756.0,NCT02921035,Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS),"Merck KGaA, Darmstadt, Germany","Korea, Republic of"
755,,1756.0,NCT02921035,Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS),"Merck KGaA, Darmstadt, Germany",Kuwait
755,,1756.0,NCT02921035,Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS),"Merck KGaA, Darmstadt, Germany",Lebanon
755,,1756.0,NCT02921035,Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS),"Merck KGaA, Darmstadt, Germany",Morocco
755,,1756.0,NCT02921035,Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS),"Merck KGaA, Darmstadt, Germany",Poland
755,,1756.0,NCT02921035,Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS),"Merck KGaA, Darmstadt, Germany",Saudi Arabia
756,,1757.0,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,Hoffmann-La Roche,United States
756,,1757.0,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,Hoffmann-La Roche,Bosnia and Herzegovina
756,,1757.0,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,Hoffmann-La Roche,Brazil
756,,1757.0,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,Hoffmann-La Roche,Canada
756,,1757.0,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,Hoffmann-La Roche,Colombia
756,,1757.0,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,Hoffmann-La Roche,Costa Rica
756,,1757.0,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,Hoffmann-La Roche,Czechia
756,,1757.0,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,Hoffmann-La Roche,Denmark
756,,1757.0,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,Hoffmann-La Roche,Egypt
756,,1757.0,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,Hoffmann-La Roche,France
756,,1757.0,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,Hoffmann-La Roche,Germany
756,,1757.0,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,Hoffmann-La Roche,Guatemala
756,,1757.0,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,Hoffmann-La Roche,Hungary
756,,1757.0,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,Hoffmann-La Roche,Ireland
756,,1757.0,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,Hoffmann-La Roche,Italy
756,,1757.0,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,Hoffmann-La Roche,Lebanon
756,,1757.0,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,Hoffmann-La Roche,Mexico
756,,1757.0,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,Hoffmann-La Roche,Morocco
756,,1757.0,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,Hoffmann-La Roche,Netherlands
756,,1757.0,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,Hoffmann-La Roche,Panama
756,,1757.0,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,Hoffmann-La Roche,Poland
756,,1757.0,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,Hoffmann-La Roche,Russian Federation
756,,1757.0,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,Hoffmann-La Roche,Saudi Arabia
756,,1757.0,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,Hoffmann-La Roche,Spain
756,,1757.0,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,Hoffmann-La Roche,United Arab Emirates
758,,1759.0,NCT00095329,"Treating Multiple Sclerosis With Sirolimus, an Immune System Suppressor",National Institute of Allergy and Infectious Diseases (NIAID),United States
759,,1760.0,NCT01235455,"Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors",Bayer,Portugal
760,,1761.0,NCT01705236,A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®,Novartis Pharmaceuticals,Germany
760,,1761.0,NCT01705236,A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®,Novartis Pharmaceuticals,Switzerland
763,,1764.0,NCT04676555,Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis,Novartis Pharmaceuticals,United States
763,,1764.0,NCT04676555,Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis,Novartis Pharmaceuticals,Australia
763,,1764.0,NCT04676555,Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis,Novartis Pharmaceuticals,United Kingdom
764,,1765.0,NCT02230969,Plegridy Observational Program,Biogen,United States
764,,1765.0,NCT02230969,Plegridy Observational Program,Biogen,Australia
764,,1765.0,NCT02230969,Plegridy Observational Program,Biogen,Austria
764,,1765.0,NCT02230969,Plegridy Observational Program,Biogen,Canada
764,,1765.0,NCT02230969,Plegridy Observational Program,Biogen,Denmark
764,,1765.0,NCT02230969,Plegridy Observational Program,Biogen,France
764,,1765.0,NCT02230969,Plegridy Observational Program,Biogen,Germany
764,,1765.0,NCT02230969,Plegridy Observational Program,Biogen,Ireland
764,,1765.0,NCT02230969,Plegridy Observational Program,Biogen,Italy
764,,1765.0,NCT02230969,Plegridy Observational Program,Biogen,Netherlands
764,,1765.0,NCT02230969,Plegridy Observational Program,Biogen,Portugal
764,,1765.0,NCT02230969,Plegridy Observational Program,Biogen,Spain
764,,1765.0,NCT02230969,Plegridy Observational Program,Biogen,Switzerland
764,,1765.0,NCT02230969,Plegridy Observational Program,Biogen,United Kingdom
765,,1766.0,NCT02097849,Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.,Biogen,United States
766,,1767.0,NCT01903291,Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS,Biogen,United States
767,,1768.0,NCT01873417,Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States,Biogen,United States
768,,1769.0,NCT01216072,"A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis",Novartis Pharmaceuticals,United States
768,,1769.0,NCT01216072,"A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis",Novartis Pharmaceuticals,Canada
768,,1769.0,NCT01216072,"A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis",Novartis Pharmaceuticals,Puerto Rico
769,,1770.0,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,Novartis Pharmaceuticals,United States
769,,1770.0,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,Novartis Pharmaceuticals,Argentina
769,,1770.0,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,Novartis Pharmaceuticals,Australia
769,,1770.0,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,Novartis Pharmaceuticals,Austria
769,,1770.0,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,Novartis Pharmaceuticals,Belgium
769,,1770.0,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,Novartis Pharmaceuticals,Brazil
769,,1770.0,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,Novartis Pharmaceuticals,Canada
769,,1770.0,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,Novartis Pharmaceuticals,Czechia
769,,1770.0,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,Novartis Pharmaceuticals,Denmark
769,,1770.0,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,Novartis Pharmaceuticals,Egypt
769,,1770.0,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,Novartis Pharmaceuticals,Estonia
769,,1770.0,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,Novartis Pharmaceuticals,Finland
769,,1770.0,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,Novartis Pharmaceuticals,France
769,,1770.0,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,Novartis Pharmaceuticals,Germany
769,,1770.0,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,Novartis Pharmaceuticals,Greece
769,,1770.0,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,Novartis Pharmaceuticals,Guatemala
769,,1770.0,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,Novartis Pharmaceuticals,Hungary
769,,1770.0,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,Novartis Pharmaceuticals,Ireland
769,,1770.0,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,Novartis Pharmaceuticals,Israel
769,,1770.0,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,Novartis Pharmaceuticals,Italy
769,,1770.0,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,Novartis Pharmaceuticals,Jordan
769,,1770.0,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,Novartis Pharmaceuticals,"Korea, Republic of"
769,,1770.0,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,Novartis Pharmaceuticals,Malaysia
769,,1770.0,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,Novartis Pharmaceuticals,Netherlands
769,,1770.0,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,Novartis Pharmaceuticals,Norway
769,,1770.0,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,Novartis Pharmaceuticals,Panama
769,,1770.0,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,Novartis Pharmaceuticals,Peru
769,,1770.0,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,Novartis Pharmaceuticals,Poland
769,,1770.0,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,Novartis Pharmaceuticals,Portugal
769,,1770.0,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,Novartis Pharmaceuticals,Romania
769,,1770.0,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,Novartis Pharmaceuticals,Russian Federation
769,,1770.0,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,Novartis Pharmaceuticals,Slovakia
769,,1770.0,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,Novartis Pharmaceuticals,South Africa
769,,1770.0,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,Novartis Pharmaceuticals,Spain
769,,1770.0,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,Novartis Pharmaceuticals,Sweden
769,,1770.0,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,Novartis Pharmaceuticals,Switzerland
769,,1770.0,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,Novartis Pharmaceuticals,Turkey
769,,1770.0,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,Novartis Pharmaceuticals,United Kingdom
770,,1771.0,NCT00424788,A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS),Biogen,United States
772,,1773.0,NCT02307838,Long-term Follow-up of Fingolimod Phase II Study Patients,Novartis Pharmaceuticals,Canada
772,,1773.0,NCT02307838,Long-term Follow-up of Fingolimod Phase II Study Patients,Novartis Pharmaceuticals,Denmark
772,,1773.0,NCT02307838,Long-term Follow-up of Fingolimod Phase II Study Patients,Novartis Pharmaceuticals,France
772,,1773.0,NCT02307838,Long-term Follow-up of Fingolimod Phase II Study Patients,Novartis Pharmaceuticals,Germany
772,,1773.0,NCT02307838,Long-term Follow-up of Fingolimod Phase II Study Patients,Novartis Pharmaceuticals,Italy
772,,1773.0,NCT02307838,Long-term Follow-up of Fingolimod Phase II Study Patients,Novartis Pharmaceuticals,Poland
772,,1773.0,NCT02307838,Long-term Follow-up of Fingolimod Phase II Study Patients,Novartis Pharmaceuticals,Portugal
772,,1773.0,NCT02307838,Long-term Follow-up of Fingolimod Phase II Study Patients,Novartis Pharmaceuticals,Spain
772,,1773.0,NCT02307838,Long-term Follow-up of Fingolimod Phase II Study Patients,Novartis Pharmaceuticals,Switzerland
772,,1773.0,NCT02307838,Long-term Follow-up of Fingolimod Phase II Study Patients,Novartis Pharmaceuticals,United Kingdom
773,,1774.0,NCT01978574,Intellectual Enrichment to Build Cognitive Reserve in MS,Kessler Foundation,United States
774,,1775.0,NCT01144117,The Effects of Erythropoietin on Clinical Disability and Brain Pathology in Patients With Progressive Multiple Sclerosis,"Rigshospitalet, Denmark",Denmark
775,,1776.0,NCT03623243,"Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients.",Novartis Pharmaceuticals,United States
775,,1776.0,NCT03623243,"Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients.",Novartis Pharmaceuticals,Puerto Rico
780,,1781.0,NCT02881567,Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab,Biogen,United States
780,,1781.0,NCT02881567,Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab,Biogen,Canada
780,,1781.0,NCT02881567,Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab,Biogen,Germany
780,,1781.0,NCT02881567,Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab,Biogen,Italy
780,,1781.0,NCT02881567,Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab,Biogen,Puerto Rico
781,,1782.0,NCT02587065,Plegridy Satisfaction Study in Participants,Biogen,Italy
785,,1786.0,NCT01633112,MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone,Novartis Pharmaceuticals,United States
785,,1786.0,NCT01633112,MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone,Novartis Pharmaceuticals,Argentina
785,,1786.0,NCT01633112,MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone,Novartis Pharmaceuticals,Brazil
785,,1786.0,NCT01633112,MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone,Novartis Pharmaceuticals,Canada
785,,1786.0,NCT01633112,MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone,Novartis Pharmaceuticals,Chile
785,,1786.0,NCT01633112,MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone,Novartis Pharmaceuticals,Mexico
785,,1786.0,NCT01633112,MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone,Novartis Pharmaceuticals,Puerto Rico
786,,1787.0,NCT01499667,Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod,Novartis Pharmaceuticals,Australia
786,,1787.0,NCT01499667,Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod,Novartis Pharmaceuticals,Austria
786,,1787.0,NCT01499667,Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod,Novartis Pharmaceuticals,Czech Republic
786,,1787.0,NCT01499667,Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod,Novartis Pharmaceuticals,Finland
786,,1787.0,NCT01499667,Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod,Novartis Pharmaceuticals,Germany
786,,1787.0,NCT01499667,Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod,Novartis Pharmaceuticals,Greece
786,,1787.0,NCT01499667,Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod,Novartis Pharmaceuticals,Hungary
786,,1787.0,NCT01499667,Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod,Novartis Pharmaceuticals,Israel
786,,1787.0,NCT01499667,Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod,Novartis Pharmaceuticals,Italy
786,,1787.0,NCT01499667,Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod,Novartis Pharmaceuticals,Spain
786,,1787.0,NCT01499667,Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod,Novartis Pharmaceuticals,Switzerland
787,,1788.0,NCT01125475,A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects,"Merck KGaA, Darmstadt, Germany",Norway
788,,1789.0,NCT00871780,"A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients",Biogen,Belgium
788,,1789.0,NCT00871780,"A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients",Biogen,Mexico
788,,1789.0,NCT00871780,"A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients",Biogen,Poland
788,,1789.0,NCT00871780,"A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients",Biogen,Romania
788,,1789.0,NCT00871780,"A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients",Biogen,Saudi Arabia
788,,1789.0,NCT00871780,"A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients",Biogen,Ukraine
789,,1790.0,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,Bayer,Argentina
789,,1790.0,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,Bayer,Bahrain
789,,1790.0,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,Bayer,Belgium
789,,1790.0,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,Bayer,Bosnia and Herzegovina
789,,1790.0,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,Bayer,Canada
789,,1790.0,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,Bayer,China
789,,1790.0,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,Bayer,Colombia
789,,1790.0,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,Bayer,Czech Republic
789,,1790.0,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,Bayer,Egypt
789,,1790.0,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,Bayer,Estonia
789,,1790.0,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,Bayer,France
789,,1790.0,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,Bayer,Germany
789,,1790.0,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,Bayer,"Iran, Islamic Republic of"
789,,1790.0,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,Bayer,Israel
789,,1790.0,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,Bayer,Italy
789,,1790.0,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,Bayer,Jordan
789,,1790.0,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,Bayer,"Korea, Republic of"
789,,1790.0,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,Bayer,Kuwait
789,,1790.0,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,Bayer,Lebanon
789,,1790.0,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,Bayer,Libyan Arab Jamahiriya
789,,1790.0,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,Bayer,Mexico
789,,1790.0,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,Bayer,Netherlands
789,,1790.0,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,Bayer,New Zealand
789,,1790.0,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,Bayer,Norway
789,,1790.0,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,Bayer,Pakistan
789,,1790.0,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,Bayer,Portugal
789,,1790.0,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,Bayer,Saudi Arabia
789,,1790.0,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,Bayer,Singapore
789,,1790.0,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,Bayer,Slovakia
789,,1790.0,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,Bayer,Slovenia
789,,1790.0,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,Bayer,Sweden
789,,1790.0,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,Bayer,Syrian Arab Republic
789,,1790.0,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,Bayer,Taiwan
789,,1790.0,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,Bayer,United Arab Emirates
789,,1790.0,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,Bayer,United Kingdom
789,,1790.0,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,Bayer,Venezuela
790,,1791.0,NCT00428584,RNF and Betaseron® Tolerability Study,EMD Serono,United States
792,,1793.0,NCT04593927,Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients,Novartis Pharmaceuticals,Japan
794,,1795.0,NCT03387670,Multiple Sclerosis-Simvastatin Trial 2,"University College, London",Ireland
794,,1795.0,NCT03387670,Multiple Sclerosis-Simvastatin Trial 2,"University College, London",United Kingdom
795,,1796.0,NCT01086371,Rhythmic Auditory Stimulation and Walking Performance in Multiple Sclerosis (MS) Patients,The Cleveland Clinic,United States
799,,1800.0,NCT02543788,CHRONIC OPTIC NEUROPATHY IN MULTIPLE SCLEROSIS,Hospices Civils de Lyon,France
802,,1803.0,NCT04657666,Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Patients With Multiple Sclerosis,GW Pharmaceuticals Ltd.,Czechia
802,,1803.0,NCT04657666,Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Patients With Multiple Sclerosis,GW Pharmaceuticals Ltd.,Poland
803,,1804.0,NCT01744444,Treatment of Pendular Nystagmus With Gabapentin and Memantine in Patients With Multiple Sclerosis,Hospices Civils de Lyon,France
806,,1807.0,NCT03453125,Improving Learning in Hispanics With TBI or MS,Kessler Foundation,United States
806,,1807.0,NCT03453125,Improving Learning in Hispanics With TBI or MS,Kessler Foundation,Spain
810,,1811.0,NCT02688985,Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS),"Genentech, Inc.",United States
810,,1811.0,NCT02688985,Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS),"Genentech, Inc.",Canada
810,,1811.0,NCT02688985,Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS),"Genentech, Inc.",Germany
810,,1811.0,NCT02688985,Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS),"Genentech, Inc.",Sweden
815,,1816.0,NCT05060354,COVID Vaccine Response in MS,Brigham and Women's Hospital,United States
819,,1820.0,NCT04998851,A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab,Hoffmann-La Roche,United States
819,,1820.0,NCT04998851,A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab,Hoffmann-La Roche,Canada
819,,1820.0,NCT04998851,A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab,Hoffmann-La Roche,France
819,,1820.0,NCT04998851,A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab,Hoffmann-La Roche,Germany
819,,1820.0,NCT04998851,A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab,Hoffmann-La Roche,Italy
819,,1820.0,NCT04998851,A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab,Hoffmann-La Roche,Spain
819,,1820.0,NCT04998851,A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab,Hoffmann-La Roche,Switzerland
819,,1820.0,NCT04998851,A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab,Hoffmann-La Roche,United Kingdom
820,,1821.0,NCT04998812,A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy,Hoffmann-La Roche,United States
820,,1821.0,NCT04998812,A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy,Hoffmann-La Roche,France
820,,1821.0,NCT04998812,A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy,Hoffmann-La Roche,Germany
820,,1821.0,NCT04998812,A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy,Hoffmann-La Roche,Italy
820,,1821.0,NCT04998812,A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy,Hoffmann-La Roche,Spain
820,,1821.0,NCT04998812,A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy,Hoffmann-La Roche,Switzerland
820,,1821.0,NCT04998812,A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy,Hoffmann-La Roche,United Kingdom
824,,1825.0,NCT04908891,"A Comprehensive Assessment of Trunk, Scapula and Upper Limb in Neurological Patients. Reliability, Validity and Interrelatedness",Hasselt University,Belgium
830,,1831.0,NCT04798651,Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis,"University Hospital, Bordeaux",France
833,,1834.0,NCT04688710,Use of Audio Recordings of Self-Hypnosis and Meditation for Fatigue Management in Multiple Sclerosis,University of Washington,United States
834,,1835.0,NCT04682548,Estimating Prevalence of COVID-19 Infection and SARS-CoV-2 Antibodies in MS Patients,NYU Langone Health,United States
839,,1840.0,NCT04639401,Auditory-motor Coupling in Multiple Sclerosis With Cerebellar Lesions,Hasselt University,Belgium
845,,1846.0,NCT04466228,Non-invasive Transcranial Electrical Stimulation in MS,"University of California, San Francisco",United States
848,,1849.0,NCT04408274,Remediation of Emotional Deficits in Multiple Sclerosis and Traumatic Brain Injury,Kessler Foundation,United States
849,,1850.0,NCT04389970,Time Restricted Eating Outcomes in Multiple Sclerosis,University of Alabama at Birmingham,United States
851,,1852.0,NCT04387110,Ocrelizumab in Breastmilk,"University of California, San Francisco",United States
854,,1855.0,NCT04314076,Rhythmic Auditory Stimulation & Gait Training,The Cleveland Clinic,United States
855,,1856.0,NCT04291456,Minocycline in MS: Confirmation of Benefit,University of Calgary,Canada
857,,1858.0,NCT04267926,MitoQ for Fatigue in Multiple Sclerosis (MS),VA Office of Research and Development,United States
860,,1861.0,NCT04202055,Immunologic Biomarker Profile of Cerebrospinal Fluid,Centre Hospitalier Universitaire de Nīmes,France
861,,1862.0,NCT04175834,Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab,Providence Health & Services,United States
865,,1866.0,NCT04061681,Efficacy of BIPAMS for Restless Legs Syndrome in Adults With Multiple Sclerosis: A Pilot Study,University of Alabama at Birmingham,United States
869,,1870.0,NCT04002102,Open-Label Placebos to Treat Fatigue in Multiple Sclerosis,University of Alabama at Birmingham,United States
870,,1871.0,NCT04000373,Pilot Study of Powered Exoskeleton Use for Gait Rehabilitation in Individuals With Multiple Sclerosis,The Cleveland Clinic,United States
872,,1873.0,NCT03951974,A Social Emotion Regulation Intervention in MS,Kessler Foundation,United States
873,,1874.0,NCT03938558,Art for MS - Controlled Trial,Hasselt University,Belgium
877,,1878.0,NCT03759249,Sleep Medical Treatment in MS Patients Suffering From Fatigue,"Charite University, Berlin, Germany",Germany
880,,1881.0,NCT03723356,Linking Cognitive Functioning to Multimodal Imaging in Multiple Sclerosis (MS),NYU Langone Health,United States
882,,1883.0,NCT03677440,Exercise Training Effects on Cognition and Brain Function in Multiple Sclerosis: Project EXACT,Kessler Foundation,United States
883,,1884.0,NCT03668990,"Feasability, Validty and Reliability of Inertial Sensors",Hasselt University,Belgium
885,,1886.0,NCT03569618,Digital Cognition in Multiple Sclerosis,"University of California, San Francisco",United States
888,,1889.0,NCT03500289,Ketamine for Treatment of MS Fatigue,Johns Hopkins University,United States
891,,1892.0,NCT03438357,Evaluation of an Automatic Segmentation Software (Pixyl.Neuro) to Track Lesions in Multiple Sclerosis Patients Via Cerebral MRI,Centre Hospitalier Universitaire de Nīmes,France
893,,1894.0,NCT03368157,PREG-MS: New England MS Pregnancy Registry,Brigham and Women's Hospital,United States
894,,1895.0,NCT03357887,Prognostic Value of Three New Biomarkers of Multiple Sclerosis in Patients With Radiologically Isolated Syndrome,Centre Hospitalier Universitaire de Nīmes,France
897,,1898.0,NCT03319732,A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS,Osmotica Pharmaceutical US LLC,United States
899,,1900.0,NCT03290131,A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS,Osmotica Pharmaceutical US LLC,Belarus
899,,1900.0,NCT03290131,A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS,Osmotica Pharmaceutical US LLC,Bosnia and Herzegovina
899,,1900.0,NCT03290131,A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS,Osmotica Pharmaceutical US LLC,Bulgaria
899,,1900.0,NCT03290131,A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS,Osmotica Pharmaceutical US LLC,Croatia
899,,1900.0,NCT03290131,A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS,Osmotica Pharmaceutical US LLC,"Moldova, Republic of"
899,,1900.0,NCT03290131,A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS,Osmotica Pharmaceutical US LLC,Poland
899,,1900.0,NCT03290131,A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS,Osmotica Pharmaceutical US LLC,Serbia
902,,1903.0,NCT03166800,MitoQ for Fatigue in Multiple Sclerosis,Oregon Health and Science University,United States
903,,1904.0,NCT03138525,Immune Profiling During Ocrelizumab Treatment in Multiple Sclerosis,Brigham and Women's Hospital,United States
904,,1905.0,NCT03108950,From Clinic to Community: An Information and Communication Technology (ICT) Home-Based Exercise Training System for Translating Clinical Findings,University of Alabama at Birmingham,United States
906,,1907.0,NCT03049969,Cognitive Remediation Augmented With Transcranial Direct Current Stimulation (tDCS),NYU Langone Health,United States
909,,1910.0,NCT02907281,Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis,Novartis Pharmaceuticals,United States
909,,1910.0,NCT02907281,Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis,Novartis Pharmaceuticals,Australia
909,,1910.0,NCT02907281,Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis,Novartis Pharmaceuticals,Canada
909,,1910.0,NCT02907281,Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis,Novartis Pharmaceuticals,Czechia
909,,1910.0,NCT02907281,Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis,Novartis Pharmaceuticals,Denmark
909,,1910.0,NCT02907281,Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis,Novartis Pharmaceuticals,Germany
909,,1910.0,NCT02907281,Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis,Novartis Pharmaceuticals,Italy
909,,1910.0,NCT02907281,Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis,Novartis Pharmaceuticals,Netherlands
909,,1910.0,NCT02907281,Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis,Novartis Pharmaceuticals,Poland
909,,1910.0,NCT02907281,Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis,Novartis Pharmaceuticals,Spain
909,,1910.0,NCT02907281,Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis,Novartis Pharmaceuticals,Switzerland
909,,1910.0,NCT02907281,Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis,Novartis Pharmaceuticals,United Kingdom
910,,1911.0,NCT02889965,The French Multiple Sclerosis Registry,Hospices Civils de Lyon,France
912,,1913.0,NCT02869425,To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS,Osmotica Pharmaceutical US LLC,United States
914,,1915.0,NCT02833142,"Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes",Biogen,United States
917,,1918.0,NCT02740296,Depression and Immune Function in Multiple Sclerosis (MS),"Charite University, Berlin, Germany",Germany
919,,1920.0,NCT02649985,Microglial Activation Positron Emission Tomography (PET) Brain Imaging in Multiple Sclerosis and Alzheimer's Disease,Brigham and Women's Hospital,United States
920,,1921.0,NCT02636829,Validation of Self-administered Questionnaire for Assessing Calcium Intake in Patients With Multiple Sclerosis or Chronic Inflammatory Arthritis,Centre Hospitalier Universitaire de Nīmes,France
922,,1923.0,NCT02538094,tDCS and Cognition in Adults With Multiple Sclerosis or Encephalitis,Johns Hopkins University,United States
923,,1924.0,NCT02533882,Lakeshore Examination of Activity and Disability Exercise Response Study,University of Alabama at Birmingham,United States
925,,1926.0,NCT02490046,D-mannose for the Prevention of UTIs in Multiple Sclerosis,"University College, London",United Kingdom
926,,1927.0,NCT02468765,Depression and Facial Identity Recognition Abilities in Patients With Multiple Sclerosis,Lille Catholic University,France
928,,1929.0,NCT02463318,The Effect of Melatonin on Gene Expression and Activity of the Sirt1 and Its Target Genes Catalase and MnSOD in Multiple Sclerosis Patients and Healthy Subjects,Tehran University of Medical Sciences,"Iran, Islamic Republic of"
930,,1931.0,NCT02170779,Developing and Testing a Comprehensive MS Spasticity Management Program,VA Office of Research and Development,United States
931,,1932.0,NCT02133664,Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis,Oregon Health and Science University,United States
933,,1934.0,NCT02065284,Effects of a Home Based Walking Program Using Rhythmic Auditory Stimulation in Patients With Multiple Sclerosis,The Cleveland Clinic,United States
937,,1938.0,NCT01964547,A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients,GW Pharmaceuticals Ltd.,Czech Republic
940,,1941.0,NCT01918748,Effect of I-TRAVLE Training on Arm Function in MS and Chronic Stroke Patients,Hasselt University,Belgium
940,,1941.0,NCT01918748,Effect of I-TRAVLE Training on Arm Function in MS and Chronic Stroke Patients,Hasselt University,Netherlands
941,,1942.0,NCT01911767,Biogen Multiple Sclerosis Pregnancy Exposure Registry,Biogen,United States
941,,1942.0,NCT01911767,Biogen Multiple Sclerosis Pregnancy Exposure Registry,Biogen,Australia
941,,1942.0,NCT01911767,Biogen Multiple Sclerosis Pregnancy Exposure Registry,Biogen,Canada
941,,1942.0,NCT01911767,Biogen Multiple Sclerosis Pregnancy Exposure Registry,Biogen,France
941,,1942.0,NCT01911767,Biogen Multiple Sclerosis Pregnancy Exposure Registry,Biogen,Germany
941,,1942.0,NCT01911767,Biogen Multiple Sclerosis Pregnancy Exposure Registry,Biogen,Ireland
941,,1942.0,NCT01911767,Biogen Multiple Sclerosis Pregnancy Exposure Registry,Biogen,Italy
941,,1942.0,NCT01911767,Biogen Multiple Sclerosis Pregnancy Exposure Registry,Biogen,Poland
941,,1942.0,NCT01911767,Biogen Multiple Sclerosis Pregnancy Exposure Registry,Biogen,Spain
941,,1942.0,NCT01911767,Biogen Multiple Sclerosis Pregnancy Exposure Registry,Biogen,United Kingdom
942,,1943.0,NCT01905527,Adherence Trial With MS LifeLines ® Services,EMD Serono,United States
945,,1946.0,NCT01844232,"One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity",Osmotica Pharmaceutical US LLC,United States
945,,1946.0,NCT01844232,"One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity",Osmotica Pharmaceutical US LLC,Russian Federation
945,,1946.0,NCT01844232,"One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity",Osmotica Pharmaceutical US LLC,Ukraine
946,,1947.0,NCT01791244,A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device,"Merck KGaA, Darmstadt, Germany",Germany
946,,1947.0,NCT01791244,A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device,"Merck KGaA, Darmstadt, Germany",Sweden
947,,1948.0,NCT01774123,Optical Coherence Tomography in Multiple Sclerosis Patients,The Cleveland Clinic,United States
949,,1950.0,NCT01610687,A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis,GW Pharmaceuticals Ltd.,United Kingdom
950,,1951.0,NCT01604265,A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple Sclerosis,GW Pharmaceuticals Ltd.,United Kingdom
951,,1952.0,NCT01578330,"A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720",Novartis Pharmaceuticals,Turkey
953,,1954.0,NCT01532154,Fampridine Pregnancy Exposure Registry,Biogen,France
957,,1958.0,NCT01444300,Dalfampridine for Imbalance in Multiple Sclerosis,Oregon Health and Science University,United States
958,,1959.0,NCT01414816,Betaferon® Regulatory Post-Marketing Surveillance,Bayer,"Korea, Republic of"
961,,1962.0,NCT01337986,Ampyra for Optic Neuritis in Multiple Sclerosis,Washington University School of Medicine,United States
966,,1967.0,NCT01207856,Randomised Controlled Clinical Trial of Cognitive Rehabilitation in Multiple Sclerosis,"University Hospital, Bordeaux",France
967,,1968.0,NCT01157728,Early Cognitive Impairment in Multiple Sclerosis,Assistance Publique - Hôpitaux de Paris,France
968,,1969.0,NCT01128075,Treatment Adherence When Using RebiSmart™ in Relapsing Multiple Sclerosis Subjects,"Merck KGaA, Darmstadt, Germany",Canada
972,,1973.0,NCT01024777,Safety and Immunologic Effect of Low Dose Versus High Dose Vitamin D3 in Multiple Sclerosis,Johns Hopkins University,United States
974,,1975.0,NCT00981643,Effects of Meditation on Multiple Sclerosis and Peripheral Neuropathy,The Cleveland Clinic,United States
975,,1976.0,NCT00947232,Motivational Interviewing to Increase Physical Activity to Treat Depression in People Aging With MS or SCI,University of Washington,United States
976,,1977.0,NCT00893217,BEYOND Pilot Study,Bayer,United States
977,,1978.0,NCT00881205,Rivastigmine in Multiple Sclerosis Patients With Cognitive Impairment,Novartis Pharmaceuticals,Germany
978,,1979.0,NCT00845338,Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity,Bayer,Germany
979,,1980.0,NCT00841321,Trial of Ginkgo as a Treatment for Cognitive Problems in Multiple Sclerosis,US Department of Veterans Affairs,United States
980,,1981.0,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),"Merck KGaA, Darmstadt, Germany",Argentina
980,,1981.0,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),"Merck KGaA, Darmstadt, Germany",Austria
980,,1981.0,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),"Merck KGaA, Darmstadt, Germany",Belgium
980,,1981.0,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),"Merck KGaA, Darmstadt, Germany",Bulgaria
980,,1981.0,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),"Merck KGaA, Darmstadt, Germany",Canada
980,,1981.0,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),"Merck KGaA, Darmstadt, Germany",Croatia
980,,1981.0,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),"Merck KGaA, Darmstadt, Germany",Czech Republic
980,,1981.0,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),"Merck KGaA, Darmstadt, Germany",Estonia
980,,1981.0,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),"Merck KGaA, Darmstadt, Germany",Finland
980,,1981.0,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),"Merck KGaA, Darmstadt, Germany",France
980,,1981.0,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),"Merck KGaA, Darmstadt, Germany",Germany
980,,1981.0,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),"Merck KGaA, Darmstadt, Germany",Greece
980,,1981.0,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),"Merck KGaA, Darmstadt, Germany",Israel
980,,1981.0,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),"Merck KGaA, Darmstadt, Germany",Italy
980,,1981.0,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),"Merck KGaA, Darmstadt, Germany",Latvia
980,,1981.0,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),"Merck KGaA, Darmstadt, Germany",Lebanon
980,,1981.0,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),"Merck KGaA, Darmstadt, Germany",Morocco
980,,1981.0,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),"Merck KGaA, Darmstadt, Germany",Poland
980,,1981.0,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),"Merck KGaA, Darmstadt, Germany",Portugal
980,,1981.0,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),"Merck KGaA, Darmstadt, Germany",Romania
980,,1981.0,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),"Merck KGaA, Darmstadt, Germany",Russian Federation
980,,1981.0,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),"Merck KGaA, Darmstadt, Germany",Serbia
980,,1981.0,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),"Merck KGaA, Darmstadt, Germany",Slovakia
980,,1981.0,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),"Merck KGaA, Darmstadt, Germany",Spain
982,,1983.0,NCT00621374,Management of Pain in Persons With Multiple Sclerosis,University of Washington,United States
987,,1988.0,NCT00300716,Trial of Memantine for Cognitive Impairment in Multiple Sclerosis,Oregon Health and Science University,United States
988,,1989.0,NCT00122954,Fish Oil for the Treatment of Depression in Patients With Multiple Sclerosis,Oregon Health and Science University,United States
991,,1992.0,NCT04047628,Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS),National Institute of Allergy and Infectious Diseases (NIAID),United States
991,,1992.0,NCT04047628,Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS),National Institute of Allergy and Infectious Diseases (NIAID),United Kingdom
993,,1994.0,NCT05005013,A Teleheath tDCS Approach to Decrease Cannabis Use,NYU Langone Health,United States
4,,2005.0,NCT04186910,In Clinic Physical Activity in Persons With Multiple Sclerosis,Fondazione Don Carlo Gnocchi Onlus,Italy
9,,2010.0,NCT03636789,Evaluation of the Prevalence of Oculomotor Disorders in Patients With Radiologically Isolated Syndrome,Centre Hospitalier Universitaire de Nīmes,France
13,,2014.0,NCT03271125,Intensive Multimodal Training for Persons With MS,Fondazione Don Carlo Gnocchi Onlus,Italy
16,,2017.0,NCT02790307,Transcutaneous Tibial Nerve Stimulation of Patients With Overactive Bladder (OAB) Syndrome,"University College, London",United Kingdom
17,,2018.0,NCT02710214,A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis,"University of California, San Francisco",United States
18,,2019.0,NCT02641041,"Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants",Biogen,United Kingdom
25,,2026.0,NCT02043964,Tear Analysis by Isoelectric Focusing in Clinically Isolated Syndrome as Multiple Sclerosis Criterion,Lille Catholic University,France
30,,2031.0,NCT01864707,Acupuncture or MBSR for Patients With Fatigue and MS,"Charite University, Berlin, Germany",Germany
33,,2034.0,NCT01743651,Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis,Osmotica Pharmaceutical US LLC,United States
33,,2034.0,NCT01743651,Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis,Osmotica Pharmaceutical US LLC,Russian Federation
33,,2034.0,NCT01743651,Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis,Osmotica Pharmaceutical US LLC,Ukraine
36,,2037.0,NCT01610310,Peginterferon Beta-1a (BIIB017) Autoinjector Pharmacokinetic Study in Healthy Volunteers,Biogen,United States
37,,2038.0,NCT01606176,A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin,GW Pharmaceuticals Ltd.,United Kingdom
38,,2039.0,NCT01451593,Neuroprotection With Phenytoin in Optic Neuritis,"University College, London",United Kingdom
42,,2043.0,NCT01166178,Zoledronic Acid in MS-patients With Osteoporosis,Novartis,Germany
43,,2044.0,NCT01031199,Evaluation of the Positron Emission Tomography (PET) Tracer ZK 6032924 in Patients With Multiple Sclerosis Compared to Healthy Volunteers,Bayer,Australia
43,,2044.0,NCT01031199,Evaluation of the Positron Emission Tomography (PET) Tracer ZK 6032924 in Patients With Multiple Sclerosis Compared to Healthy Volunteers,Bayer,Sweden
46,,2047.0,NCT00861172,"Longitudinal (Weekly) Follow-up of Active Plaques in Multiple Sclerosis With 3 Teslas Multi-modality MRI Using Diffusion, Perfusion, Venography and Proton Spectroscopy",Hospices Civils de Lyon,France
47,,2048.0,NCT00856518,Expiratory Muscle Training for Persons With Neurodegenerative Disease,VA Office of Research and Development,United States
49,,2050.0,NCT00794352,Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System,National Institute of Allergy and Infectious Diseases (NIAID),United States
50,,2051.0,NCT00711646,A Study of Sativex® for Relief of Spasticity in Subjects With Multiple Sclerosis.,GW Pharmaceuticals Ltd.,United Kingdom
51,,2052.0,NCT00702468,Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis,GW Pharmaceuticals Ltd.,United Kingdom
52,,2053.0,NCT00681538,"A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)",GW Pharmaceuticals Ltd.,United Kingdom
53,,2054.0,NCT00678795,A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple Sclerosis,GW Pharmaceuticals Ltd.,United Kingdom
61,,2062.0,NCT00039988,Treatment of Multiple Sclerosis With Copaxone and Albuterol,National Institute of Allergy and Infectious Diseases (NIAID),United States
63,,2064.0,NCT02988401,Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis,Johns Hopkins University,United States
64,,2065.0,NCT02506751,Open-label Study of Liothyronine in MS,Johns Hopkins University,United States
65,,2066.0,NCT02305264,Imaging of Intracerebral Inflammation in MS,Assistance Publique - Hôpitaux de Paris,France
69,,2070.0,NCT04688788,Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis,"Rigshospitalet, Denmark",Denmark
71,,2072.0,NCT00813969,Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS,The Cleveland Clinic,United States
73,,2074.0,NCT01371071,Cohort Study of Clinically Isolated Syndrome and Early Multiple Sclerosis,"Charite University, Berlin, Germany",Germany
74,,2075.0,NCT04466150,Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset,"University of California, San Francisco",United States
75,,2076.0,NCT02254304,Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™,"Merck KGaA, Darmstadt, Germany",Germany
76,,2077.0,NCT02804594,A Study of Oxidative Pathways in MS Fatigue,"University of California, San Francisco",United States
78,,2079.0,NCT03872583,Understanding Magnetic Resonance Imaging in Multiple Sclerosis,Universitätsklinikum Hamburg-Eppendorf,Germany
81,,2082.0,NCT03691077,Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714,Assistance Publique - Hôpitaux de Paris,France
83,,2084.0,NCT05010902,Pregnancy Cohort in Multiple Sclerosis (MS),"Charite University, Berlin, Germany",Germany
84,,2085.0,NCT02695394,Emotional Processing in Multiple Sclerosis / Clinically Isolated Syndrome: A Neuropsychological fMRI-study,"Charite University, Berlin, Germany",Germany
85,,2086.0,NCT01567553,The Inflammatory Process and the Medical Imaging in Patients With an Inflammatory Disease of the Central Nervous System.,Rennes University Hospital,France
86,,2087.0,NCT02076841,Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen,Biogen,Czech Republic
86,,2087.0,NCT02076841,Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen,Biogen,Switzerland
96,,2097.0,NCT02361697,DTI in Children With Multiple Sclerosis,University Hospital Muenster,Germany
103,,2104.0,NCT01051817,POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler,Novartis Pharmaceuticals,Czech Republic
103,,2104.0,NCT01051817,POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler,Novartis Pharmaceuticals,Russian Federation
103,,2104.0,NCT01051817,POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler,Novartis Pharmaceuticals,Ukraine
104,,2105.0,NCT00884481,Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS,Biogen,Austria
104,,2105.0,NCT00884481,Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS,Biogen,Denmark
104,,2105.0,NCT00884481,Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS,Biogen,Norway
104,,2105.0,NCT00884481,Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS,Biogen,Sweden
107,,2108.0,NCT01436643,Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression,Novartis Pharmaceuticals,Germany
115,,2116.0,NCT04634994,Novel Assessment of Synaptic Density in Progressive MS,Brigham and Women's Hospital,United States
125,,2126.0,NCT04694534,"Remediation Program Via a ""Serious Game"" for the Cognitive Functions of Multiple Sclerosis Patients",Lille Catholic University,France
128,,2129.0,NCT04386863,Taxonomy of Neurorehabilitation Treatments and Outcome Measures: a Multicentre Italian Study,Fondazione Don Carlo Gnocchi Onlus,Italy
129,,2130.0,NCT04355611,Epidemiological Characteristics of COVID-19 in Patients With MS or NMO,Assistance Publique - Hôpitaux de Paris,France
138,,2139.0,NCT03570268,Preventing Falls and Participation Restrictions in Neurological Diseases,Fondazione Don Carlo Gnocchi Onlus,Italy
140,,2141.0,NCT03418376,Carnosine Loading and Periodized Training in MS and HC,Hasselt University,Belgium
144,,2145.0,NCT03201692,Improving Dynamic Balance and Gait Adaptability Using Treadmill Training,Fondazione Don Carlo Gnocchi Onlus,Italy
148,,2149.0,NCT02474940,MS Symptom Management Study,University of Washington,United States
149,,2150.0,NCT02391961,Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis,VA Office of Research and Development,United States
151,,2152.0,NCT02137044,Multiple Sclerosis-Collaborative Approach to Rehabilitation Effectiveness Study,University of Washington,United States
155,,2156.0,NCT01606137,A Study of the Long-term Safety of Sativex Use,GW Pharmaceuticals Ltd.,United Kingdom
156,,2157.0,NCT00772525,Single Oral Doses Study of Nerispirdine on Visual Function in Patients With Multiple Sclerosis,Sanofi,United States
159,,2160.0,NCT00338637,Measuring the Balance Improvement on Multiple Sclerosis Patients After a Short Training Period With an APOS (All Phase Of Step Cycle) Kit,Sheba Medical Center,Israel
160,,2161.0,NCT00280592,Cranberry for Prevention of Urinary Tract Infections in Multiple Sclerosis Patients,Rennes University Hospital,France
174,,2175.0,NCT03154801,Early Detection and Paramedical Care of Sexual Difficulties in Nervous System Diseases: Example of Multiple Sclerosis and Brain Tumors (NEUROSEX),Assistance Publique - Hôpitaux de Paris,France
177,,2178.0,NCT01563900,Continuous Positive Airway Pressure (CPAP) for Fatigue in Patients With Multiple Sclerosis (MS) and Obstructive Sleep Apnea (OSA),Northwestern University,United States
178,,2179.0,NCT00883142,Functional and Physiological Responses to Lokomat Therapy (Pilot Study),US Department of Veterans Affairs,United States
179,,2180.0,NCT00376506,A Comparison of an Implanted Neuroprosthesis With Sensory Training for Improving Airway Protection in Chronic Dysphagia,National Institute of Neurological Disorders and Stroke (NINDS),United States
180,,2181.0,NCT00202397,Effect of Riluzole as a Symptomatic Approach in Patients With Chronic Cerebellar Ataxia,S. Andrea Hospital,Italy
181,,2182.0,NCT00168714,Pregnancy Exposure Registry for Avonex (Interferon Beta-1a),Biogen,United States
183,,2184.0,NCT04893590,Adapting mHealth Technology to Improve Patient Activation,Washington University School of Medicine,United States
188,,2189.0,NCT03183791,RELAXaHEAD for Headache Patients,NYU Langone Health,United States
191,,2192.0,NCT02504840,Natural History of Multiple Sclerosis and Its Mimickers,National Institute of Neurological Disorders and Stroke (NINDS),United States
198,,2199.0,NCT00715598,Cognitive Testing for the Pain Quality Assessment Scale (PQAS),University of Washington,United States
207,,2208.0,NCT02301247,Treating New Learning and Memory Deficits in Progressive Multiple Sclerosis (MS),Kessler Foundation,United States
